Clinical trial NCT02692248
Conditions: Diffuse Large B-Cell Lymphoma
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Start date: 2016-04-07; Completion date: 2021-01-19
Enrollment: 64 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
Multicentric phase II trial to evaluate efficacy and safety of ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maintenance in patients with refractory/relapsed non-GCB DLBCL non candidates to autologous stem-cell transplantation (ASCT) An extensive biological study will be conducted in order to further characterize this population of DLBCL patients and correlate the response obtained with the biological profile of the tumor.

Detailed description:
The use of highly effective rituximab-containing therapy for treating diffuse large B-cell lymphoma (DLBCL) makes it more difficult to salvage relapsed or refractory patients. In addition, patients with advanced age or significant comorbidities, who are consequently not candidates for high-dose consolidative therapy, have a very poor prognosis. Prospective studies investigating new salvage regimens are essential.

The combination of rituximab, gemcitabine and oxaliplatin (R-GEMOX) is an effective salvage regimen for patients with relapsing or refractory DLBCL, with a favourable toxicity profile for unfit and/or elderly patients. Ibrutinib, an oral Bruton's tyrosine kinase inhibitor, is a potent killer of ABC DLBCL cell lines in vitro and in xenografts.

It is expected that the combination of ibrutinib with R-GEMOX-Dexa could be effective and well tolerated. Thus, it is proposed an open-label, non-randomized, multicentre, phase II trial, to investigate the safety and efficacy of the combination of ibrutinib with rituximab, gemcitabine, oxaliplatine and dexamethasone followed by ibrutinib maintenance as salvage therapy for patients with relapsed or refractory non-GCB DLBCL non-candidates to stem cell transplant.

Arms: arm 1: Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:

Induction phase:

* Rituximab 375 mg/m2 IV day 1
* Gemcitabine 1000 mg/m2 IV on day 1 or 2 (at investigator discretion).
* Oxaliplatine 100 mg/m2 on day 1 or 2 (after Gemcitabine administration);
* Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.
* Ibrutinib 560 mg daily for 14 days.

Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.

Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity.
Interventions: intervention 1: Ibrutinib intervention 2: Rituximab intervention 3: Gemcitabine intervention 4: Oxaliplatin intervention 5: Dexamethasone
Intervention descriptions: intervention 1: Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years). intervention 2: Rituximab 375 mg/m2 IV day 1 during 4 cycles. intervention 3: Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days. intervention 4: Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days. intervention 5: Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.

Protocol documents:
Prot_ICF_000.pdf: 
Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
CLINICAL TRIAL PROTOCOL
CODE: IBDCL-GELTAMO-2015
Sponsor:
GEL/TAMO (Spanish Group of Lymphoma/Autologous Bone Marrow
Transplantation)
Hospital Universitario M. Valdecilla (Hematology Service)
Av. Marqués de Valdecilla s/n
39008 Santander
Telephone/Fax: +34 942203450
Coordinator
Researchers:
Drs. Dolores Caballero and Alejandro Martín
Hematology Service
University Hospital of Salamanca
Paseo de San Vicente, 55-182
37007 Salamanca
Telephone: +34 923 291 100, ext. 55384
Monitoring:
Pharmaceutical Marketing & Clinical Research, SL (MFAR, SL)
C/ Secretari Coloma 64-68. Esc. B – entlo. 5.ª
08024 Barcelona
Phone: +34 93.434.44.12
Fax: +34 93.253.11.68
Email: investigacion@mfar.net
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
1 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
SIGNATURE PAGE PROTOCOL
Protocol Number: IBDCL-Geltamo-2015
Ollie # EudraCT: 2015-005390- 21
Protocol version: 2, October 21, 2016
I have read this protocol and agree to perform this trial in accordance with all provisions of the
protocol and in accordance with the Declaration of Helsinki.
Signature of the sponsor
Dr. Dolores Caballero
President of GELTAMO
Signature of the Coordinating Investigator:
Dr. Dolores Caballero
Dr. Alejandro Martín
I have read this protocol and agree to carry out this trial in accordance with all the provisions of the
protocol and in accordance with the Declaration of Helsinki.
Principal Investigator: ...........................................
Name:
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
2 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Confidentiality Statement
This document contains confidential information of GEL/TAMO that should not be disclosed to
anyone other than the study staff and members of the Ethics Committee. This information cannot
be used for any other purpose than the evaluation or conduct of clinical research without the prior
written consent of GEL/TAMO.
Investigator Acknowledgment
I have read the attached protocol entitled “Ensayo clínico fase II multicéntrico para evaluar la
eficacia y la seguridad de ibrutinib en combinación con rituximab, gemcitabina, oxaliplatino y
dexametasona seguido de ibrutinib como tratamiento de mantenimiento en pacientes con linfoma
difuso de células B grandes de tipo no GCB resistente al tratamiento o recidivante no candidatos a
recibir un TACM”, version: 2, October 21, 2016, and I agree to comply with all the provisions
stipulated therein.
I agree to act in accordance with the Tripartite Guide for Good Clinical Practice standards.
I agree to ensure that the confidential information contained herein is not used for any
purpose other than the evaluation and conduct of clinical research, without the prior written
consent of GEL/TAMO.
Signature
Principal investigator
Date (DD/month/YYYY)
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
3 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Index
Content index
0. GENERAL INFORMATION
7
1. REVIEW SHEET
16
2. JUSTIFICATION AND OBJECTIVES
19
2.1 JUSTIFICATION
19
2.2 OBJECTIVES
21
3. STUDY DESIGN AND TREATMENT DESCRIPTION
22
3.1 PHASE DEVELOPMENT
22
3.2 OUTLINE OF THE STUDY
22
3.3 TREATMENT PLAN
23
3.4 MEDICATION PROTOCOL
26
3.5 dose adjustments
31
3.6 CRITERIA FOR WITHDRAWAL OF TREATMENT
37
3.7 TREATMENTS CONCOMITANTS
38
4. ELIGIBILITY OF THE PATIENT
42
4.1 CRITERIA FOR INCLUSION
42
4.2 CRITERIA EXCLUSION
43
4.3 cOMPLETION CRITERIA OF STUDY
44
5. MAKING AND EVALUATION OF RESPONSE
45
5.1 endpoints STUDY
45
5.2 EMBODIMENT OF THE STUDY
45
5.3 CRITERIA RESPONSE AND TOXICITY
48
5.4 TREATMENT AFTER cOMPLETION OF STUDY
49
5.5 STUDY PROCEDURES
49
6. ADVERSE EVENT REPORTING
53
6.1 DEFINITIONS
53
6.2 SPECIAL REPORTING SITUATIONS
55
6 .3 PROCEDURES
55
6.4 MANAGEMENT OF PRODUCT QUALITY COMPLAINTS
58
6.5 PREGNANCY NOTIFICATION
59
6.6 CONTACT INFORMATION FOR SAE, PREGNANCY, DEATH AND QUALITY CLAIMS
59
NOTIFICATIONS7. STATISTICAL
60
CONSIDERATIONS8. ETHICAL CONSIDERATIONS
61
8.1 CONSIDERATIONS GENERAL
61
8.2 INFORMED CONSENT IN WRITING
61
8.3 CONFIDENTIALITY OF DATA
62
8.4 INSURANCE OF THE CLINICAL TRIAL
62
8.5 INTRODUCTION TO THE CE
63
9. PRACTICAL CONSIDERATIONS
63
9.1 RESPONSIBILITIES UNDER THE RULES OF BPC
63
9.2 MODIFICATIONS AND DIVERSION OF THE PROTOCOL
65
9.3 MONITORING
65
9.4 MANAGEMENT DATA
66
9.5 FILE DOCUMENTATION OF THE STUDY
66
9.6 CONTROL AND QUALITY ASSURANCE
67
9.7 INSPECTION AND AUDIT
67
9.8 ENDING EARLY IN THE STUDY
68
9.9 ECONOMICS OF THE TEST
68
9.10 Publication Policy
68
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
4 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
10. BIBLIOGRAPHIC REFERENCES
69
ANNEXES
72
I List of participating centers
73
II. Patient information sheet and study consent form – version 2.0 of October 07, 2016
74
III. Molecular Substudy Patient Information Sheet and Consent Form
90
IV. Patient Information Sheet and Biobank Consent Form
97
V. ECOG Functional Status
105
VI. NCI CTCAE Criteria V4.03
106
VII. Centralized PET/TC review
107
VIII. Biological Substudy
112
IX. Revised Criteria for Response Assessment
125
X. Comorbidity Questionnaire
127
XI. Technical sheet Ibrutinib
143
XII. Screening procedure and Inclusion
144
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
5 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
ABBREVIATIONS
AAG
Adverse Event serious
CRD
Notebook data collection
ECOG
oncological Cooperative East(EasternCooperative OncologyGroup)
MRD
minimal residual disease
GEL / OCA
Group Spanish Lymphoma / Autologous Bone Marrow
HC
Hemogram complete
HLA
human leukocyte antigen(human leukocyte antigen)
DLBCL
diffuse large B Cell
NHL
nonHodgkin
ULN
upper limit of normal
WHO
World Health Organization
PET
positron emission tomography(positron emission tomography)
RAN
absolute neutrophil count
RC
PR
EE
complete remission
Partial response
Stable disease
RG
overall response
R-GEMOX
Rituximab-GEMOX
SG
Survival overall
SLA
free survival events
SLP
freeSurvival progression
CNS
Central nervous system
ASCT
autologous stem cell transplant
TFT
time to treatment failure
TRG
overall response rate
​
(V Version 2: October 21, 2016)
​
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
6 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
0. GENERAL INFORMATION
Study Title
Ensayo clínico fase II multicéntrico para evaluar la eficacia y la seguridad de ibrutinib en
combinación con rituximab, gemcitabina, oxaliplatino y dexametasona seguido de
ibrutinib como tratamiento de mantenimiento en pacientes con linfoma difuso de células
B grandes de tipo no GCB resistente al tratamiento o recidivante no candidatos a recibir
un TACM
Protocol number IBDCL-GELTAMO-2015
Protocol version
2.0 dated October 21, 2016
Chief
investigators
Dr. Dolores Caballero and Dr. Alejandro Martín
Hematology Service
University Hospital of Salamanca
Paseo de San Vicente, 55-182
37007 Salamanca
Telephone: +34 923 291 100, ext. 55384
Application type
Clinical trial of a drug marketed in a new indication.
Phase of the
study
Phase II
Indication
Diffuse large B-cell lymphoma (DLBCL) Primary
objective
1.
To assess the efficacy of the IR-GEMOX-dexa combination as salvage
treatment in patients with refractory or relapsed non-GCB diffuse large
B-cell lymphoma , in terms of overall response rate (ORR).
Secondary
objectives
1.
To assess the efficacy of the combination of IR-GEMOX-dexa followed
by ibrutinib as maintenance treatment in terms of secondary endpoints
(complete remission [CR], overall survival [OS], event-free survival
[EFS], survival progression-free [PFS] and duration of response).
2.
To determine the safety and tolerability of ibrutinib in combination with
R-GEMOX-dexa.
3.
To determine the safety and tolerability of ibrutinib as maintenance
treatment.
4.
Identify clinical and biological prognostic factors that influence response
and survival rates.
5.
Establish a correlation between mutational status and response and
survival.
6.
Evaluate the relationship of PET/TC results with biological markers.
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
7 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
7.
Establish a correlation between HLA polymorphisms and response and
survival.
8.
Establish a correlation between minimal residual disease (MRD) at the
end of treatment (6-8 cycles of IR-GEMOX) with the response observed
in PET/TC and survival.
Study design
Phase II multicentre clinical trial to evaluate the efficacy and safety of ibrutinib in
combination
with
rituximab,
gemcitabine,
oxaliplatin
and
dexamethasone
followed
by
ibrutinib
as
maintenance
treatment
in
patients
with
treatment-resistant or relapsed non-GCB DLBCL who are not candidates for
treatment. receive an autologous stem cell transplant (ASCT).
An extensive biological study will be carried out in order to further characterize
this population of patients with DLBCL and establish a correlation between the
response obtained and the biological profile of the tumor.
In addition, centralized PET/TC reviews will be carried out.
Primary endpoint
1.
Overall response rate (complete remission + partial response) of ibrutinib
in
combination
with
rituximab,
gemcitabine,
oxaliplatin,
and
dexamethasone.
Secondary
endpoints
1.
CR rate during the induction and maintenance phases.
2.
Conversion rate from EE or PR to PR or CR during the maintenance
phase
3.
Duration of the response.
4.
Progression free survival.
5.
event-free survival.
6.
overall survival.
7.
Safety
and
tolerability
of
ibrutinib
in
combination
with
rituximab,
gemcitabine, oxaliplatin, and dexamethasone.
8.
Safety and tolerability of ibrutinib as maintenance treatment.
9.
Influence of clinical and biological prognostic factors on response and
survival rates.
10. Establish a correlation between mutational status and response and
survival.
11. Establish a correlation between HLA polymorphisms and response and
survival.
12. Establish a correlation between the response observed in the PET/TC
and the biological markers.
13. Establish a correlation between MRD at the end of treatment (6 - 8
cycles of IR-GEMOX) with the response observed in PET/TC, PFS and
OS.
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
8 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Sample size:
Inclusion of a total of 62 patients during an approximate period of 24 months.
Summary of
patient eligibility
criteria
INCLUSION CRITERIA
1.
Patients with confirmed histological diagnosis of diffuse large B-cell
lymphoma.
2.
Patients 18 years of age or older.
3.
Non-germinal center B cell subtype (non-GCB) according to the Hans
algorithm (local laboratories).
Centralized evaluation will be performed to confirmB cell subtype non-germinal
center(non-GCB) , but a negative result will not exclude the patient from the
study if clinical benefit (CR, PR, or SE) is obtained after the study. 4th cycle.
(Version 2: October 21, 2016)
4.
Recurrent or refractory disease after:
●
At least one prior line of treatment, including rituximab in combination
with chemotherapy; or,
●
After a previous ASCT; or,
●
Following
allogeneic
transplant
with
reduced-intensity
conditioning,
unless
the
patient
is
receiving
immunosuppressive
drugs or has
graft-versus-host disease at the time of study enrollment.
(Resistance to treatment is defined as the inability to achieve CR after treatment
latest.)
5.
Functional status of the Eastern Cooperative Oncology Group (ECOG) ≤
2.
6.
FDG PET basal demonstrating positive lesions (Deauville 4 or 5)
compatible with the anatomical tumor locations defined on CT.
7.
Hematological values ​should be within the following limits:
a. Absolute neutrophil count (ANC) ≥1000/μl regardless of growth factor
treatment.
b.
Platelets
≥100,000/μL
or ≥50,000/μL in case of bone marrow
involvement, regardless of transfusion therapy in either situation.
8.
Biochemical values ​within the following limits:
a. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
≤2.5 times the upper limit of normal (ULN).
b. Total bilirubin ≤1.5 times the ULN, unless the increase in bilirubin is
due to Gilbert's syndrome or non-hepatic in origin.
c. Serum creatinine ≤2 times the ULN or estimated creatinine clearance
(CCr) ≥30ml/min.
9.
Females of reproductive capacity and sexually active males must use a
highly effective method of contraception during and after the study, in
accordance with local regulations regarding the use of contraceptive
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
9 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
methods for participants in clinical trials. Men must agree not to donate
sperm during and after the study. For females, these restrictions apply for
1 month after the last dose of study drug. In males, these restrictions
apply for 3 months after the last dose of study drug.
10. Females
of
reproductive
capacity
must
have
a
negative
serum
(beta-human chorionic gonadotropin [pregnancy test atβ-potentialhCG])
or urine screening. Pregnant or lactating women cannot participate in this
study.
11. Signature (or signature of the legal representative) of an informed
consent document indicating that they understand the purpose and
procedures required by the study and express their desire and ability to
participate in the study.
EXCLUSION CRITERIA
1.
Previous malignancy other than DLBCL, with the exception of adequately
treated basal cell carcinoma and squamous cell carcinoma, cervical
cancer in situ, or other tumors that have not recurred for at least 2 years
or will not limit survival to <2 years (Note: these cases should be
discussed with the principal investigator).
2.
Autologous stem cell transplant candidates.
NOTE: Young patients who have received more than one line of
treatment and are refractory may be considered ineligible for
autologous stem cell transplantation and are therefore eligible for
this study.
(Version 2: October 21, 2016)
3.
Life-threatening disease, condition, or organ dysfunction that, in the
opinion of the investigator, could compromise patient safety, interfere
with the absorption and metabolism of ibrutinib, or pose an undue risk to
treatment outcomes. study.
4.
Significant cardiovascular disease, such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6
months prior to screening, or any class 3 or 4 heart disease New York
Heart Association.
5.
Malabsorption syndrome, disease significantly affecting gastrointestinal
function, or resection of the stomach or small intestine or ulcerative
colitis, symptomatic inflammatory bowel disease, or partial or complete
intestinal obstruction.
6.
Treatment with any immunotherapy, chemotherapy, radiation therapy or
experimental treatment within 3 weeks prior to the first dose of the drug
of the study (allowed the use of corticosteroids for symptoms related to
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
10 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
the disease as indicated in paragraph 3.7). (Version 2: October 21,
2016)
7.
Prior treatment with ibrutinib or other BTK inhibitors.
8.
Central nervous system (CNS) involvement by lymphoma.
9.
History of stroke or intracranial hemorrhage in the 6 months prior to
inclusion.
10. Need
for
anticoagulation
with
warfarin
or
equivalent
vitamin
K
antagonists.
11. Need for treatment with potent CYP3A inhibitors (see the ”Potential for
Drug-Drug
Interactions”
section
of the Investigator's Manual).
(Version 2: October 21, 2016)
12. Grade ≥2 toxicity (except alopecia) related to prior anticancer therapy,
including radiation.
13. History of human immunodeficiency virus (HIV) infection, active hepatitis
C virus infection (HCV; positive RNA polymerase chain reaction [PCR]),
or active hepatitis B virus infection ( HBV; DNA PCR positive) or any
active uncontrolled systemic infection requiring IV antibiotics Patients
with negative HBV PCR are allowed to be included.
14. Major surgery within 4 weeks prior to the first dose of study drug.
15. Administration of live attenuated vaccines in the 4 weeks prior to
inclusion.
16. Pregnancy or lactation.
Medication
formulation and
administration
schedule Patients will receive ibrutinib in combination with R-GEMOX-dexa
followed by ibrutinib as maintenance treatment, according to the following
schedule:
Induction phase:
- Patients will initially receive 4 cycles every 14 days of ibrutinib + RI-GEMOX-D,
consisting of:
●
375 mg/m2 rituximab iv on day 1.
●
1000 mg/m2 Gemcitabineiv on day 1 or 2 (at investigator's discretion).
●
100 mg/m2 oxaliplatin on day 1 or 2 (after gemcitabine administration).
●
Dexamethasone 20 mg orally or IV on day 1 and orally on days 2 and 3.
●
Ibrutinib 560 mg daily for 14 days.
Patients who show clinical benefit (PR, CR or EE) will receive 2 (in the case of
CR) or 4 (in the case of PR or EE) additional cycles of 14 days each. If the
centralized review does not confirm the diagnosis of non-GCB type
DLBCL, the patient may continue in the clinical trial if the local investigator
and trial coordinators consider that the patient is benefiting from the
clinical trial.
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
11 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
(Version 2: October 21, 2016)
Maintenance phase:
After the induction phase, patients will receive 560mg ibrutinib daily. Continuous
cycles for up to 2 years, until disease progression or unacceptable toxicity
occurs (whichever comes first).
Patients with an inferior response to EE after the induction phase and patients
experiencing disease progression at any time during induction should complete
the study.
The PET/TC will be reviewed by thePET platform GELTAMO (see annex VI).
Treatment decisions will be made pursuant to centralized review.
Janssen is providing both the drug ibrutinib and the funding for the study.
(Version 2: October 21, 2016)
Study
Procedures
A. Prior to Initiation of Treatment: No later
than 28 days* (8 days for CBC and chemistry) prior to initiation of treatment,
baseline data should be determined and obtained. the following clinical and
biological data:
●
Informed consent.
●
Clinical history, concomitant medication, demographic data, physical
examination, ECOG.
●
Height, weight and vital signs.
●
Local histological diagnosis. Obtaining a tumor biopsy at the start of the
study
is
recommended,
especially
in
cases
of
recurrence.
Paraffin-embedded blocks of biopsies will be sent for central diagnostic
validation and biological studies (see Annex VII). A centralized evaluation
will be performed to confirm the subtype non-GCB before administration
of the 4th cycle.
(Version 2: October 21, 2016);
●
Complete blood count (CBC).
●
Biochemistry: creatinine, urea, uric acid, Na, K, Ca, Mg, glucose, total
protein, protein electrophoresis, albumin, IgG, IgA, and IgM, bilirubin,
alkaline phosphatase, GGT, AST, ALT, LDH, and β2-microglobulin.
●
Basal coagulation: PT, aPTT, fibrinogen.
●
Serology: HBV (including HBsAg, HBsAc, and HBcAc; HBV DNA in
cases with positive serology), HCV, HIV.
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
12 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
Pregnancy test (carried out on blood or urine) in women of reproductive
capacity.
●
Disease assessment: PET/TC.
●
Electrocardiogram.
●
Left ventricular ejection fraction (optional, mandatory only in patients with
a history of heart disease).
●
Bone marrow biopsy.
●
Peripheral blood samples for biological studies (see Annex VII).
●
Questionnaires on comorbidities (see Annex X).
An extensive biological study will be performed in order to further characterize
this population of DLBCL patients with AUC and to evaluate the response
obtained with the mutational profile of the tumor. In the event that patients agree
to participate in the biological study, peripheral blood, paraffin-embedded blocks
from the original diagnostic lymph node biopsy, and lymph node biopsy
performed at the time of recurrence (if available) are sent to a central laboratory
to perform phenotypic subtyping tests, molecular studies, mutational spectrum,
and determination of the cell of origin using NanoString technology (NanoString
Technologies, WA, USA) (13).
**The baseline analysis must be performed, at most, in the previous week.
B. During treatment with IR-GEMOX-dexa:
1. Before each cycle of treatment:
●
History, physical examination, ECOG, vital signs.
●
CH and biochemistry (creatinine, urea, uric acid, Na, K, Ca, Mg, glucose,
total protein, albumin, bilirubin, alkaline phosphatase, GGT, AST, ALT
and LDH).
●
Concomitant medication.
●
Adverse events.
2. Evaluation of the response during induction:
●
PET/TC 10-14 days after the start of the 4th cycle).
●
Peripheral blood samples for MRD studies (see Annex VII).
C. Evaluation of response at the end of induction:
21-35 days after the start of the 6th or 8th cycle:
●
History, ECOG, physical examination, concomitant medication, adverse
events.
●
GH and biochemistry (creatinine, urea, uric acid, Na, K, Ca, Mg, glucose,
total protein, protein electrophoresis, albumin, IgG, IgA and IgM, bilirubin,
alkaline phosphatase, GGT, AST, ALT, LDH and microglobulin β2).
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
13 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
PET/TC.
●
Bone marrow biopsy (in case of infiltrate at the time of inclusion in the
study).
●
Peripheral blood samples for MRD studies (see Annex VII).
D. Maintenance treatment:
Visits will be made every 8 weeks, which will include the following:
●
History, physical examination, ECOG, vital signs.
●
Biochemistry and HC.
●
Concomitant medication.
●
Adverse events.
An evaluation of response will be performed:
●
chest, abdominal and pelvic TC every 6 months. PET/TC in case of
suspected recurrence or progression or to confirm CR.
●
Peripheral blood samples for MRD studies (see Annex VII), at the same
time as imaging evaluations.
E. End of Treatment Visit:
On day 30 after completion or discontinuation of study treatment:
●
History, physical examination, ECOG, vital signs.
●
Biochemistry and HC.
●
Concomitant medication.
●
Adverse events.
●
Reason for termination of treatment.
●
PET/TC to assess response, if not done in the last 3 months.
●
Peripheral blood samples for MRD studies (see Annex VII).
F. Follow-up visits (PFS):
Visits will be made every three months until disease progression is observed or
until the end of the study, which will include the following:
●
History, physical examination, ECOG, vital signs.
●
Biochemistry and HC.
●
Monitoring of adverse events.
●
Thoracic, abdominal, and pelvic TC every 6 months for the first 2 years.
PET/TC in case of suspected recurrence or progression or to confirm
CR.
●
Peripheral blood samples for MRD studies (see Annex VII), at the same
time as imaging evaluations.
G. Follow-up Visits (OS):
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
14 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
Data on overall survival.
Calendar
Presentation: December 2015
Start of inclusion: March 2016
inclusion: April 2018
End date ofEnd date of the study: September 2020
Presentation of results: to be determined (Version 1.2: July 7, 2016)
Protocol IBDCL-GELTAMO-2015 – Version 2, October 21, 2016
15 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib
Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
1. REVISION SHEET
Version
Date
Detail/
Modification
Summary of changes
Justification
1.0
-
1st Version
presented to the
CEIC
NA
-
1.1
4/Jan/2016
1st Version
approved by the
CEIC
Administrative changes.
Response to the questions raised by the CEIC during the initial
evaluation of the study.
1.2
7/Jul/2016
Non-substantial
modification
Screening and Inclusion Procedure
Section 3.4: The recommended premedication in relation
to Rituximab is detailed. (Version 2: 2016-Oct-21)
Pg. 28: Grade ≥3 Neutropenia (ANC <1 x 109/L [ie,
<1000/mm3]) with infection or fever.
Translation errors and administrative changes.
The inclusion procedure will be carried out through an online platform
24/7, specific to this study. Annex XII is incorporated.
The recommended pre-medication is unequivocally clarified based on
the Technical Sheet and clinical practice of each center.
Page 28: Conforms to the criteria NCI-CTCAE(version 4.03)
Translation errors and administrative changes
2.0
21/Oct/2016
Substantial
modification
Update of the safety information
changes are being implemented to incorporate new safety information
described
in
the
latest
edition
of
the
Investigator's
Manual,
Investigator's
Brochure - Edition 10 for the investigational drug
IBRUTINIB whose manufacturer is JANSSEN Cilag International NV
(approval number EU /1/14/945/002). In order to prevent the safety
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
16 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib
Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Clarification in one of the inclusion criteria
Medication of the protocol / concomitant treatments
Treatment Plan
information detailed in the protocol from becoming out of date as a
result of regular safety updates to the Investigator's Manual, it is
decided to make direct reference to the most current edition of this
manual and to the Summary of Product Characteristics at the points of
the protocol (except for the patient information sheet) where the safety
information of the investigational product is already collected in
accordance with said manual.
A clarification has also been added to one of the study's exclusion
criteria to emphasize the possibility of including young patients who are
not candidates for autologous transplantation because they have
received more than one line of treatment and are refractory. This
aspect was not explicitly reflected in the patient selection criteria,
although it was implicitly contemplated in the following exclusion
criteria: Candidates for autologous stem cell transplantation.
Section 3.4 (Protocol Medication) is amended to state that adequate
G-CSF prophylaxis should be given after cycles of chemotherapy to
reduce the duration of neutropenia and the incidence of febrile
neutropenia. Because this treatment is performed routinely in patients
receiving R-GemOX-type regimens and, therefore, in the patients
included in this trial, this modification is made to recommend the
specific regimen to be followed during chemotherapy cycles with the
The objective is to do it in the same way in all the patients in the trial,
although the regimen recommended in the specific protocols (if any) of
each center may be used.
Due to the fact that the tumor samples must be evaluated for
centralized review of the histopathological diagnosis in the Pathological
Anatomy Service of the Marqués de Valdecilla Hospital in the first place
and then in the Pathological Anatomy Service of the Hospital Clinic of
Barcelona to determine the cell of origin (GCB vs. ABC-like DLBCL) by
the 20-gene digital stringent expression test (NanoString), the
NanoStringcell of origin assignment result may not be available at
the time the patient receives the 4th cycle of the study's R-GemOx
scheme. As a consequence, the sponsor has decided that the
assessment of the decision to continue in the trial at the end of the 4th
cycle of treatment be made based on the result obtained in the
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
17 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib
Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT
GemOx Adjustment
Typographical/Formatting Protocol errors
centralized review reflected in the histopathological diagnosis report of
the service of Pathological Anatomythe H Marquis of Valdecilla. In this
way, the sections of the protocol that refer to the treatment plan after
the 4th cycle are modified as detailed below:
●
Those
patients
in
Complete
Remission
(CR),
Partial
Response (PR) or Stable Disease (SE), and with centralized
review report confirming the diagnosis of non-germinal center
B-cell (non-GCB) DLBCL, they may continue to receive trial
treatment according to the criteria established in section 3.3
(Treatment plan).
●
Those
patients
in
Progression
must
abandon
the
trial
treatment.
●
Those patients with a centralized review report that does not
confirm the local diagnosis of non-GCB DLBCL, may continue
to receive the treatment of this study within the clinical trial as
long as the investigator of the center confirms that the patient
is obtaining a clinical benefit and improvement of their disease
as a consequence of the administration of the study treatment.
These cases will be discussed with the study coordinators and
the
center
investigator
must
inform
the
patient
of the
centralized diagnosis, as well as confirm the patient's decision
to continue in the clinical trial.
Based
on
the
experience
of
the
group
GELTAMO
with
the
R-GemOx-Dexa regimen and the results obtained in a previous clinical
trial in the same study population (5), it was decided to modify section
3.5.3 (GemOx dose adjustments ) where the criterion of the number of
platelets that the patient must present to receive the next cycle of
GemOx is indicated: from 70,000 / μl it is extended to 50,000 / μl.
Finally, typographical and formatting errors are rectified and corrected.
​
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
18 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
2. RATIONALE AND OBJECTIVES
​
2.1 RATIONALE
​The use of highly effective rituximab treatments for the treatment of diffuse large B-cell lymphoma
(DLBCL) makes recovery more difficult for patients with relapse or resistance to treatment (1, 2). In
addition, patients who are elderly or have significant comorbidities, who are therefore not
candidates for high-dose consolidation treatment, have a worse prognosis (3). In this context,
prospective studies evaluating new salvage treatments are essential.
​The combination of rituximab, gemcitabine, and oxaliplatin (R-GEMOX) is an effective salvage
regimen for patients with relapsed or refractory DLBCL, with a favorable toxicity profile for
noncompliant and/or noncompliant patients. elderly (3, 4). A phase II trial included 49 patients with
relapsed (DLBCL who weren= 6) or refractory (n= 43)not candidates for ASCT. The median age
was 69 years. After four cycles, 21 patients (44%) had complete remission (CR) and 8 (17%)
partial response (PR), resulting in an overall response rate (ORR) of 61%. However, patients
previously exposed to rituximab had significantly worse ORR (23% vs. 65%; p= 0.004), as well as
significantly worse progression-free survival (PFS) (median 4 months vs. 11 months; median 4
months vs. 11 months; p=0.02) than patients who have not received prior treatment with rituximab
(3). Therefore, new therapeutic regimens are needed for these patients, and GEMOX could be a
good therapy for new combinations with targeted treatments (4,5).
​Using gene expression profiling (PEG), DLBCL can be divided into prognostically important
subgroups, with germinal center B cell (GCB), activated B cell (ABC) gene expression profiling or
type 3 (6,7). The GCB type group has a significantly better survival than the ABC type group. The
type 3 group is heterogeneous and not well defined, but has a similar poor outcome to the type
ABC group. The initial requirement for fresh frozen tissue biopsies and microarray technology has
been shown to be an obstacle to the implementation of molecular subtyping of cell of origin (CDO)
in
routine
clinical
practice.
To
overcome
these
obstacles,
several
algorithm-based
immunohistochemical (IHC) studies have been proposed (8,9,10). However, these are limited by
their binary nature (not identifying the 10% to 15% of unclassified biopsies by PEG), as well as
significant interlaboratory and interobserver variability. These factors have contributed to the
presence of important discrepancies in the literature regarding the prognostic significance of the
CDO subtypes determined by IHC (11,12,13). Recent improvements in technology have provided
the opportunity to use formalin-fixed paraffin-embedded tissue (TFFIP) biopsies to obtain reliable
PEG (14). The feasibility of applying digital gene expression to analyze TFFIP samples for CDO
assignment has recently been published. The Lymph2Cx trial identified groups of patients with
significantly different outcomes after R-CHOP treatment, independent of IPI score, and was shown
to be a reliable test, with excellent agreement in CDO assignment between different laboratories
(15 ,16).
​Recent studies indicate that new therapeutic agents have selective activity on the ABC and GCB
subtypes (17,18,19). Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is a potent killer of ABC-type
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
19 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
DLBCL cell lines in vitro and in xenografts (20). It exhibits monotherapy activity in relapsed and
refractory B-cell malignancies, with few toxic side effects (21,22,23,24). In a phase I study, patients
with relapsed or refractory B-cell malignancies had a 60% overall response, with 16% of patients in
complete remission when given ibrutinib (25). In patients with relapsed DLBCL, ibrutinib showed
preferential activity against tumors with the ABC subtype, with a 37% response, with very little
activity (5% response) in the GCB subtype (26). Ibrutinib has also been evaluated in combination
with immunochemotherapy. In a phase I-II study, ibrutinib was combined with R-CHOP in patients
with previously untreated CD20-positive B-cell non-Hodgkin's lymphoma. In the dose escalation
phase (part 1), patients with diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular
lymphoma were included. Patients received ibrutinib 280 mg, 420mg, or 560mg daily in
combination with an R-CHOP regimen every 21 days. The safety of the recommended phase II
dose was subsequently evaluated in a dose-expansion population composed of patients with newly
diagnosed diffuse large B-cell lymphoma (Part 2). Thirty-three patients were included (Part 1: 17;
Part 2: 16) and 32 received treatment with ibrutinib plus R-CHOP (one patient withdrew from the
Part 2 cohort). The maximum tolerated dose was not reached and the recommended dose in
phase II of ibrutinib was 560mg daily. The most common grade 3 or higher adverse events were
neutropenia (73% [24 of 33 patients]), thrombocytopenia (21% [seven patients]), and febrile
neutropenia and anemia (18% each [six patients]). The most frequently reported serious adverse
events were febrile neutropenia (18% [six patients]) and hypotension (6% [two patients]). Thirty
(94%) of the 32 patients who received one or more doses of the combination treatment achieved
an overall response. All 18 patients with diffuse large B-cell lymphoma who received the
recommended dose in phase II had an overall response. For those patients subtyped and treated
with the recommended dose in phase II, five (71%) of the seven patients with germinal center
B-cell subtype and two (100%) patients with B-cell subtype non-germinal center presented a
complete response (27). These results demonstrate that ibrutinib is well tolerated when added to
immunochemotherapy, and that it may improve responses in patients with B-cell non-Hodgkin's
lymphoma.
​
​Taking these data together, we hope that the combination of ibrutinib with R-GEMOX-dexa may be
effective and well tolerated.
​
​Therefore, we propose a phase II, multicenter, open-label, non-randomized study to assess the
safety and efficacy of the combination of ibrutinib with rituximab, gemcitabine, oxaliplatin, and
dexamethasone followed by ibrutinib as maintenance treatment for the salvage treatment of
patients with relapsed or refractory non-GCB DLBCL who are not candidates for stem cell
transplantation.
​
​
2.2 OBJECTIVES
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
20 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Primary
1.
To assess the efficacy of the combination (IR-GEMOX-dexa) as salvage treatment in
patients with refractory or relapsed non-GCB DLBCL, in terms of overall response rate
(ORR).
Secondary
1.
To assess the efficacy of the combination of IR-GEMOX-dexa followed by ibrutinib as
maintenance treatment in terms of secondary endpoints (complete remission (CR), overall
survival (OS), event-free survival (EFS), of progression [PFS] and duration of response).
2.
To determine the safety and tolerability of ibrutinib in combination with R-GEMOX-dexa.
3.
To determine the safety and tolerability of ibrutinib as maintenance treatment.
4.
Identify clinical and biological prognostic factors that influence response and survival rates.
5.
Establish a correlation between mutational status and response and survival.
6.
Evaluate the relationship of PET/TC results with biological markers.
7.
Establish a correlation between HLA polymorphisms and response and survival.
8.
Establish a correlation between minimal residual disease (MRD) at the end of treatment
(6-8 cycles of IR-GEMOX) with the response observed in PET/TC and survival.
​
​
​
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
21 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
3. STUDY DESIGN AND TREATMENT DESCRIPTION
​
​
3.1 DEVELOPMENT PHASE
​
​
Phase II exploratory clinical trial.
​
​
3.2 STUDY DIAGRAM
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
22 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
3.3 TREATMENT PLAN
Patients will receive ibrutinib in combination with R-GEMOX-dexa followed by ibrutinib as
maintenance treatment, according to the following schedule:
Induction phase:
●
375 mg/m2 rituximab iv on day 1.
●
1000 mg/m2 gemcitabine iv on day 1 or 2 (at investigator's discretion).
●
100 mg/m2 oxaliplatin on day 1 or 2 (after gemcitabine administration).
●
Dexamethasone 20 mg orally or IV on day 1 and orally on days 2 and 3.
●
Ibrutinib 560 mg daily for 14 days.
Evaluation of response will be done after the 4th cycle (10-14 days after the start of the 4th cycle).
Patients who show clinical benefit (RP, CR or EE) will receive 2 (in the case of CR) or 4 (in the
case of PR or EE) additional cycles of 14 days each. Evaluation of response will be done after the
6th or 8th cycle (21-35 days after the start of the 6th or 8th cycle).
Those patients with a centralized review report that does not confirm the diagnosis local
non-GCB DLBCL, may continue to receive the treatment of this study according to the
previous response criteria within the clinical trial as long as the investigator of the center
confirms that the patient is obtaining a clinical benefit and improvement of their disease as
a consequence of the administration of the study treatment. These cases will be discussed
with the study coordinators and the center investigator must inform the patient of the
centralized diagnosis, as well as confirm the patient's decision to continue in the clinical
trial.
(Version 2: October 21, 2016)
Maintenance phase:
After the induction phase, patients who present a response will receive ibrutinib 560mg daily.
Continuous cycles for up to 2 years, until disease progression or unacceptable toxicity occurs
(whichever comes first).
Patients with an inferior response to EE after the induction phase and patients experiencing
disease progression at any time during induction should terminate treatment. The PET/TC will be
reviewed by the PET platform GELTAMO (see annex VI). Treatment decisions will be made
pursuant to centralized review.
(Version 2: October 21, 2016)
This clinical trial includes:
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
23 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
Centralized review of response by imaging. See annex VI.
●
Central histological review of the diagnosis. See annex VII.
●
Associated biological projects. See annex VII.
1.
Patient selection procedure:
Before starting the selection period, informed consent must be obtained from the patient, using the
latest version in force throughout the study. The different procedures performed as part of the
patient's usual clinical treatment (eg, blood tests, diagnostic imaging tests, etc.) and performed
before the signing of the informed consent may be used for screening or considered baseline if
these Tests were performed as specified in this protocol. Once the informed consent has been
signed, each patient will be assigned a selection number (selection code). Each center will receive
in the investigator's center file the selection form in which the default numbers for selection are
assigned. This document must always remain at the study center under the custody of the
research team. This screening number will identify the patients during the period between signing
the informed consent and inclusion in the study.
2.
Procedures screening and inclusion of the patient:
The procedure for screening and inclusion will be made through the following platform:
mfar.es/ce/ibdclgeltamo2015,from MFAR it will be provided usernames and passwords to
researchers and people assigned by them to the performance of the procedure. Through
the registration of patients on the platform, an email confirming the screening or inclusion
will be automatically generated.
It is important to remember that the patient will not be able to receive treatment until the
center
has
received
the
inclusion
confirmation
email
that
the
system
generates
automatically.
For the correct fulfillment of the procedure, Annex XII is attached.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
24 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
3.4 PROTOCOL MEDICATION
1.
560mg ibrutinib daily for 14 days during induction cycles. Maintenance phase: continuous
cycles until disease progression or unacceptable toxicity occurs (maximum of 2 years).
Supply of ibrutinib: ibrutinib will be supplied by the sponsor, through Janssen Laboratory. Ibrutinib
(4 capsules for a 560mg dose) should be administered orally with a glass of water, at
approximately the same time each day. The capsules must be swallowed whole with water and
must not be opened, broken or chewed. Avoid consumption of grapefruit and blood orange during
treatment with ibrutinib. If the dose is not taken at the scheduled time, it can be taken as soon as
possible on the same day with a return to the normal schedule the following day. The patient
should not take additional capsules to make up for a missed dose.
Ibrutinib is authorized by the EMA, but not for the indication proposed in this protocol.
2.
R-GEMOX-dexa; 4 cycles every 14 days:
●
rituximab 375mg/m2 iv on day 1.
●
1000mg/m2 Gemcitabineiv (30-minute infusion) on day 1 or 2.
●
100mg/m2 Oxaliplatin(3-hour infusion) on on day 1 or 2 (after gemcitabine
administration).
●
Dexamethasone 20mg orally or IV on day 1 and orally on days 2 and 3.
*Patients with clinical benefit (PR, CR, or EE) will receive 2 (for CR) or 4 (for the case of PR or
EE) additional cycles of 14 days each.
(Version 2: October 21, 2016)
Before the infusion of rituximab, it is recommended to administer the usual pre-medication of
each center that includes:
●
Antipyretic
●
Antihistamine
●
Optionally,
and
at
the
investigator's
discretion,
use
of
glucocorticoids
(eg,
methylprednisolone 60 mg IV) as part of pretreatment and if a reaction to rituximab
occurs.
Rituximab will be administered intravenously. The first infusion will start at a rate of 50mg/hour. If
well tolerated, increments of 50 mg/hour can be made every 30 minutes, up to a maximum of
400mg/hour. Subsequent infusions can be given at an initial rate of 100mg/hour, with increments of
up to 100mg/hour at 30-minute intervals to a maximum of 400mg/hour.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
25 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Rituximab supply: Rituximab, a treatment marketed and used in an authorized indication, will be
supplied by the participating hospital through the local supply procedure.
Prior to oxaliplatin infusion, the following should be administered:
●
Appropriate antiemetic therapy (anti-5HT3).
The patient will be warm and away from cold drafts.
Likewise, every effort will be made to keep the extremity being infused warm. Dexamethasone can
be associated with Polaramine, and the infusion can be slowed down from 4 to 6 hours in patients
who experience some type of previous reaction and present late vomiting.
In order to reduce the duration of neutropenia and the incidence of neutropenia febrile after
each cycle of chemotherapy, prophylaxis with G-CSF should be administered according to
the protocols established in each center (except for contraindications or intolerance). One
of the following guidelines is recommended (as applicable):
●
Administer between days +2 and +4 (of the cycle) G-CSF at a dose of 300
μgr/Kg up to a total of 6 -8 days.
●
Administer between days +2 and +4 (of the cycle) Pegfilgrastim 6 mg, single
dose.
(Version 2: October 21, 2016)
3.4.1 Possible adverse events of ibrutinib
Possible adverse events of ibrutinib, The information regarding contraindications, warnings, special
precautions for use, as well as possible interactions with other drugs, should be consulted in:
- Latest version of the Investigator's Manual available in the archive of the investigator's center.
- Latest version of the Summary of Product Characteristics (SPC), available in the file of the
investigator's center or on the EMA website
http://www.ema.europa.eu/ema/index.jsp?curl=
pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124
​
3.4.2 Possible adverse events of other drugs used in the study
​
​
For the rest of the drugs administered to the patients in the study, information regarding
contraindications, warnings, special precautions for use, as well as possible interactions,
available at:
​
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
26 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
- Summary of Product Characteristics (SPC), available in the file of the investigator's center
or on the EMA website:
​
​
http://www.ema.
europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac05
8001d124
​
​
3.5 DOSE ADJUSTMENTS
3.5.1 Adjustments of ibrutinib
Treatment with ibrutinib should be interrupted in the following cases:
●
Non Toxicity hematological d and grade ≥3.
●
Grade ≥3 neutropenia (ANC <1 x 109/L [ie, <1,000 /mm3]) with infection or fever. (Version
1.2: July 7, 2016)
●
Grade 4 neutropenia (ANC <0.5 x 109/l [ie, <500/mm3]).
●
Grade 3 thrombocytopenia (platelets <50 x 109/L [ie, <50,000/mm3]) in the presence of
major bleeding (ie, ≥Grade 2 bleeding).
●
Grade 4 thrombocytopenia (platelets <25 x 109/L [ie, <25,000/mm3]).
●
Other significant toxicities not reflected in the previous points if the investigator
considers that the risk of administering Ibrutinib outweighs the benefits.
(Version 2: October 21, 2016)
Once symptoms of toxicity have resolved to grade 1 or baseline (recovery), ibrutinib treatment may
be resumed at the starting dose. If toxicity recurs, the daily dose should be reduced by one capsule
(140mg). If necessary, a second dose reduction of 140 mg may be considered. If such toxicities
persist or recur after two dose reductions, the drug should be discontinued. Study drug may be
withheld for up to 21 consecutive days. Study drug administration should be permanently
discontinued in the event of toxicity lasting more than 21 days, unless site investigators consider
that the benefit of continuing ibrutinib treatment outweighs the risk.
​
Recommended dose modifications are described below:
​
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
27 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Modifications to ibrutinib dose
Appearance of the same
adverse event
Action
First
Interrupt study drug until recovery to ≤Grade 1 or baseline; can be reset to
the original dose level.
Second
Interrupt study drug until recovery to ≤Grade 1 or baseline; restart at a lower
dose level (3 capsules [ie 420mg daily]).
Third
Interrupt study drug administration until recovery to ≤Grade 1 or baseline;
restart at a lower dose level (2 capsules [ie 280mg daily]).
Fourth
The study drug is suspended.
Dosage level
Dose
0
560mg/día
-1
420mg/día
-2
280mg/día
Ibrutinib suspension
Missed dose
If dose is not taken at scheduled time, it can be taken as soon as possible on the same day with a
return to normal schedule the next day . The patient should not take additional capsules to make
up for a missed dose.
Special warnings and precautions for use
The following study documents should be consulted:
- Latest version of the Investigator's Manual available on file at the investigator's center.
- Latest version of the Summary of Product Characteristics (SPC), available in the file of the
investigator's center or on the EMA website
http://www.ema.europa.eu/ema/index.jsp?curl = pages / medicines / landing /
epar_search.jsp & mid = WC0b01ac058001d124
(version2: October 21, 2016)
3.5.2 Titration of rituximab
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
28 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
No possibility of modifications contemplated by the dose. Mild or moderate infusion reactions
usually resolve by slowing the infusion rate and increasing it when symptoms improve.
Patients should be closely monitored for the onset of cytokine release syndrome. The infusion
should be stopped immediately in patients who develop any evidence of serious reactions,
especially severe dyspnoea, bronchospasm or hypoxia. Evidence of tumor lysis syndrome should
then be evaluated, including appropriate laboratory tests and, in the case of evidence of pulmonary
infiltration, with a chest X-ray. The infusion should not be restarted until complete remission of all
symptoms and normalization of laboratory values ​and chest X-ray results. From this point on, the
infusion can be resumed at half the rate of the previous infusion. If the same serious adverse
reactions are observed a second time, the decision to terminate treatment should be discussed
with the lead study (investigatorinvestigation@mfar.net) on a case-by-case basis.
Anaphylactic and hypersensitivity reactions have been reported to occur following iv administration
of murine proteins, usually occurring within the first few minutes of infusion. Drugs used to combat
hypersensitivity reactions, ie, epinephrine, antihistamines, and corticosteroids, should be available
for immediate use in case an allergic reaction occurs during administration. The clinical
manifestations of anaphylaxis may resemble those of cytokine release syndrome (described
above). Reactions attributed to hypersensitivity have been reported less frequently than those
attributed to cytokine release.
Since hypotension may occur during rituximab infusion, discontinuation of antihypertensive
treatments within 12 hours prior to infusion should be considered. Cases of angina pectoris or
cardiac arrhythmias such as atrial flutter and fibrillation, heart failure and/or myocardial infarction
have been reported in patients treated with rituximab. Therefore, careful monitoring should be
performed
in
patients
with
a
history
of
heart
disease
and/or
chemotherapy-associated
cardiotoxicity.
Cases of reactivation of hepatitis B, including cases of fulminant hepatitis, have been observed in
patients who were treated with rituximab with cytotoxic chemotherapy. When rituximab is used in
combination with cytotoxic chemotherapy, patients with a history of hepatitis B should be closely
monitored for signs of active hepatitis B virus infection and antiviral therapy initiated if clinically
indicated (see section 2.7).
The prepared solution must be administered as an intravenous infusion through a specific line. It
should not be administered as a direct or rapid intravenous infusion.
3.5.3 GEMOX dose adjustments
Before each cycle, an analytical follow-up will be carried out, with which the following criteria will be
established to be applied in the following cycle:
●
Neutrophils >1000/μl
●
Platelets > 50,000/μl
(Version 2: October 21, 2016)
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
29 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
If the patient does not show hematological recovery on day 14 of the cycle, a new analysis will be
performed every 7 days until the patient's recovery.
If haematological recovery is delayed for more than one week, the gemcitabine and oxaliplatin
dose will be reduced by one level (-1) in the next cycle.
If haematological recovery is delayed for more than two weeks, gemcitabine and oxaliplatin doses
will be reduced by 2 levels (-2) in the next cycle.
If for any reason the patient is unable to receive study treatment for 3 consecutive weeks,
treatment should be discontinued after discussion with the study chief investigator.
Patients experiencing grade 4 non-hematologic toxicity will be withdrawn from the study if the
toxicity is deemed unacceptable by the investigator's team.
Dose modifications - non-hematologic toxicity
GRADE
DOSAGE LEVEL
0-2
0
3
-1
4
-2
Dose modifications - liver or kidney failure
Bilirrubin
Creatinine
2,0-4,0
>4
1,5 - 2,0
>2
Gemcitabine
-1
-2
-1
-2
Oxaliplatin
0
0
-1
-2
Oxaliplatin dosage
level
Dose
0
100mg/m2
-1
80mg/m2
-2
65mg/m2
Gemcitabine
dosage level
Dose
0
1000mg/m2
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
30 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
-1
800mg/m2
-2
650mg/m2
3.5.4 Protocol modifications based on toxicity (phase)
Pre-inclusionToxicity will be thoroughly evaluated in the first 4 induction cycles with the IR-GEMOX
regimen in the first 6 - 12 patients included in the study, such that if a minimum of 3 of 6 or 6 of 12
patients experience any ≥3 grade hematologic toxicity and/or dose level reductions are required,
the dose schedule would be modified. the following eligible patients in this study (ibrutinib level -1,
gemcitabine and oxaliplatin). Should these dose modifications be made after enrollment of the first
6 and 12 patients in the study, 2 additional cohorts of 6 and 12 patients will be enrolled. Toxicities
occurring in the first 4 cycles of these cohorts will be reassessed. If the regimen is considered toxic
for this patient population, the study will be closed.
​
​
3.6 TREATMENT WITHDRAWAL CRITERIA
1.
Disease Progression: Patients who progress will discontinue treatment but will continue to
attend study visits for treatment and long-term follow-up.
2.
Patients with a response less than EE after 4 cycles of induction phase.
3.
Unacceptable toxicity.
4.
Researcher's decision.
5.
Refusal of the patient to continue with the study treatment.
(Version 2: October 21, 2016)
​
3.7 CONCOMITANT TREATMENTS
Concomitant treatments include all prescription and non-prescription drugs or treatments used by
the patient from 7 days before starting study treatment to 30 days after the last medication of the
studio. The doctor responsible for the treatment will prescribe the necessary treatments for the
concomitant diseases presented by any patient included in the study. The patient must inform the
investigator and record all concomitant medication in the corresponding CRDe.
Patients undergoing treatment with oral contraceptives, hormone replacement therapy or other
maintenance treatments should continue with this treatment.
to. Pretreatment Steroids Steroid use
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
31 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Is permitted up to 10 days prior to the start of study treatment (ie, up to 100mg prednisone or
equivalent). If steroids are given, they should be given after screening radiologic evaluation,
baseline laboratory evaluations, and baseline performance status assessment.
b. Treatment and prophylaxis for neutropenia
G-CSF
should
be
administered
as
primary
prophylaxis
for
neutropenia
(unless
contraindicated or intolerable), as indicated in section 3.4 of this protocol.
(Version 2: October 21, 2016)
c. Hepatitis B reactivation prophylaxis hepatitis B
Patients who are surface antigen positive or antinuclear antibody positive should receive
appropriate prophylaxis according to local standards.
d. Antimicrobial prophylaxis
The
use
of
antimicrobial
prophylaxis
(eg,
prophylaxis
for Pneumocystis pneumonia with
sulfamethoxazole and trimethoprim or equivalent) is recommended, according to institutional
guidelines.
It is allowed for the central nervous system prophylaxis in accordance with local guidelines.
CNS prophylaxis with iv methotrexate is not allowed
f. The use of erythropoietic drugs when the hemoglobin level is <10 g/dl and will be discontinued
when the level is >12g/dl.
g. Prohibited Concomitant Medications Concurrent
Anychemotherapy, antineoplastic immunotherapy, experimental treatment, or radiation therapy is
prohibited. The use of corticosteroids when administered as premedication or to treat rituximab
infusion-related reactions or contrast medium allergies, as well as short courses (<14 days) of
corticosteroid therapy for medical reasons not related to cancer, is permitted. (eg, treatment for
autoimmune cytopenias), in doses not to exceed 100mg/day of prednisone or equivalent. In
contrast, corticosteroid doses equivalent to >20mg/day of prednisone are not allowed; routine
pre-infusion
medication
with
corticosteroid
doses
>100mg
prednisolone
(or
equivalent)
intravenously is not permitted.
g. Invasive procedures:
The following guidelines should be applied perioperatively for patients who require surgery or an
invasive procedure while receiving ibrutinib:
●
For surgery or invasive procedures requiring sutures or staples for closure, ibrutinib should
be discontinued at least 7 days before the intervention and It will be administered for at
least 7 days after the procedure or intervention, and will be resumed at the discretion of the
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
32 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
investigator when the surgical wound is reasonably healed, without serohematic drainage
or the need for drainage tubes.
●
For minor procedures (such as central line placement, core needle biopsy, thoracentesis, or
paracentesis), ibrutinib should be stopped at least 3 days before the procedure and not
restarted for at least 3 days after the procedure. In the case of bone marrow biopsies
performed while the subject is on ibrutinib treatment, interruption of ibrutinib treatment will
not be necessary.
●
For procedures in emergency situations, administration of ibrutinib should be withheld after
the procedure and until the surgical wound is reasonably healed, for at least 7 days
following emergency surgery.
3.7.1 Interaction of ibrutinib with other medicinal products and other forms of interaction
The following study documents should be consulted:
- Latest version of the Investigator's Manual available on file at the investigator's site.
- Latest version of the Summary of Product Characteristics (SPC), available in the file of the
investigator's center or on the EMA website
http://www.ema.europa.eu/ema/index.jsp?curl
=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124
(Version 2: October 21, 2016)
3.7.2 Interaction of rituximab/gemcitabine/oxaliplatin/dexamethasone with other medicinal
products and other forms of interaction
Information on the possible interactions with other drugs of other therapeutic drugs indicated in the
study schedule, available at:
Summary of product characteristics available on file with the investigator's center or on the EMA
website:
http://www.ema.
europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d
124
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
33 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
4. PATIENT ELIGIBILITY
​
CRITERIA 4.1 INCLUSION CRITERIA
1.
Patients with confirmed histological diagnosis of diffuse large B-cell lymphoma. Patients
≥18 years of age.
2.
Non-germinal center B cell subtype (non-GCB) according to Hans' algorithm (local
laboratories).
Centralized
evaluation
will
be
performed
to
confirmB
cell
subtype
non-germinal
center(non-GCB), but a negative result will not exclude the patient from the study if
clinical benefit (CR, PR, or SE) is obtained after the study. 4th cycle.
(Version 2: October 21, 2016)
3.
Recurrent or refractory disease after:
●
At least one prior line of treatment, including rituximab in combination with
chemotherapy; or,
●
After a previous TACM; or,
●
Following allogeneic transplant with reduced-intensity conditioning, unless the
patient is receiving immunosuppressive drugs or has graft-versus-host disease at
the time of study enrollment.
(Resistance to treatment is defined as the inability to achieve CR after treatment latest.)
4.
Performance status Eastern Cooperative Oncology Group (ECOG) ≤2.
5.
PET with baseline FDG showing positive lesions (Deauville 4 or 5) consistent with the
anatomical tumor locations defined on CT.
6.
Hematological values ​should be within the following limits:
a. Absolute neutrophil count (ANC) ≥1000/μl regardless of growth factor treatment.
b. Platelets ≥100,000/μL or ≥50,000/μL in case of bone marrow involvement independent of
transfusion therapy in either situation.
7.
Biochemical values ​within the following limits:
a. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the
upper limit of normal (ULN).
b. Total bilirubin ≤1.5 times the ULN, unless the increase in bilirubin is due to Gilbert's
syndrome or non-hepatic in origin.
c. Serum creatinine ≤2 times the ULN or estimated creatinine clearance (CCr) ≥30ml/min.
8.
Females of reproductive potential and sexually active males must use a highly effective
method of contraception during and after the study, in accordance with local regulations
regarding the use of contraceptive methods for participants in clinical trials. Men must
agree not to donate sperm during and after the study. For females, these restrictions apply
for 1 month after the last dose of study drug. In males, these restrictions apply for 3 months
after the last dose of study drug.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
34 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
9.
Females of reproductive age must have a negative serum (beta-human chorionic
gonadotropin [pregnancy test atβ-potentialhCG]) or urine screening. Pregnant or lactating
women cannot participate in this study.
10. Signature (or signature of the legal representative) of an informed consent document
indicating that they understand the purpose and procedures required by the study and
express their desire and ability to participate in the study.
​
4.2 EXCLUSION CRITERIA
1.
Prior malignancy other than DLBCL, with the exception of adequately treated basal cell
carcinoma and squamous cell carcinoma, cervical cancer in situ, or other tumors that have
not recurred for at least 2 years or will not limit survival to <2 years (Note: these cases
should be discussed with the principal investigator).
2.
Autologous stem cell transplant candidates.
NOTE: Young patients who have received more than one line of treatment and are
refractory may be considered ineligible for autologous stem cell transplantation and
are therefore eligible for this study.
(Version 2: October 21, 2016)
3.
Life-threatening disease, condition, or organ dysfunction that, in the opinion of the
investigator, could compromise patient safety, interfere with the absorption and metabolism
of ibrutinib, or pose an unreasonable risk to treatment outcomes. study.
4.
Significant cardiovascular disease, such as uncontrolled or symptomatic arrhythmias,
congestive heart failure, or myocardial infarction within 6 months prior to screening, or
anyclass 3 or 4 heart disease New York Heart Association.
5.
Malabsorption
syndrome,
disease
significantly
affecting
gastrointestinal
function,
or
resection of the stomach or small intestine or ulcerative colitis, symptomatic inflammatory
bowel disease, or partial or complete intestinal obstruction.
6.
Treatment with any immunotherapy, chemotherapy, radiotherapy, or experimental treatment
within 3 weeks prior to first dose of study drug (corticosteroids permitted for disease-related
symptoms and as noted in section 3.7). (Version 2: October 21, 2016)
7.
Prior treatment with ibrutinib or other BTK inhibitors.
8.
Central nervous system (CNS) involvement by lymphoma.
9.
History of stroke or intracranial hemorrhage in the 6 months prior to inclusion.
10. Need for anticoagulation with warfarin or equivalent vitamin K antagonists.
11. Need for treatment with potent CYP3A inhibitors (see the ”Potential for Drug-Drug
Interactions” section of the Investigator's Manual). (Version 2: October 21, 2016)
12. Grade ≥2 toxicity (except alopecia) related to prior anticancer therapy, including radiation.
13. History of human immunodeficiency virus (HIV) infection, active hepatitis C virus infection
(HCV; positive RNA polymerase chain reaction [PCR]), or active hepatitis B virus infection (
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
35 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
HBV; DNA PCR positive) or any active uncontrolled systemic infection requiring IV
antibiotics Patients with negative HBV PCR are allowed to be included.
14. Major surgery within 4 weeks prior to the first dose of study drug.
15. Administration of live attenuated vaccines in the 4 weeks prior to inclusion.
16. Pregnancy or lactation.
​
4.3 STUDY COMPLETION CRITERIA
Investigators should encourage patients to complete the trial; however, patients may voluntarily
withdraw from the trial at any time. The investigator may also, at his discretion, withdraw patients
from this trial or the sponsor may suspend the trial.
The causes of premature withdrawal from the study must be documented in the data collection
notebook (CRF) as:
●
Closure/termination of the trial.
●
Patient lost follow-up.
●
Researcher's decision.
●
Withdrawal of informed consent from the patient.
●
Important deviation from the protocol, when appropriate.
●
Death.
The date of withdrawal from the study and the reason for withdrawal must be recorded on the CRF.
Subsequent treatment and follow-up until death will be determined by ensuring the patient's
medical care in accordance with clinical practice. In the event of death, an autopsy certificate with
cause of death should be obtained, if possible.
Note: Patients who discontinue the study for any reason cannot be re-enrolled.
​
​
​
​
​
5. CONDUCT OF THE STUDY AND ASSESSMENT OF RESPONSE
​
​
5.1 STUDY
ENDPOINTS Primary endpoint:
1.
Overall response rate (complete remission + partial response) of ibrutinib in combination
with rituximab, gemcitabine, oxaliplatin, and dexamethasone.
Secondary endpoints:
1.
CR rate during the induction and maintenance phases.
2.
Conversion rate from EE or PR to PR or CR during the maintenance phase.
3.
Response duration.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
36 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
4.
Progression free survival.
5.
event-free survival.
6.
overall survival.
7.
Safety and tolerability of ibrutinib in combination with rituximab, gemcitabine, oxaliplatin,
and dexamethasone.
8.
Safety and tolerability of ibrutinib as maintenance treatment.
9.
Influence of clinical and biological prognostic factors on response and survival rates.
10. Establish a correlation between mutational status and response and survival.
11. Establish a correlation between HLA polymorphisms and response and survival.
12. Establish a correlation between the response observed in the PET/TC and the biological
markers.
13. Establish a correlation between MRD at the end of treatment (6-8 cycles of IR-GEMOX)
with the response observed in PET/TC, PFS and OS.
​
5.2 CONDUCT OF THE STUDY
​
All the data of patients included in the study will be collected in the data collection notebook (CRD).
Active patient monitoring includes history, physical examination, laboratory tests, ECOG status,
vital signs, assessment of adverse events, and concomitant medication.
Information on adverse events and concomitant medication will be collected up to 30 days after the
last administration of study medication. In the case of serious adverse events (and related to
concomitant medication), the data recording will be extended until the SAE has resolved or is
considered clinically stable according to medical criteria.
When a patient completes the protocol procedures, no additional diagnostic tests will be
performed, only survival data will be collected.
The tests and evaluations that will be carried out in the different periods of the study are detailed
below.
5.2.1 Before the start of treatment:
Within a maximum period of 28 days* (8 days for complete blood count and biochemistry) before
the start of treatment, the following clinical and biological data must be determined and obtained:
●
Informed consent.
●
Clinical history, concomitant medication, demographic data, physical examination, ECOG.
●
Height, weight and vital signs.
●
Local histological diagnosis. Obtaining a tumor biopsy at the start of the study is
recommended, especially in cases of recurrence. Paraffin-embedded blocks of biopsies will
be sent for central diagnostic validation and biological studies (see Annex VII). A
centralized evaluation will be carried out to confirm the subtype non-GCB before
administration of the 4th cycle.
(Version 2: October 21, 2016)
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
37 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
Complete blood count (HC).
●
Biochemistry: creatinine, urea, uric acid, Na, K, Ca, Mg, glucose, total protein, protein
electrophoresis, albumin, IgG, IgA, and IgM, bilirubin, alkaline phosphatase, GGT, AST,
ALT, LDH, and β2-microglobulin .
●
Basal coagulation: PT, aPTT, fibrinogen.
●
Serology: HBV (including HBsAg, HBsAc, and HBcAc; HBV DNA in cases with positive
serology), HCV, HIV.
●
Pregnancy test (carried out on blood or urine) in women of reproductive capacity.
●
Disease assessment: PET/TC.
●
Electrocardiogram.
●
Left ventricular ejection fraction (optional, mandatory only in patients with a history of heart
disease).
●
Bone marrow biopsy.
●
Peripheral blood samples for biological studies (see Annex VII).
●
Questionnaires on comorbidities (see Annex X).
An extensive biological study will be performed in order to further characterize this population of
DLBCL patients with AUC and to evaluate the response obtained with the mutational profile of the
tumor. In the event that patients agree to participate in the biological study, peripheral blood,
paraffin-embedded blocks from the original diagnostic lymph node biopsy, and lymph node biopsy
performed at the time of recurrence (if available) are sent to a central laboratory to perform
phenotypic subtyping tests, molecular studies, mutational spectrum, and determination of the cell
of origin using NanoString technology (NanoString Technologies, WA, USA) (13). The biological
studies will be coordinated by Dr. Santiago Montes-Moreno, Dr. Miguel Ángel Piris, Dr. Marcos
González, Dr. Armando López-Guillermo and Dr. Elías Campo.
5.2.2 Tests and determinations during treatment
1. During treatment with IR-GEMOX-dexa:
Before each cycle of treatment:
●
History, physical examination, ECOG, vital signs.
●
CH and biochemistry (creatinine, urea, uric acid, Na, K, Ca, Mg, glucose, total protein,
albumin, bilirubin, alkaline phosphatase, GGT, AST, ALT and LDH).
●
Concomitant medication.
●
Adverse events.
Evaluation of response during induction:
●
PET/TC 10-14 days after the start of the 4th cycle).
●
Peripheral blood samples for biological studies (see Annex VII).
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
38 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
2. Evaluation of response at the end of induction:
21-35 days after the start of the 6th or 8th cycle:
●
History, ECOG, physical examination, concomitant medication, adverse events.
●
CH and biochemistry (creatinine, urea, uric acid, Na, K, Ca, Mg, glucose, total protein,
protein electrophoresis, albumin, IgG, IgA and IgM, bilirubin, alkaline phosphatase, GGT,
AST, ALT, LDH and β2 -microglobulin).
●
PET/TC.
●
Bone marrow biopsy (in case of infiltrate at the time of inclusion in the study).
●
Peripheral blood samples for MRD studies (see Annex VII).
3. Maintenance treatment:
Visits will be made every 8 weeks, which will include the following:
●
Anamnesis, physical examination, ECOG, vital signs.
●
Biochemistry and HC.
●
Concomitant medication.
●
Adverse events.
An evaluation of response will:
●
Be performed a TC scan of the chest-abdominal-pelvic (and cervical if clinically indicated)
will be performed every 6 months. PET/TC, if clinically indicated, in case of suspected
recurrence or progression or to confirm CR.
●
Peripheral blood samples for biological studies (see Annex VII), at the same time as
imaging evaluations.
5.2.3 End of treatment visit (30 +/- 5 days)
On day 30 after completion or discontinuation of study treatment:
●
History, physical examination, ECOG, vital signs.
●
Biochemistry and HC.
●
Concomitant medication.
●
Adverse events.
●
Reason for termination of treatment.
●
PET/TC to assess response, if not done in the last 3 months.
●
Peripheral blood samples for biological studies (see Annex VII).
5.2.4 Follow-up until progression (after the end of treatment)
Visits will be made every three months until disease progression is observed or until the end of the
study and will include the following:
●
History, physical examination, ECOG, vital signs.
●
Biochemistry and HC.
●
Monitoring of adverse events.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
39 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
A thoracic-abdominal-pelvic (and cervical if clinically indicated) TC scan will be performed
every 6 months for the first 2 years. PET/TC, if clinically indicated, in case of suspected
recurrence or progression or to confirm CR.
●
Peripheral blood samples for biological studies (see Annex VII), at the same time as
imaging evaluations.
5.2.5 Post-progression:
●
follow-upOverall survival follow-up (alive/dead/lost to follow-up).
​
​
5.3 RESPONSE AND TOXICITY CRITERIA
Response to treatment will be assessed according to the Lugano Response Evaluation Criteria for
Non-Hodgkin's Lymphoma (28).
5.3.1 Response definitions
Response will be classified according to the 2014 criteria of Cheson et al. (see annex IX). The
PET/TC will be reviewed by the PET platform GELTAMO (see Annex VI). Treatment decisions will
be made pursuant to centralized review.
5.3.2 Assessment of toxicity
Toxicity will be classified according to theCommon Terminology Criteria for Adverse Events
National Cancer Institute (CTCAE V 4.03).
​
5.4 TREATMENT AFTER COMPLETION OF THE STUDY
In the event of therapeutic failure and subsequent withdrawal from the protocol treatment program,
each center will apply the treatment they consider most appropriate.
​
5.5 STUDY PROCEDURES
The following pages summarize the procedures that will be carried out in each of the study stages:
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
40 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
tests
Before
treatment
initiation
Induction
phase
End of induction
period
Maintenance
phase
End of study
visit study
Follow-up unt
progression
Day -28 and
day 0
Before each
cycle
(every 14 days)
21 - 35 days
after the start of
the 6th or 8th
cycle
(every 8
weeks for 2
years)
30 days after
completion of
treatment
Informed consent
X
Inclusion/exclusion
criteria
X
Date of birth, date of
diagnosis, medical
history, weight, height
X
History/physical
examination (including
ECOG status and vital
signs)
X
X
X
X
X
X
Local histological
diagnosis (1)
X
Complete blood count
(CBC) (2)
X
X
X
X
X
X
Biochemistry (3)
X
X
X
X
X
X
Coagulation (4)
X
Serology (HIV, hepatitis
B and C) (5)
X
Pregnancy test
(in urine or blood )
X
PET/TC
X
X
Perform 10 - 14
days after start
of the 4th cycle
X
X
If clinically
indicated or to
confirm CR
X
If not
performed in
the last 3
months
X
If clinically
indicated
TC (6)
X
Every 6
months
(Version 1.2:
July 7, 2016)
X
Every 6 month
during the first
years
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
41 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
tests
Before
treatment
initiation
Induction
phase
End of induction
period
Maintenance
phase
End of study
visit study
Follow-up unt
progression
Day -28 and
day 0
Before each
cycle
(every 14 days)
21 - 35 days
after the start of
the 6th or 8th
cycle
(every 8
weeks for 2
years)
30 days after
completion of
treatment
Electrocardiogram
X
Ejection fraction:
optional (8)
X
Bone marrow biopsy
X
X (in case of
infiltrate at the
time of inclusion
in the study)
Concomitant
medication.
X
X
X
X
X
Adverse events.
X
X
X
X
X
Follow-up of overall
survival
Comorbidity
questionnaires
X
Initial diagnosis
paraffin-embedded
block (Version 1.2:
July 7, 2016)
X
Lymph node biopsy at
recurrence (if available)
X
(7) Blood peripheral
X
10 - 14 days
after the start of
the 4th cycle
X (for MRD
studies)
X
X
X
1: Obtaining a tumor biopsy at the start of the study is recommended, especially in cases of recurrence.
Paraffin-embedded blocks of biopsies will be sent for central diagnostic validation and biological studies
(see Annex VII).
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
42 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
2: Hemoglobin, leukocytes with leukocyte formula and platelets. The baseline determination must be
made in the 8 (Version 1.2: July 7, 2016) days prior to the start of treatment. Determinations made
before each of the cycles must be made within 48 hours before the cycles.
(Version 1.2: July 7,
2016)
3: Basal period and at the end of induction: creatinine, urea, uric acid, Na, K, Ca, Mg, glucose, total
protein, protein electrophoresis, albumin, IgG evaluation, IgA and IgM, bilirubin, alkaline phosphatase,
GGT, AST, ALT, LDH and β2microglobulina (version 1.2: July 7,2016).The baseline determination must
be made within 8 days prior to the start of treatment.
Rest of the study: creatinine, urea, uric acid, Na, K, Ca, Mg, glucose, total protein, albumin, bilirubin,
alkaline phosphatase, GGT, AST, ALT and LDH. Determinations made before each of the cycles must
be made within 48 hours before the cycles. (Version 1.2: July 7, 2016)
4: PT, TTP, fibrinogen.
5: Including HBsAg, HBsAc and HBcAc; HBV DNA in cases with positive serology.
6: TC chest, abdominal and pelvic, cervical (if clinically indicated).
7: Peripheral blood samples for MRD studies, at the same moments as the imaging evaluations.
8: Only mandatory in patients with a history of heart disease.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
43 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
6. REPORTING OF ADVERSE EVENTS
The monitoring of the safety of the study will be governed by the provisions of the EU Directive
2001/20/EU and the detailed guide on obtaining, verifying and reporting adverse reactions/events
that have appeared in clinical trials. They are medicines for human use.
The sponsor, through the lead study investigator, will assess the reported serious adverse events
(SAEs) and determine the predictability of the reported events using available safety documents. In
addition, it will urgently report all SAEs that are considered "suspected unexpected serious adverse
reaction, SRAGI" to the competent authorities, with the help of the monitor and the center's staff.
Notification to the competent authorities (drug agencies, reference EC, local EC and other local
competent bodies, according to local guidelines) and principal investigators of any reportable event
is the responsibility of the sponsor, within the time limits established by local regulations (Suspicion
of serious and unexpected adverse reactions must be reported to the competent authorities and
the relevant Ethics Committees as soon as possible, within a maximum of 15 days from the time
the sponsor first becomes aware; this period is reduced to 7 days in the event of SARS fatal and
life-threatening).
All adverse events that occurred during the clinical trial (in the case of SAE, from the signing of the
informed consent) and up to 30 days after the last dose of study medication must be recorded in
the CRD. In the case of serious adverse events (SAEs), the data record will be extended until the
SAE has resolved or is considered clinically stable, based on medical judgment.
​
6.1 DEFINITIONS
6.1.1 Definition and classification of adverse events
Adverse event
Adverse event is any adverse medical event in a patient in a clinical study who has been
administered a drug (investigational or not). An adverse event does not necessarily have a causal
relationship with the treatment. An adverse event can therefore be any unfavorable and
unexpected sign (including an abnormal result), symptom or disease temporarily associated with
the use of a medicine (clinical investigational or non-investigational product), considered or not
related to the aforementioned drug (product in the clinical investigation phase or that is not in the
investigation phase). (International Conference on Harmonization [ICH] definition).
This includes the appearance of new symptoms or worsening in severity or frequency from
baseline or abnormal results of diagnostic procedures, including laboratory abnormalities.
Note: the sponsor collects the adverse events that appear from the signing of the FCI (see section
5.3.1., All adverse events, during the time of the last record of adverse events).
Serious adverse event
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
44 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Serious adverse event, according to the guidelines of the ICH and the EU on Pharmacovigilance
with medicinal products for human use, is any untoward medical event that, at any dose:
●
Causes death.
●
It is potentially deadly.
●
(The patient was at risk of death at the time of the event. It does not refer to an event that
hypothetically could have caused death if it had been more intense.)
●
Requires hospitalization or extension of an existing hospitalization.
●
Causes persistent or significant disability/incapacity.
●
It is a congenital anomaly.
●
It is a suspicion of transmission of any infectious agent through a drug.
●
Is medically important.*
*Medical and scientific criteria will be applied to decide whether expedited notification is also
appropriate
in
other situations, such as a major medical event that is not immediately
life-threatening and does not result in death or hospitalization of the patient , but may endanger the
patient or require medical intervention in order to avoid one or more of the other outcomes included
in the definition above. These should also be considered serious.​
6.1.2 Adverse event definitions and classifications​
​Unlisted adverse event (unexpected) reference safety information
​An adverse event is considered unlisted if its nature or intensity is not consistent with the
corresponding product's reference safety information. For ibrutinib, the predictability of an adverse
event will be determined based on whether or not it has been listed in the Investigator's Manual.
​
​Drug-Related Adverse Event
​
​An adverse event is considered to be drug-related if attribution is possible, likely, or very likely,
based on the definitions provided below.
​
​Definitions of attribution
​No related
​An adverse event that is unrelated to the use of the drug.
​Equivocal
​An adverse event for which an alternative explanation is more likely, eg, concomitant drug(s),
concomitant disease(s), or where the temporal relationship indicates that a causal relationship is
unlikely.
​Possible
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
45 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​An adverse event that could be due to the use of the drug. An alternative explanation, for example
concomitant drug(s) or concomitant disease(s), is not conclusive. The temporal relationship is
reasonable, and therefore a causal relationship cannot be ruled out.
​Probable
​An adverse event that could be due to the use of the drug. The temporal relationship is indicative
(eg demonstrated by withdrawal). An alternative explanation, for example concomitant drug(s) or
concomitant disease(s), is less likely.
​Very likely
​An AE that is listed as a possible adverse reaction and cannot be reasonably justified by an
alternative explanation, e.g. concomitant drug(s) or concomitant disease(s). The temporal
relationship is highly indicative (eg demonstrated by withdrawal and reintroduction).
​Criteria for determining intensity
​An evaluation of the degree of intensity will be made using the NCI-CTCAE criteria (version 4.03).
The investigator must use clinical judgment in assessing the severity of events not directly
experienced by the patient (eg, laboratory abnormalities).
​
​
6.2 SPECIAL REPORTING SITUATIONS
​
Safety events of concern with a Sponsor Study Drug that may require urgent reporting and/or
safety evaluation include, but are not limited to:
●
Sponsor Study Drug Overdose.
●
Suspected abuse/misuse of a study drug by the sponsor.
●
Unintentional or accidental exposure to a sponsor's study drug.
●
Medication errors involving a sponsor's product (with or without patient exposure to the
sponsor's study drug, eg, name confusion).
Special notification situations must be recorded in the CRD. Any special notification situation that
meets the criteria for a serious adverse event should be recorded on the serious adverse events
page of the CRD.
​
​
​6.3 PROCEDURES
​6.3.1 All adverse events
​
​All adverse events and special notification situations, whether serious or not, will be reported from
the time the signed and dated ICF is obtained and until the last procedure related to the patient's
study ( which may include contact for security follow-up). Serious adverse events, including those
reported spontaneously to the investigator within 30 days of the last dose of study drug, must be
reported.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
46 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​All events that meet the definition of a serious adverse event are recorded as serious adverse
events, regardless of whether they are protocol-specific assessments.
​All adverse events, regardless of severity, intensity, or suspected relationship to study drug, must
be recorded using medical terminology in the original document and on the CRD. Whenever
possible, diagnoses should be provided when signs and symptoms are due to a common etiology
(eg, cough, runny nose, sneezing, sore throat, and cold should be reported as "upper respiratory
infection"). Investigators must record their opinion regarding the relationship of the adverse event
to the study treatment on the CRF. All necessary measures for the treatment of adverse events will
be recorded in the original documentation.
​The sponsor assumes the responsibility of making the pertinent notification of adverse events to
the health authorities. The sponsor will also notify Janssen of all unlisted (unexpected) serious
adverse events related to the use of the study drug. The sponsor must notify these events to the
Clinical Research Ethics Committee (CEIC) that has approved the protocol, unless the CEIC
requires and documents something different.
​6.3.2 Serious Adverse Events
​
​Study site personnel must notify Janssen of all serious adverse events that occur during the course
of the study within 24 hours of becoming aware of the event.
​
All serious adverse events that have not resolved at the end of the study or when the
patient ends their participation in the study should until:
●
be followed upThe event is resolved.
●
The event stabilizes.
●
The event returns to baseline, if baseline value/state is available.
●
The event is attributable to agents other than the study drug or to factors unrelated to the
conduct of the study It is
●
unlikely that additional information can be obtained (patient or healthcare professional
refusal to provide further information, loss to follow-up after showing due diligence with efforts to
keep track).
​Suspected transmission of an infectious agent by a drug will be reported as a serious adverse
event. Any event requiring hospitalization (or prolonged hospitalization) that occurs during the
course of a patient's participation in a study will be reported as a serious adverse event, except
hospitalizations for the following reasons:
●
Hospitalizations not indicated to treat acute illness or adverse events (eg, for social
reasons, such as pending admission to a long-term care facility).
●
Surgery or procedure scheduled prior to study inclusion (must be documented on CRF).
Note: hospitalizations scheduled before the signing of the FCI will not be considered as SAEs, nor
those in which the condition for which the hospitalization was scheduled has not worsened. Any AE
that results in an extension of the originally scheduled length of hospitalization will be reported as a
new AE.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
47 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
Disease progression will not be recorded as an adverse event or serious adverse event
term; instead, signs and symptoms of clinical sequelae resulting from disease progression/lack of
efficacy will be reported if they meet the definition of a serious adverse event.
●
A standard procedure for administration of study treatment will not be reported as a serious
adverse event. Hospitalization or prolonged hospitalization for a complication of treatment delivery
will be reported as a serious adverse event.
●
The
administration of a blood or platelet transfusion. Hospitalization or prolonged
hospitalization for a complication of such a transfusion remains a serious adverse event that
should be reported.
●
A procedure for investigations related to the protocol/investigation (e.g., surgery, imaging
tests,
endoscopy,
laboratory
sampling,
bone
marrow
sampling,
blood
sampling
for
pharmacokinetics or biomarkers ). Hospitalization or prolonged hospitalization for a complication of
such procedures remains a serious adverse event that should be reported.
●
Prolongation of hospitalization for technical, practical or social reasons in the absence of an
adverse event.
●
A scheduled procedure prior to study inclusion (must be documented on CRF). Prolonged
hospitalization for a complication considered to be possibly related to the study drug remains a
serious adverse event that should be reported.
​
​6.3.3 Adverse events of interest
​Standard safety monitoring of specific adverse events, or groups of adverse events, will be
performed as part of the monitoring activities performed. These events will be reported to Janssen
within 24 hours of becoming aware of them, regardless of severity (eg, serious and non-serious
adverse events), following the procedure described above for SAEs, and will require further data
collection.
​
​6.3.3.1 Major hemorrhage
​
​A major hemorrhage is defined as any bleeding episode of grade 3 or greater intensity, or leading
to one of the following: intraocular hemorrhage resulting in loss of vision, the need for transfusion
of 2 or more units of red blood cells or equivalent amount of blood, hospitalization or prolonged
hospitalization.
​
​6.3.3.2 Intracranial hemorrhage
​Any adverse event of intracranial hemorrhage, including subdural haematoma/hemorrhage,
epidural haematoma/hemorrhage and intracerebral hemorrhage, of any severity, will be recorded
as an event of special interest.
​
​6.3.4 Other malignant neoplasms
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
48 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​In addition to routine reporting of all AEs, all malignancies, including solid tumors, skin cancer, and
hematologic malignancies, must be reported during study treatment and during protocol-specified
follow-up periods, including post-treatment follow-up. progression for determination of overall
survival.
​
​6.3.5 Pregnancy
​Study site personnel must notify Janssen of all initial reports of pregnancy within 24 hours of
becoming aware of the event. Abnormal pregnancy outcomes (eg miscarriage, stillbirth and
congenital anomaly) are considered serious adverse events and should be reported as a serious
adverse event. Study treatment will be discontinued in any patient who becomes pregnant during
the study.
​Because the effect of study drug on sperm is unknown, pregnancies of partners of male study
participants will be reported to study site personnel within 24 hours of knowledge of the event.
​Follow-up information will be required on the outcome of the pregnancy, as well as on any
postnatal sequelae of the newborn.
​
​
6.4 MANAGEMENT OF PRODUCT QUALITY COMPLAINTS
​A product quality complaint (PQC) is defined as any suspicion of a product defect related to
manufacturing, labeling or packaging, that is, any dissatisfaction with respect to the identity, quality,
durability or reliability of a product, including its labeling or the integrity of the package. A PCR may
have some effect on the safety and efficacy of the product. Timely, accurate, and complete
reporting and analysis of PCR data from clinical trials is critical to the protection of patients,
investigators, and the sponsor, and is mandated by health agencies around the world.
​
​6.4.1 Procedures
​Study site personnel must notify Janssen of all CPRs within 24 hours of knowledge of the event.
​If the defect is combined with a serious adverse event, the research staff must report the PCR to
Janssen in accordance with the reporting timelines for serious adverse events. A sample of the
suspected product should be retained for possible further investigation, if requested by Janssen.
​
​6.5 NOTIFICATION OF PREGNANCY
The pregnancy of a female patient or the partner of a male patient, not being a serious adverse
event in itself, should be managed immediately also as an SAE. It must be registered and notified
with a specific form for pregnancy events and must be notified immediately (within 24 hours of
knowledge), even if a voluntary or spontaneous termination occurs, describing the details of the
birth and the presence or absence of a defect in the fetus or a congenital anomaly.
Potential effects on spermatogenesis: Pregnancies that occur in the partner of a male patient
should also be reported within 24 hours using the specific pregnancy form and should be followed
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
49 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
until the end of the pregnancy, even if there is an interruption voluntary or spontaneous, describing
the details of the birth and the presence or absence of any defects in the fetus or a congenital
anomaly. The pregnant partner of the patient will also be instructed to contact their doctor
immediately.
In order to carry out monitoring of clinical data during pregnancy, authorization must be requested
from the pregnant woman, either a study patient or the partner of a study patient, which will be
documented by signing a “Rapid Disclosure Consent”. medical data during pregnancy. This form
will not be sent to the monitor/CRO, but will be kept on file with the rest of the study documentation
at the center.
​
​6.6 CONTACT INFORMATION FOR NOTIFICATIONS OF SAE, PREGNANCY, DEATH AND
QUALITY CLAIMS
RESEARCH DEPARTMENT MFAR, SL
Fax: +34 93 253 11 68
E-mail: investigacion@mfar.net
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
50 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
7.STATISTICAL CONSIDERATIONS
7.1 CALCULATION OF SAMPLE SIZE
Using a 23% as the baseline overall response rate for R-GEMOX in relapsed or refractory DLBCL
patients previously exposed to R(3), sample size calculation assumes 80% power (beta is 20%) to
detect a significant improvement greater than 25% and an alpha level of significance of 0.05, for a
one-sided exact test of a single proportion. Assuming a target ORR of 48% and a dropout rate of
10%, it will be necessary to include 62 patients.
7.2 STATISTICAL ANALYSIS
The analysis populations are defined as:
- Population of all treated patients: defined as all patients receiving at least 1 dose of study drug.
- Evaluable Responder Population: Defined as all patients who have measurable disease at
baseline, receive at least 1 dose of study drug, and have at least 1 adequate post-baseline disease
evaluation. An adequate evaluation of the disease is defined as having sufficient evidence to
correctly indicate whether or not disease progression has occurred. Patients who have died due to
progression are also considered to have an adequate evaluation.
- Safety population: defined as all patients receiving at least 1 dose of study drug, which is the
same definition as for the population of all treated patients.
- Patient information: the distribution of the populations of all treated patients and of those with
evaluable response will be provided. Information regarding the distribution of patients will be
summarized, including the number of patients receiving treatment, completing the trial, and
withdrawing treatment, as well as the reason for withdrawal. Baseline demographics and
characteristics will be summarized.
- Efficacy analysis: the final analysis of the primary endpoint, ORR (CR + PR) after 4 cycles, can
be carried out 4 months after the last patient enrollment, and will be based on the population of all
patients treated. Response rates with confidence intervals (95% interval) will be presented. ORR
will be assessed according to local and centralized PET/TC assessments.
Overall survival, PFS, event-free survival, and duration of response are defined as follows (Cheson
et al., 2007):
•
Overall survival (OS): defined as the time between entry in the trial and death from any
cause. It will be analyzed using the Kaplan-Meier method. Data from patients withdrawing from the
study or not available for follow-up will be censored at the date of last contact.
•
Progression free survival. It is defined as the time elapsed from the inclusion of the first
patient in the study until the progression of the disease or death due to any cause.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
51 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
•
Event-free survival. It is defined as the time elapsed from trial inclusion to lymphoma
progression, treatment failure, or death from any cause. It will be analyzed using the Kaplan-Meier
method.
•
Response duration. It will be calculated from the date when there is an indication of CR or
PR until the date of recurrence or progression of the disease. It will be analyzed using the
Kaplan-Meier method.
​
8. ETHICAL CONSIDERATIONS
​
8.1 GENERAL CONSIDERATIONS
This study will be carried out in accordance with the requirements of the «Declaration of Helsinki»
adopted at the 18th General Assembly of the World Medical Association held in Helsinki, Finland,
in June 1964, and all relevant reviews. The standards of Good Clinical Practice (GCP) published
by
the
working
group
on
the
Efficacy
of
Medicines
of
the
European
Union
(1990)
(CPMP/ICH/135/95) and the regulatory requirements and applicable laws in the country will also be
applied. in which the study is carried out.
In accordance with Directive 95/46 of the European Parliament and Directive 2001/20/EC, which
establish the requirements for conducting a clinical trial, the information obtained during the clinical
trial may only be used by the sponsor of the clinical trial. in order to evaluate the results according
to the regulations indicated above.
​
8.2 WRITTEN INFORMED CONSENT
It is the obligation of the investigator to obtain written informed consent from patients (in
accordance with the requirements of the European Clinical Trials Directive), before including a
patient in the study, or when necessary, before evaluating the patient's eligibility for the study.
Each patient or their legal representative must, in terms of the provisions of the European Directive
on clinical trials, freely give their informed consent in writing after having received oral and written
information about the objectives of the study, the procedures that will be performed, the possible
anticipated benefits, drawbacks, and risks, possible therapeutic alternatives, and your rights and
responsibilities. The patient or their representative must be informed that their participation is
voluntary and that they can withdraw at any time without consequence. It will also be informed that
the sponsor, its representatives and the competent authorities will have access to the clinical data.
The investigator will be responsible for providing each patient or their representative with a Patient
Information Sheet and an Informed Consent Form authorized by the corresponding Ethics
Committee.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
52 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
If the patient agrees to participate in the study, the patient or their legal representative must sign
the consent form. The investigator must also sign and date this form, indicating that informed
consent has been obtained and that the patient has had an opportunity to ask questions and these
have been answered appropriately.
The patient or their representative will receive a copy of the Patient Information Sheet and the
signed informed consent form.
The investigator will file in the patient records of each patient the original signed and dated
informed consent forms. No patient can participate in the study until the signing of the informed
consent.
​
​
8.3 DATA CONFIDENTIALITY
The confidentiality of the data of each patient will be respected at all times, complying with the
requirements established in Law 15/99 on the protection of personal data and in RD 1720/2007 of
December 21. With the In order to guarantee the confidentiality of the study data in accordance
with Directive 95/46 of the European Parliament and Directive 2001/20/EC, personal and clinical
data may only be accessed by the study sponsor or its designated personnel, for purposes of
monitoring/audit, the researcher and team of collaborators, the Ethics Committee of the research
center, or the one that supervises the center, and relevant health authorities.
Study patients will be identified by a unique code made up of the center number (two digits) and a
consecutive number in chronological order of inclusion (two digits).
The researcher will inform the study patients that the data obtained in this study will be kept and
analyzed
by
computer
and
that
the
European
regulations
regarding
computerized
data
management will be followed. Data protection is described in the written patient information sheet.
The investigator agrees that the sponsor has the right to use the results of the clinical trial,
including the forms or copies of the CRD. In order to allow the use of the information obtained in
this clinical study, the investigator understands his obligation to offer the results of the analyzes
and all the information developed during the study to the sponsor.
​
8.4 CLINICAL TRIAL INSURANCE
​
The study will have an insurance policy that will cover all possible damages that patients may
suffer as a result of the evaluated product, in accordance with the applicable legislation in the
country in which the study is carried out.
​
8.5 PRESENTATION TO THE EC
​
This protocol and all the required documentation will be submitted for evaluation to the relevant
Ethics Committee, following the procedure established in current European regulations and the
instructions of the health authorities in the countries where the study is carried out.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
53 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
The study will not begin until the CEIC gives its positive vote and the competent authority is
available for the study, and until other local requirements established by current legislation are met.
The investigator will provide the sponsor with a copy of the relevant documents.
The Ethics Committee and the relevant health authorities will be informed of all changes in the
protocol that may affect the safety of patients or the development of the study and of serious and
unexpected reactions and other information that may alter the design of the study or imply a risk to
patients. The corresponding approvals/authorizations will be obtained in the event of substantial
modifications to the protocol, as established in the European Directive and the guidelines in force.
​
9. PRACTICAL CONSIDERATIONS
​
9.1 RESPONSIBILITIES UNDER GCP REGULATIONS
The sponsor, monitor and investigators will comply with the responsibilities established in GCP
regulations.
9.1.1 INVESTIGATOR
1.
Agree and sign the study protocol.
2.
Know in depth all the characteristics of the study drugs.
3.
Obtain informed consent from patients prior to inclusion in the study.
4.
Ensure that appropriate medical care is provided to the patient in the event of any adverse
event (including clinically significant laboratory values) related to the study.
5.
Collect, record and report data correctly.
6.
Immediately notify the sponsor of all SAEs and unexpected adverse events.
7.
Accept the responsibility that all persons involved in the study will respect the confidentiality
of any information about study patients.
8.
Keep the Ethics Committee regularly informed about the facts of the study.
9.
Take responsibility for the preparation of the final report of the study, providing its
acceptance and signature.
9.1.2 SPONSOR
1.
The sponsor is responsible for implementing and maintaining quality assurance and control
systems with written SOPs so that trials are performed and data generated, documented
(registered) and reported in accordance with the protocol , GCP standards and applicable
regulatory requirements.
2.
Sign the protocol and any modifications to it with the pertinent investigator.
3.
Select the most appropriate investigator based on their qualifications and availability of
resources, and ensure the investigator's agreement to conduct the study as specified in the
protocol.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
54 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
4.
Provide all available basic and clinical information on the investigational product and keep it
updated throughout the study.
5.
Request the report of the Clinical Research Ethics Committee and the authorization of the
Spanish Agency for Medicines and Health Products and send the notification or request, as
appropriate and without prejudice to the notification of the autonomous communities, in the
event of any modification or breach of the protocol , discontinuation of the trial and including
the reasons for discontinuation of treatment.
6.
Provide investigational medicinal products free of charge and ensure that they have been
prepared in accordance with good manufacturing standards and that they have been
properly packaged and labeled. The sponsor is also responsible for the conservation of the
investigational products, as well as for keeping the records of their manufacturing process
and quality control, keeping the records of the supplied investigational products and
guaranteeing that the center where the study is carried out establishes a procedure for the
correct handling, conservation and use of the investigational products supplied.
In exceptional cases, other supply routes may be agreed with the centre.
1.
Designate the monitor who will supervise the performance of the trial.
2.
Notify the health authorities and the Clinical Research Ethics Committees involved in the
trial of serious or unexpected adverse events, according to the procedures established in
the European and local directives.
3.
Immediately inform the investigator and the Clinical Research Ethics Committee of any
relevant new information that becomes available during the trial.
4.
Provide compensation to patients in the event of study-related injury or death. Provide legal
and economic coverage to the researcher, except for those damages resulting from
malpractice or negligence on the part of the researcher.
5.
Agree with the researcher on the assignment of responsibilities for data processing,
reporting and publication of results. In any case, the sponsor is responsible for preparing
the final or partial reports of the trial and their presentation to the competent authorities.
6.
The sponsor will have a point of contact, where the patients of the trial can obtain more
information about it, which may be delegated to the investigator.
9.1.3 MONITOR
The Sponsor delegates the monitoring tasks to MFAR.
a) Work according to the sponsor's standard operating procedures, visit the investigator
before, during and after the study to monitor compliance with the protocol and ensure that
all data is recorded and reported correctly and completely, and that informed consent is
obtained of all patients prior to inclusion in the study.
b) Guarantee that both the investigators and the centers where the trial will be carried out are
suitable for this purpose throughout the trial.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
55 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
c)
Ensure that both the principal investigator and all personnel assisting the investigator are
duly informed and ensure immediate communications between the investigator and the
sponsor at all times.
d) Verify that the researcher complies with the authorized protocol and all its modifications.
e) Check that the storage, dispensing, return and documentation of the supply of products in
the clinical investigation phase are safe and adequate.
f)
Submit written reports to the sponsor after each monitoring visit and after all relevant
contacts with the investigator.
​
​
9.2 MODIFICATIONS AND DEVIATIONS OF THE PROTOCOL
After reviewing and signing the protocol, neither the investigator nor the sponsor may make
modifications or changes without the written consent of both.
In case of any modification or change of the protocol once signed, this modification must be
discussed and agreed between the principal investigator and the sponsor, and be signed by both
parties. Protocol modifications must form an integral part of the original protocol. The Ethics
Committee must be informed of all changes to the protocol that may affect the safety of patients or
the development of the study. In case of relevant modifications, approval of the modification must
be
obtained,
in
accordance
with
European
and
local
regulations,
before
applying
said
modifications.
​
9.3 MONITORING
A team of monitors designated by the sponsor will periodically monitor the study to ensure that the
rights and well-being of patients are protected, that the protocol is followed, that applicable
regulations and ethical requirements are met, that all documentation is available in the centers and
that the data is collected accurately.
The investigator must provide the monitor with access to patient charts, study records, CRFs,
original signed informed consent forms, and all original documents.
Any deficiencies observed during the monitoring visits will be discussed with the investigator and
an agreement will be reached on the corrective measures to be applied.
​
​
9.4 DATA MANAGEMENT
All data (personal, clinical, economic, derived from biological material) obtained from patients will
be treated in accordance with Directive 95/46/EC of the European Parliament and of the Council,
dated October 24, 1995 regarding the protection of natural persons with regard to the processing
of personal data. In accordance with said legislation, patients may exercise their rights of access,
modification, opposition and cancellation of their data, for which they must contact the clinical study
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
56 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
doctor. The content of the CRFs, as well as the documents generated during the study, will be
considered strictly confidential and will not be disclosed to third parties.
The investigator must keep a detailed record of all persons involved in the study.
The investigator will collect and record the study data in the medical records of each patient and
will then transfer the information to the CRFs provided by the sponsor. All data must be fully,
promptly, accurately and intelligibly recorded in the CRD.
The investigator must date and sign each of the CRDs in the specific field of the CRDe.
The investigator must keep all the original documentation (analytical results, treatment sheets,
signed informed consent, etc.).
The data recorded in the CRD will be reviewed and analyzed; the database data will also be
checked for inconsistencies. Questionable, inconsistent, or incomplete data will be resolved by the
investigator in writing and the correction will be recorded in the CRF audit trail.
Computerized data correction procedures will apply.
​
9.5 FILING OF STUDY DOCUMENTATION
It is the investigator's responsibility to ensure that the trial file is maintained at the study center. In
this study, the file will contain the following documentation, among others:
1.
Study
protocol,
current
and
previous
versions,
review
and/or modifications (when
applicable).
2.
Patient
information
sheet
and
consent
form,
revision
and/or
modifications
(when
applicable).
3.
Researcher commitment.
4.
Contract for clinical research.
5.
CV of the investigator and sub-investigators.
6.
Positive vote of the CE to carry out the study and modifications (when applicable) and the
rest of the relevant communications with the CE.
7.
Authorization from the CA to carry out the study and modifications (when applicable) and
the rest of the relevant communications with the CA.
8.
Correspondence between the investigators, the EC and the sponsor related to this study.
9.
Annual reports and security reports.
10. Laboratory normality intervals, where the necessary determinations in this study will be
detailed. Laboratory quality certification.
11. PEI documentation (count forms, conservation, etc.).
12. Updated clinical study staff signature list and task delegation record.
13. Patient identification list, for patients included in the study.
The investigator must keep the patient identification list and all signed informed consents on file for
at least 15 years after the end of the trial. Any original information related to the study that allows
the verification of the inclusion and exclusion criteria, including the clinical history, a copy of all the
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
57 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
data collection notebooks and the documents for its use of the product in the clinical phase must
be kept for the maximum time interval allowed in the center.
9.6 CONTROL AND QUALITY GUARANTEE
The study will be supervised by monitors from MFAR, SL. The study monitor will contact the
investigators on a regular basis. In these contacts, the progress of the study will be discussed with
the investigator and it will be verified that the CRDs are completed in full and consistently. The
study monitor (and, when requested, a representative of the sponsor) will also check the informed
consent forms.
With proper supervision and ensuring confidentiality, the investigator will allow the sponsor's
representative or study monitor to compare the data entered into the CRF with the original data at
the study site (source documents) and to observe study procedures in order to verify compliance
with the study protocol.
9.7 INSPECTION AND AUDIT
Quality assurance audits may be carried out at any time during the trial or after its completion. In
addition, the relevant authorities may review the study in the terms established in European and
local regulations.
At the request of the monitor, the auditor, the Ethics Committee or the health authorities, the
investigator must provide direct access to all the documentation related to the clinical trial.
9.8 PREMATURE TERMINATION OF THE STUDY
The sponsor may, at any time, suspend the participation of an investigator in the study. In the event
that an investigator's participation in a study is suspended, the sponsor shall promptly and in
writing inform the CEIC and the AC of the reason(s) for the suspension.
Reasons for premature study termination may include, but are not limited to:
●
New available information justifying that continuation of the study is not feasible.
●
Unsatisfactory inclusion in terms of quantity or quality.
●
Collection of inaccurate or incomplete data.
●
Protocol breach.
9.9 ECONOMIC ASPECTS OF THE TRIAL
The economic aspects of the study will also be sent to the CEIC for evaluation at the time of
presentation of the protocol.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
58 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
9.10 PUBLICATION POLICY
The sponsor and the researchers agree to publish the results of this study. All publications and
presentations proposed by the investigators or their team and collaborators derived from or related
to the study must be sent to the sponsor for review before being sent for publication or
presentation.
In the publications, the signing authors will be ordered according to the number of patients
included, from highest to lowest.
If the proposed publication or submission contains patentable material, which, in the opinion of the
sponsor, ensures intellectual property protection, the publication or submission may be delayed for
a reasonable period of time to achieve this protection.
​
10. BIBLIOGRAPHICAL REFERENCES
1.
Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. R-ESHAP as
salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence
of
prior
exposure
to
rituximab
on
outcome.
A
GEL/TAMO
study.
Haematology.
2008;93(12):1829-36.
2.
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Lynch DC, Trneny M, et al. Salvage
Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab
Era. Journal of Clinical Oncology. 2010;28(27):4184-90.
3.
Mounier N, El Gnaoui T, Tilly H, Canioni D, Sebban C, Casasnovas RO, et al. Rituximab
plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma
who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Haematology. 2013;98(11):1726-31.
4.
López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, et al. GEMOX-R
regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell
lymphoma: a phase II study. European Journal of Haematology. 2008;80(2):127-32.
5.
López A, Martin A, Soler J, et al. Gemcitabine, oxaliplatin and dexamethasone plus
rituximab as salvage treatment in relapsed/refractory patients with diffuse large B-cell (DLBCL) and
mantle cell (MCL) lymphoma. A phase II multicenter study conducted by the Spanish GELTM10
group. Hematol Oncol 2013; 31 (Suppl. 1), abs 408.
6.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma
identified by gene expression profiling. Nature. 2000 503-511.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
59 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
7.
Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival
after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937-1947
8.
Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification
of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood
103:275-282, 2004.
9.
Choi WW, Weisenburger DD, Greiner TC, et al: A new immunostain algorithm classifies
diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res
15:5494-5502, 2009.
10.
Meyer PN, Fu K, Greiner TC, et al: Immunohistochemical methods for predicting cell of
origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin
Oncol 29: 200-207, 2010
11.
de Jong D, Rosenwald A, Chhanabhai M, et al: Immunohistochemical prognostic markers
in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical
applications—A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25:
805-812, 2007.
12.
Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al: Gene-expression profiling and
not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma
treated with immunochemotherapy. Blood 117:4836-4843, 2011.
13.
Read JA, Koff JL, Nastoupil LJ, et al: Evaluating cell-of-origin subtype methods for
predicting diffuse large B-cell lymphoma survival: A meta-analysis of gene expression profiling and
immunohistochemistry algorithms . Clin Lymphoma Myeloma Leuk 14:460-467, 2014
14.
Geiss GK, Bumgarner RE, Birditt B, et al: Direct multiplexed measurement of gene
expression with color-coded probe pairs. Nat Biotechnol 26:317-325, 2008
15.
Scott DW, Wright GW, Williams PM, et al: Determining cell-of-origin subtypes of diffuse
large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood
123:1214-1217, 2014.
16.
Scott DW, Mottok A, Ennishi D, et al. J Clin Oncol 33:2848-2856, 2015. Prognostic
Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene
Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
17.
Dunleavy K, Pittaluga S, Czuczman MS, et al: Differential efficacy of bortezomib plus
chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069-6076,
2009.
18.
Nowakowski GS, LaPlant B, Macon WR, et al: Lenalidomide combined with R-CHOP
overcomes
negative prognostic impact of non-germinal center B-cell phenotype in newly
diagnosed diffuse large B-cell lymphoma: A phase II study. J Clin Oncol 33:251-257, 2015.
19.
Roschewski
M,
Staudt
LM,
Wilson
WH:
Diffuse
large
B-cell
lymphoma-treatment
approaches in the molecular era. Nat Rev Clin Oncol 11:12-23, 2014
20.
Yang Y, Shaffer .AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, et al. Exploiting
synthetic
lethality
for
the
therapy
of
ABC
diffuse
large
B
cell
lymphoma.
CancerCell2012;21:723-37.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
60 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
21.
Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic
lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.
22.
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib
(PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin
Oncol 2013; 31: 88–94. 17
23.
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory
mantle-cell lymphoma. N Engl J Med 2013; 369: 507–16. 18
24.
O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with
chronic lymphocytic leukemia or small lymphocytic lymphoma: an open-label, multicentre, phase
1b/2 trial. LancetOncol 2014; 15:48–58..15–18
25.
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib
(PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin
Oncol 2013; 31: 88–94
26.
Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in
diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922-6
27.
Younes A, Thieblemont C, Morschhauser FMD, et al. Combination of ibrutinib with
rituximab,
cyclophosphamide,
doxorubicin,
vincristine,
and
prednisone
(R-CHOP)
for
treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised,
phase 1b study. The Lancet Oncology, Volume 15, Issue 9, Pages 1019 – 1026
28.
Cheson et al, Recommendations for initial evaluation, staging, and response assessment of
Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep
20;32(27):3059-68
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
61 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
​
ANNEXES:
I.
List of participating centers
II.
Patient information sheet and consent form for the study
III.
Patient information sheet and consent form for the molecular substudy
IV.
Patient information sheet and consent form for Biobank
V.
ECOG
VI.
Performance Status NCI CTCAE Criteria V4.03
VII.
PET/TC
VIII.
Centralized Review Biological Substudy
IX.
Lugano Response Evaluation Criteria for Non-Hodgkin Lymphoma (28)
X.
Comorbidity Questionnaire (CIRS and GAH)
XI.
Ibrutinib SmPC
XII.
Procedure of Screening and Inclusion (Version 1.2: July 7, 2016)
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
62 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
I. List of participating centers
The list of participating centers will be provided in a separate document.
II. Patient Information Sheet and Study Consent Form – Version 2.0, October 07, 2016
Patient Information Sheet
Study Title: Ensayo clínico fase II multicéntrico para evaluar la eficacia y la seguridad de ibrutinib
en combinación con rituximab, gemcitabina, oxaliplatino y dexametasona seguido de ibrutinib
como tratamiento de mantenimiento en pacientes con linfoma difuso de células B grandes de tipo
no GCB resistente al tratamiento o recidivante no candidatos a recibir un TACM
EudraCT: 2015-005390-21
Protocol number: IBDCL-GELTAMO-2015
Sponsor: GEL/TAMO (Spanish Group of Lymphoma/Autologous Bone Marrow Transplantation) -
Hospital Universitario M. Valdecilla (Hematology Service) - Av. Marqués de Valdecilla s/n - 39008
Santander - Spain
Coordinators: Dres. Dolores Caballero and Alejandro Martín - Hematology Service - University
Hospital of Salamanca - Salamanca, Spain. Contact details Researcher of the Center:
Dr/a.................... ........................................................... .
Hospital: ............................................... ................
Contact
telephone number:.............................. ............
Dear patient:
Your doctor has invited you to participate in the clinical trial entitled “Ensayo clínico fase II
multicéntrico para evaluar la eficacia y la seguridad de ibrutinib en combinación con rituximab,
gemcitabina, oxaliplatino y dexametasona seguido de ibrutinib como tratamiento de mantenimiento
en pacientes con linfoma difuso de células B grandes de tipo no GCB resistente al tratamiento o
recidivante no candidatos a recibir un TACM”, which could improve the treatment strategy for their
disease.
This study is carried out (sponsor) by the group GELTAMO(Spanish Group of
Lymphoma/Autologous Bone Marrow Transplantation).
The drugs will be provided by the Legal
Sponsor of the study, the GELTAMO Group, which has signed an agreement with Janssen
Laboratories, which will provide the investigational drug Ibrutinib and is the funding entity for this
clinical trial.
Before you decide to participate, it is important that you understand why the study is being done
and what your participation entails. Please take the time to carefully read the following information,
which you can discuss with others if you wish. Ask your doctor if anything is not clear or if you need
more information. Please take the time you need to decide if you want to participate in this study.
You can also discuss the study with your GP or others before making a decision.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
63 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
You decide whether or not you want to participate. If you decide to participate, you will be asked to
sign the consent form attached to this sheet and a copy will be given to you to keep.
You are not required to participate. If you decide to participate, you are completely free to withdraw
at any time and without giving any reason. The fact that you decide to withdraw at any time or that
you decide not to participate without having to justify this decision will not affect the care you
receive in the future. If you decide not to participate, the study doctor will explain the best available
standard treatment.
In
cases
like
yours,
the
most
commonly
used
treatments
are
R-GEMOX
combination
chemotherapy, other regimens used in young patients, such as (DHAP (dexamethasone,
cytarabine, and platinum), ESHAP (etoposide, methylprednisolone, cytarabine, and platinum) or
ICE (ifosfamide, carboplatin and etoposide), but at low doses, or other chemotherapeutic agents
alone. In this case, your doctor will consider the advantages and disadvantages of these drugs,
and jointly decide the best alternative.
The doctor in charge of This study is at your entire disposal to answer any questions you may
have. If you agree to participate, it is mandatory to sign this Informed Consent Form. This signature
is confirmation that you freely agree to participate in this study. The signature does not release
your doctor nor to the sponsor of his responsibilities with respect to you
During the study, your doctor will provide you with any new information that may affect your
decision.
We inform you that the research team will not receive any financial compensation for conducting
this clinical trial in which you are offered to participate.
In addition, this study does not contemplate the payment of extraordinary expenses to patients. If
for any particular reason, they occur, the Sponsor will only cover those extraordinary expenses that
have been previously agreed with the Sponsor and have been approved by the same.
1. WHAT IS THE OBJECTIVE OF THE STUDY?
Your doctor has diagnosed you with refractory or recurrent non-GCB diffuse large B-cell
lymphoma. The standard treatment for your disease usually includes different options based on a
combination with rituximab. However, there is currently no treatment that can be considered the
gold standard for treatment-resistant or recurrent diffuse large B-cell lymphoma of the non-GCB
type. For this reason, we invite you to participate in this study in which we will evaluate the efficacy
of ibrutinib in combination with rituximab-GEMOX-dexamethasone as a therapeutic alternative in
diffuse large B-cell lymphoma.
It is an investigational medicine so it may not benefit you or even harm you.
two. WHAT IS THE MECHANISM OF ACTION OF IBRUTINIB?
Ibrutinib works by blocking Bruton's tyrosine kinase, a protein in the body that helps these cancer
cells grow and survive. By blocking this protein, ibrutinib helps kill and reduce the number of
cancer cells. It also slows down the worsening of cancer.
3. WHAT IS THE PLAN STUDY?
This study plans to include approximately 62 patients with treatment-resistant or recurrent diffuse
large B-cell lymphoma of the non-GCB type who are not candidates for autologous transplantation
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
64 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
(ASCT) in different centers GELTAMOin Spain. The study is divided into different periods that
include the selection of candidates, the treatment period and follow-up.
1. Do you meet all the criteria to participate?
If you agree to participate in this clinical study and after signing the Informed Consent Form, you
will go to a study visit with your doctor, in which you will be asked questions about your disease,
the treatments you have received, your medical history and associated treatments . Some tests will
also be done, which mainly include: clinical examination, blood tests, urine tests, an EKG, imaging
tests (PET/TC), a bone marrow biopsy, and a centralized review of your tumor sample where the
initial diagnosis was made to confirm the diagnosis. You will also be asked to give your consent to
collect biological blood and tumor samples necessary to carry out additional biological tests, which
will allow better definition of certain characteristics of your disease, and the detection of traces of
disease using techniques that are more sensitive than the usual ones (determinations of minimal
residual disease (MRD)).
Some of these tests are allowed to be done within 28 days before the start of treatment; According
to the detailed conditions of the protocol, it will not be necessary to perform them for inclusion in
the study.
Your participation in this study will depend on the results of these tests. If the tests performed
during the screening period indicate that you can participate in the study, you will have a visit that
will finally confirm the opportunity to start the study treatment.
2. Treatment period You
will receive ibrutinib in combination with R-GEMOX-dexa according to the following schedule:
Induction phase:
- Patients will initially receive 4 cycles of 14 days each of ibrutinib + R-GEMOX-D, consisting of:
​560 mg of ibrutinib per day;
​375 mg/m2 rituximab intravenously (iv) on day 1;
​1000 mg/m2 gemcitabine iv on day 1 or 2;
​100 mg/m2 oxaliplatin on day 1 or 2;
​Dexamethasone 20 mg IV on day 1 and orally on days 2 and 3.
If you respond to treatment, you will receive 2 or 4 additional cycles of 14 days each.
Maintenance phase:
After the induction phase, you will receive 560 mg of ibrutinib per day. Continuous cycles until
disease progression or unacceptable toxicity occurs (maximum of 2 years).
If you do not respond to treatment after the first 4 cycles, or experience disease progression at any
time during the induction phase, maintenance treatment will be discontinued.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
65 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
For each patient, the clinical study will last a maximum of 4 years from the date of inclusion.
However, the monitoring of the status of your disease will be carried out indefinitely, in accordance
with normal practice.
Clinical and laboratory determinations will be made every 14 days until the end of treatment with
the IR-GEMOX cycles. During the maintenance phase every 8 weeks and after the end of
treatment, every 3 months until the end of the study follow-up, unless otherwise indicated by your
doctor's discretion.
PET/TC will be performed after the 4th and 6th or 8th cycle of IR-GEMOX and at the end of
treatment. In addition, they will also be performed in case of suspicion of relapse or progression to
confirm the response. The PET/TC studies will be reviewed by a group of nuclear medicine experts
(GELTAMO PET platform).
During maintenance treatment, TC scans will be performed every 6 months. Also, if clinically
indicated, during follow-up every 6 months in the first 2 years.
EMR studies will be performed on peripheral blood at the end of the 6th or 8th cycles of
IR-GEMOX, and at the same time that imaging studies are performed (if you are also participating).
in biological substudies).
Bone marrow biopsy will be obtained at the end of IR-GEMOX treatment, if necessary.
You will also be asked to give your informed consent to collect biological samples necessary to
perform the associated biological substudy. This participation is optional, and such consent will be
given to you separately.
3. Termination of study treatment and follow-up period
You may discontinue your participation at any time without prejudice and without affecting the
treatment you require. If you or your study doctor decide to discontinue study treatment, follow-up
will continue unless you decide to completely withdraw your consent for the study.
At the end of the treatment period, a follow-up visit will be made 30 days later. Thereafter, you will
continue to have visits every 3 months and/or regular contacts until the end of the trial. In the event
of disease progression, your doctor will discuss with you the best treatment for you.
In addition to the visits provided for in the protocol, your doctor may ask you to attend additional
visits to monitor your condition, based on his or her clinical judgment and/or normal clinical
practice.
The interruption of participation, by the Principal Investigator or the Sponsor, can only be carried
out in cases that are clinically justified or legally provided for. The trial may be terminated
prematurely for the following reasons: New information available justifying that continuation of the
trial is not feasible, unsatisfactory inclusion, collection of inaccurate or incomplete data or
non-compliance with the trial protocol.
Your trial doctor may withdraw you from this study for not complying with the instructions given to
you (for example, not attending the scheduled visits), because you need a treatment not allowed
by the protocol, because you do not consider it to be better for your health or welfare or because
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
66 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
the study is canceled. If this occurs, you will be informed of the reason for the termination. In either
case, you will continue to receive appropriate medical care for your illness.
4. YOUR RESPONSIBILITY DURING THE STUDY
You must go to the study center for each scheduled visit and to inform your doctor of any changes
in your health and any symptoms you may feel, even if you think they are not related to the
treatment of the study. study.
In addition, you will need to take the study medication as prescribed. You must return all unused
treatments as well as empty containers at each visit. It is also very important that you tell your
doctor about any other medications you are taking and those you take during the study. Study
treatment may interfere with your medications. Your doctor has a list of all the medicines that you
should avoid or take with caution.
During the study, you will be asked not to take any herbal preparations or other alternative
medications. Some treatments should not be taken concomitantly with the study drug (eg,
chemotherapy, immunotherapy, hormonal treatment).
5. REPRODUCTIVE EFFECTS
The effects of ibrutinib on the developing fetus are unknown, therefore pregnant or lactating
women cannot participate in this study. No one knows yet what risks there may be. Some
medicines cause women to have babies prematurely (early) or their children to be born with
defects.
If you are able to have children, you must use highly effective birth control while taking study
treatment, and for 1 month for women or 3 months for men, after you stop taking study treatment ,
to prevent pregnancy in both you and your partner. A "highly effective method of contraception" is
defined as a method that has a low failure rate (i.e., less than 1% per year) if used consistently and
correctly and includes implants, injectables, dual-hormonal contraceptive pill, some intrauterine
devices (IUDs), sexual abstinence (defined as abstinence from all aspects of sexual activity), or
having an infertile partner. If you are using hormonal contraceptives, such as birth control pills or
contraceptive devices, a second barrier method of contraception (eg, condoms) should be used.
Note: Some birth control pills may not be effective when certain medications are taken. If you have
any questions about this, please discuss them with the study doctor.
Keep in mind that even if you use an acceptable birth control method, you can still get pregnant.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
67 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Males: If your partner becomes pregnant while taking study treatment or 3 months after the last
dose of ibrutinib, you must notify study staff. Study staff will discuss this further with you. You
should not donate sperm while taking the study drug and for 3 months after you stop taking it.
Women: If you become pregnant while taking study treatment or 1 month after the last dose of
ibrutinib, you must notify study staff. If you become pregnant during the study, you must stop taking
the study treatment immediately. The sponsor will continue to collect information about the
pregnancy and the birth of your child even after you have stopped study treatment.
In the event of a pregnancy, both parents must give prior authorization for access to the data of the
pregnancy and the baby in a consent separate from and subsequent to the current one, validated
by the CEIC.
6. WHAT ARE THE POSSIBLE RISKS AND SIDE EFFECTS?
If your condition is getting worse, if side effects become severe, or if new information indicates that
this treatment is not in your favor, your doctor will notify you and discuss alternative treatment with
you.
You may develop side effects during your participation in this study. You should tell the study doctor
about any side effects you develop.
6.1. Side effects of ibrutinib:
The following side effects have been reported by patients who have received ibrutinib in clinical
studies.
The most common side effects, occurring in at least 1 in 5 patients, have been:
●
Increased frequency of loose or liquid stools (diarrhea)
●
Muscle and joint pain
●
Neutropenia
●
Bruising
●
Skin rash
●
Nausea
​(Version 2.0, October 21, 2016 )
​
Side effects that have been seen in at least 1 in 10 patients include:
●
Mouth
●
sores Sinus infection
●
Fever
●
Low white blood cells (the cells that help fight infection)
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
68 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
Low platelets (the cells that help blood to clot)
●
Constipation
●
Swelling of the hands or feet
●
Joint pain
●
Vomiting
●
Skin infection
●
Pneumonia
●
Headache
●
Muscle spasms High
●
blood pressure
​
(Version 2.0, October 21, 2016)
​
Side effects that have been observed at least in 1 in 100 patients, include:
●
Dizziness
●
Urinary tract infection
●
Nosebleed
●
Petechiae (small bright red spot that appears on the skin) him because of a
hemorrhage)
●
Cutaneous
●
Basal carcinoma
●
Squamous cell carcinoma
●
Broken nails (Onychoclasis)
●
Interstitial lung disease
●
Blurred vision
●
Increased level of uric acid in the blood
●
Lack of fluids in the body (dehydration)
●
Abnormal heart rhythm (atrial fibrillation) High number
●
of white blood cells
●
low white blood cells with fever
●
skin redness
●
Increasing the level of lymphocytes
●
extended severe infection throughout the body
​
version 2.0, October 21, 2016)
side effects that have been observed at least 1of 1000 patients, include:
●
Unusual levels of chemicals in the blood caused by the rapid breakdown of cancer
cells, which can lead to changes in kidney function, abnormal heart rhythms, or
seizures. (Tumor lysis syndrome)
●
Itchy skin rash (Urticaria)
●
Bleeding around the brain (subdural hematoma)
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
69 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
●
Swelling of the face, lips, mouth, tongue or throat (angioedema)
●
Severe increase in white blood cell count which may cause
cells
to
aglomerate
(leukostasis syndrome)
●
Severe blistering and peeling skin rash, particularly
around
the
mouth,
nose,
eyes, and genitals (Stevens-Johnson syndrome)
●
Liver failure
(Version 2.0, October 21, 2016)
Most of these side effects has been mild to moderate in intensity; however, serious side effects
have
also
occurred.
Some
of these have been serious enough to lead to study drug
discontinuation, dose modification or reduction, patient hospitalization, disability, and sometimes
death.
You should tell your doctor or study team about any adverse reaction you experience. The study
doctor may give you medicine to help treat side effects and keep them from getting worse. The
study doctor may also decide to stop ibrutinib treatment for a short time or reduce your dose to
allow you to recover from side effects.
Bleeding
It is possible to may experience bruising or nosebleeds during treatment with ibrutinib.
Serious internal bleeding, such as bleeding in the stomach, intestines or brain, can occur very
rarely, some cases being fatal. If you are taking other medicines or supplements that increase the
risk of bleeding, such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or medicines
used to prevent or treat blood clots or stroke, ibrutinib may increase this risk. Anticoagulants, such
as warfarin or other vitamin K antagonists, should not be taken concomitantly with ibrutinib. The
use of supplements such as fish oil or vitamin E preparations should be avoided while taking
ibrutinib. Contact the study doctor if you develop signs or symptoms of serious bleeding, such as
blood in the stool or urine, or bleeding that lasts for a long time or that you cannot control.
Effects on the heart
Heartbeat disturbances (atrial fibrillation and/or atrial flutter) have been reported in patients treated
with ibrutinib, especially also in those patients with heart disease, increased blood pressure,
acute infections, or who had abnormal heartbeats in the past. Atrial fibrillation and atrial flutter
are a common form of heartbeat disturbance. The heartbeat may be fast or irregular and cause
symptoms such as palpitations, dizziness, weakness, feeling light-headed, or shortness of breath.
You must notify the study doctor immediately if you experience any of these symptoms while
participating in the study.
(Version 2.0, October 21, 2016)
Infections
You may experience viral, bacterial or fungal infections during treatment with ibrutinib. Some of
these infections have led to hospitalizations and death. Contact the study doctor if you develop
fever, chills, weakness, confusion, body aches, cold or flu-like symptoms, tiredness, or shortness of
breath, as these could be signs of an infection.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
70 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
A rare viral disease in the brain that is usually fatal: progressive multifocal leukoencephalopathy
(PML) has been reported in patients treated with ibrutinib in combination with rituximab and in
patients who had previously received rituximab treatment. If you experience symptoms such as
weakness, paralysis, vision loss, and/or impaired speech, please notify the study doctor
immediately.
(Version 2.0, October 21, 2016).
Lymphocytosis and leukostasis
It is possible to experience an increased number of lymphocytes, a type of white blood cell, in your
blood (lymphocytosis). This can happen in the first few weeks of treatment and you should not
assume that this increase in white blood cells means that your disease is getting worse. This
increase can be sustained for several weeks or months. The increase in white blood cells in the
bloodstream can alter blood flow and cause bleeding or clots (leukostasis). Isolated cases of such
events have been reported in patients treated with ibrutinib. The study doctor will monitor your
blood count and may give you additional treatment as needed. You can ask the study doctor what
the test results mean.
Decreased blood cell counts
Marked decreases in white blood cell, red blood cell and platelet counts (neutropenia, anemia and
thrombocytopenia) have been reported in patients treated with ibrutinib. If you develop symptoms
such as fever, weakness, or frequent bruising and/or bleeding, please notify the study doctor
immediately.
Allergic Reactions
Some
people
experience
allergic
reactions
to
drugs.
Severe
allergic
reactions
can
be
life-threatening. If you have an allergic reaction to ibrutinib you may experience a skin rash,
difficulty breathing, wheezing, sudden low blood pressure with dizziness, swelling around the
mouth, throat or eyes, a racing heart and/or sweating.
Before starting treatment with the study drug, you must tell the study doctor if you have any
allergies to any drugs. You should inform the study doctor immediately if you experience any of the
allergic symptoms listed.
Skin rash
Frequent cases of maculopapular skin rash (red, flat areas of skin with small bumps) have been
reported in patients treated with ibrutinib alone or in combination with other medicinal products.
Most skin rashes are mild to moderate in intensity and begin 2-3 weeks or later after initiation of
ibrutinib.
Rarely, severe skin rash (over 50% of the body) or rash with blisters and peeling skin, which may
include open ulcers or sores in the mouth or other areas (Stevens-Johnson syndrome), have been
reported. This reaction could be life-threatening. You should notify your study doctor immediately if
you develop a rapidly spreading rash, or if you notice any peeling of the skin, with or without ulcers
or mouth sores.
Cutaneous Carcinoma and Other cancers
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
71 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Cutaneous carcinoma (basal cell carcinoma and squamous cell carcinoma) have been
reported more frequently and possibly related to ibrutinib treatment. Other types of cancer
have been seen in patients who have been treated with ibrutinib. These include skin cancer, solid
tumors, and various types of blood cancers. The causal relationship with ibrutinib is unknown. You
will need to tell the study doctor if you develop a new cancer during your stay in the study.
(Version 2.0, October 21, 2016).
Tumor lysis syndrome (TLS)
Unusual levels of chemicals in the blood caused by rapid breakdown of cancer cells have been
observed during cancer treatment and sometimes even without treatment. This can cause changes
in kidney function, an abnormal heartbeat, or seizures. The study doctor may perform blood tests
for TLS.
Hypertension
Common cases of hypertension have been reported in patients treated with ibrutinib.
Sometimes,
patients
with
high
blood
pressure
may
have
headaches,
dizziness,
nervousness, sweating, trouble sleeping, flushing of the face, or nosebleeds, but in some
cases, there may be no symptoms and they may go unnoticed. After starting ibrutinib, your
doctor may check your blood pressure regularly. The study doctor should know if you have
any of the symptoms of high blood pressure which could mean that you have developed
high blood pressure or that your high blood pressure is getting worse. The study doctor
may adjust existing antihypertensive medications and/or initiate antihypertensive treatment
where appropriate.
(Version 2.0, October 21, 2016).
Hepatic failure
Rare cases of hepatic failure have been reported in patients treated with ibrutinib. Symptoms of
liver failure include yellowing of the eyes and skin (jaundice), itchy skin, dark urine, gray or
clay-colored stools, confusion, nausea, loss of appetite, fatigue, or diarrhea. You should tell
your study doctor immediately if you have any of these symptoms that may indicate liver
disease. The study doctor may be able to diagnose and provide you with the necessary
medical care.
(Version 2.0, October 21, 2016).
Interstitial lung
Interstitial lung disease is a group of lung diseases in which tissues become inflamed and
can be damaged. Interstitial lung disease is not associated with infections (e.g. bacteria,
viruses, fungi) and cases have been reported in patients treated with ibrutinib. You should
tell your doctor if you have a cough, any signs of new or worsening respiratory symptoms,
such as shortness of breath or difficulty breathing.
(Version 2.0, October 21, 2016).
Interference with other medications
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
72 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Some foods, such as grapefruit juice or bitter oranges, can interfere with the way the body
processes ibrutinib. This interference could make the concentrations of ibrutinib in the body too
high or too low. It's also possible that taking the study drug with your regular medications or
supplements, including fish oil, vitamin E, or other vitamins, could change the way those regular
medications or supplements work. It is very important that you avoid drinking grapefruit juice and
bitter oranges and that you tell the study doctor about any medications, supplements, or herbal
products (such as St. John's wort) that you are taking during the study. You should notify the study
doctor immediately of any side effects to avoid possible harm.
Suspension of treatment for any type of surgical intervention
Ibrutinib may increase the risk of bleeding in any surgical intervention. Ibrutinib should be
discontinued at least 3 to 7 days before and after an intervention, depending on the type of
intervention and the risk of bleeding. Please contact the study doctor if you have any type of
surgery scheduled. For emergency procedures, administration of ibrutinib should be withheld
(interrupted)
after
the
procedure
until
the
surgical
wound
is
sufficiently
healed (without
suppuration).
Contact your study doctor as soon as possible and he or she will tell you when to stop ibrutinib and
when to start treatment again after surgery.
In addition to the risks listed above, there may be unknown or unexpected side effects associated
with the use of ibrutinib. You will be duly informed, verbally or in writing, of any new information,
findings, or changes in the way the research will be conducted that may influence your willingness
to continue participating in the study.
You may experience some, all, or none of the ibrutinib side effects listed. Study doctors and
nursing staff will monitor you closely for side effects. You may receive medications or other
treatments to prevent or reduce some of these effects. You should tell your doctor or study staff
immediately if you experience any side effects. You should also tell them if you have any other
health problems or how you feel during the study, whether or not you think they are related to the
study drug.
You should get medical help and contact your doctor or study staff if you experience any of these
side effects or others during the study.
6.2. Side effects R-GEMOX-Dexa
Your doctor will explain the adverse effects of the drugs used in this clinical trial (Rituximab,
Gemcitabine, Oxaliplatin and Dexamethasone), all of them marketed in Spain and used in the
treatment of Lymphomas.
Data on the combination of ibrutinib and rituximab-GEMOX-dexa are limited and no relevant
problems have been reported to date.
7. WHAT ARE THE BENEFITS OF PARTICIPATING IN THE STUDY?
With your participation in this study, you will receive ibrutinib, the study drug, along with
rituximab-GEMOX-dexa. This treatment may be effective and well tolerated, but there is no
guarantee that this will be the case, as this is an exploratory trial, you may not derive any clinical
benefit from the trial.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
73 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
However, the information obtained from this study will help improve the treatment of other patients
with your disease in the future.
8. WHAT ARE MY RIGHTS AND THE LEGAL PROVISION OF THIS STUDY?
Medical research is strictly regulated by law. Legal provisions guarantee a series of rights. Please
read this section carefully.
Insurance and compensation system:
The
sponsor
has
contracted
insurance
with
the
company
HDI-GERLING
INDUSTRIE
VERSICHERUNG AG policy number 08057782-14021 in accordance with Spanish Law 29/2006,
of July 26, on guarantees and rational use of medicines and health products and Royal Decree
223/2004, of February 6, which regulates clinical trials with medicines to cover the risks related to
their participation in this study.
We inform you that it is possible that your participation in this clinical trial may modify the general
and particular conditions (coverage) of your insurance policies (life, health, accident...), therefore,
we recommend that you contact your company and inform you of your participation in it to
determine if it could affect your current insurance policy, validated by the CEIC.
Approval of the competent authorities:
This protocol has been approved by the Spanish Medicines Agency and has obtained the
favorable opinion of the Ethics Committee of the Hospital de Clínico de Salamanca as CEIC of
Reference, implying the Approval of the Ethics Committees of all the participating centers. The last
task is to verify if the conditions related to your protection and your rights have been respected, as
well as to verify your rights and well-being as a participant in a clinical trial in accordance with Law
15/1999 on the Protection of Personal Data. Personnel and Royal Decree 1720/2007.
Right to anonymity
Your identity will never be revealed. The data obtained as part of the investigation will remain
completely anonymous.
Your medical information, identified by a code, as well as data about your lifestyle, since it is data
necessary for research and your ethnicity, will be protected following local standards and
regulations.
No individual patient will be identified at the time of publication of the results.
The data collected in the study will be identified by a code and only the study doctor or
collaborators will be able to relate it to you and your medical history. Therefore, your identity will not
be revealed except in case of medical emergency or legal requirement.
Right to confidentiality
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
74 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
The transmission and communication of data will be carried out under the rules of professional
secrecy. None of the people who have access to this data will be able to disclose or reveal said
information.
Access to your personal information will be restricted to the study doctor and his collaborators,
health authorities, the Clinical Research Ethics Committee and the study monitors and auditors,
who will be subject to the duty of secrecy inherent to their profession, when they need it, they will
be able to verify the data and procedures of the study, but always maintaining their confidentiality
in accordance with current legislation. By signing this document, you are allowing direct access to
your medical records to the persons mentioned in this same paragraph, accredited for it. The
sponsor of this study will in no case have access to your personal data or know your identity.
In the event that the data is sent to third countries, the level of protection established by Spanish
Legislation will be maintained. Your data will be anonymized prior to sending it to avoid any type of
identification that may be related to you.
Right to data protection
In accordance with current regulations on data protection, you expressly consent to the inclusion of
data from your clinical history as well as those resulting from your participation in this study in a
personal data file under the responsibility of GELTAMO that has invited you to participate in this
clinical trial. The treatment, communication and transfer of your personal data will be adjusted at all
times to the provisions of Organic Law 15/1999, of December 13, on the protection of personal
data and its development regulations. Know that in addition to the doctor who treats you, there may
be other agents who access your personal data when they need it to check the data and
procedures of the study, but always maintaining their confidentiality in accordance with current
legislation.“
In all the publications that are generated with the results of the clinical trial,will appear
no identifying information about you(Name, surnames, social security number, address...).
Rights of access, rectification, cancellation and opposition
The provisions of the Data Protection Law 15/1999 guarantee access to databases relating to your
data and right of opposition and rectification. This right must be claimed from your doctor who
knows your identity.
The trial data may be consulted in the Spanish Registry of Clinical Trials, intended for the
knowledge of patients and health professionals.
Access to medical records
You can also access directly or through a doctor of your choice to all medical information under the
provisions of local regulation.
Right to information
If you have any questions about this study, ask your study doctor, who will provide you with any
information you need about the study drug or your participation.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
75 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
During the course of the study, you have the right to be informed about this research. Your doctor
will provide you with any new information that may affect your decision.
Right to withdraw from the study
You can withdraw your consent at any time without having to justify the reason and end your
participation in the study. In order to ensure and preserve your safety, we will ask that you inform
the study doctor of your decision immediately. In this case and if you wish, your doctor will offer you
an appropriate treatment.
Right of access to global research results
Your participation in this study favors the improvement of biological and medical knowledge. You
will be able to know the global results of this study. The design of the protocol and its results will be
published and made available on at least one public website such as the Spanish Registry of
Clinical
Trials
(https://reec.aemps.es/reec/faces/buscador/index.xhtml)
and/or
the
American
database (https://www.clinicaltrials.gov), intended for the knowledge of patients and professionals
Of the health.
The results of the study will be published in a scientific journal and presented at international
scientific conferences.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
76 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Informed consent form
Study title: Ensayo clínico fase II multicéntrico para evaluar la eficacia y la seguridad de ibrutinib
en combinación con rituximab, gemcitabina, oxaliplatino y dexametasona seguido de ibrutinib
como tratamiento de mantenimiento en pacientes con linfoma difuso de células B grandes de tipo
no GCB resistente al tratamiento o recidivante no candidatos a recibir un TACM
EudraCT: 2015-005390-21
Protocol number: IBDCL-GELTAMO-2015
Sponsor: GEL/TAMO (Spanish Group of Lymphoma/Autologous Bone Marrow Transplantation) -
M. Valdecilla University Hospital (Hematology Service) - Av. Marqués de Valdecilla s/n - 39008
Santander - Spain
Coordinators: Dres . Dolores Caballero and Alejandro Martín - Hematology Service - Salamanca
University Hospital – Salamanca, Spain.
I, the undersigned (name, surname): …………………………………………………
The
doctor…………………………………………of
the
Hospital
........................................................... ............. has provided me with all the information I have
requested about the conditions of the treatment, its duration, its effectiveness and its side effects. I
have had the opportunity to ask all the questions necessary to understand the study.
I understand that my participation in the study is completely voluntary and that I can withdraw my
consent at any time without providing a reason. Deciding not to participate or to withdraw from the
study will not harm or have any effect on my future treatment. My consent does not relieve the
researchers of their responsibilities. I retain all my rights guaranteed by law.
I understand that my doctor can withdraw me from the study at any time if he or she thinks it is in
my best interest.
Based on the conditions specified in the “Patient Information Form” of this document.
My participation in this study is completely voluntary
YES NO 
I freely accept that samples may be obtained and processed for
research purposes:
YES NO 
- A sample of the tumor (for centralized review)
YES NO 
Date:
Date:
Signature of the patient :
Researcher's signature:
Name and surnames:
Name and surnames:
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
77 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
III. Molecular Substudy Patient Information Sheet and Consent Form
Translational Research - OPTIONAL - Patient Information Sheet
Study Title: “Ensayo clínico fase II multicéntrico para evaluar la eficacia y la seguridad de ibrutinib
en combinación con rituximab, gemcitabina, oxaliplatino y dexametasona seguido de ibrutinib
como tratamiento de mantenimiento en pacientes con linfoma difuso de células B grandes de tipo
no GCB resistente al tratamiento o recidivante no candidatos a recibir un TACM”
EudraCT: 2015-005390-21
Protocol number: IBDCL-GELTAMO-2015
Sponsor: GEL/TAMO (Spanish Group of Lymphoma/Autologous Bone Marrow Transplantation) -
Hospital Universitario M. Valdecilla (Hematology Service) - Av. Marqués de Valdecilla s/n - 39008
Santander - Spain
Coordinators: Drs. Dolores Caballero and Alejandro Martín - Hematology Service - Salamanca
University Hospital – Salamanca, Spain.
Substudy coordinators:
-
Central
review
of
molecular
and
histopathological
diagnostic
studies:
Dr.
Santiago
Montes-Moreno and Dr. Miguel Ángel Piris (M. Valdecilla University Hospital)
- Analysis of the mutational spectrum of 45 genes and evaluation of MRD in patients with
treatment-resistant or recurrent diffuse large B-cell lymphoma included in the phase II clinical study
IBDCL-GELTAMO-2015: Dr. Marcos González (H. Universitario de Salamanca)
-
Evaluation
of
the
cell of origin (germinal center B versus activated) in patients with
treatment-resistant
or
relapsed
diffuse
large
B-cell
lymphoma
included
in
the
phase
II
IBDCL-GELTAMO-2015 study: Dr. Armando López-Guillermo and Dr. Elías Campo (H. Clínic de
Barcelona)
Estimated /a patient:
Your doctor has invited you to participate in the biological substudies of the study entitled «Ensayo
clínico fase II multicéntrico para evaluar la eficacia y la seguridad de ibrutinib en combinación con
rituximab, gemcitabina, oxaliplatino y dexametasona seguido de ibrutinib como tratamiento de
mantenimiento en pacientes con linfoma difuso de células B grandes de tipo no GCB resistente al
tratamiento o recidivante no candidatos a recibir un TACM», which could improve the strategy
treatment of your illness. This study is carried out (sponsor) by the group GELTAMO (Spanish
Group of Lymphoma/Autologous Bone Marrow Transplantation).
Before you decide to participate, it is important that you understand why the study is being done
and what your participation entails. Please take the time to carefully read the following information,
which you can discuss with others if you wish. Ask your doctor if anything is not clear or if you need
more information. Please take the time you need to decide if you want to participate in this study.
You decide whether or not you want to participate. If you decide to participate, you will be asked to
sign the consent form attached to this sheet and a copy will be given to you to keep.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
78 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
You are not required to participate in this substudy. If you decide to participate, you are completely
free to withdraw at any time and without giving any reason. Your decision to withdraw at any time
will not affect the care you receive in the future.
The doctor in charge of this study is at your entire disposal to answer any questions you may have.
If you agree to participate in this sub-study, it is mandatory to sign this Informed Consent Form.
This signature is confirmation that you freely agree to participate in this study. Signature does not
relieve your physician or sponsor of their responsibilities to you.
Why have I been invited to participate?
Along with the clinical part of the study, IBDCL-GELTAMO-2015, an in-depth biological study is
also planned to characterize this population of patients with diffuse large B-cell lymphoma (DLBC)
and to evaluate the response obtained with the tumor mutational profile. Clinical studies as
IBDCL-Geltamo-2015 offer the ideal platform for biological studies, because patients receive
treatment and followup evenly; therefore, the integration of these clinical data with biological
characteristics results in high-quality information with reduced bias.
The goal of these substudies is to see if we can discover biomarkers in the blood or tumor tissue
that could identify in the future which patients will benefit from the study treatment. This will not
affect your treatment, but may provide prognostic information about your disease. It will also be
evaluated if we can identify markers in the blood in early stages that show the progression of the
disease (recurrence) before it can be seen in diagnostic imaging tests. This would allow clinicians
to modify and/or select the best treatment alternatives for diffuse large B-cell lymphoma in the
future. It is important to keep in mind that you, as the patient donor of the biological samples, are
not expected to derive any direct benefit from participation in this substudy.
Blood
and
tumor
samples
from
patients
participating
in
clinical
studies,
such
as
the
IBDCL-GELTAMO-2015 study, are extremely valuable as accurate clinical information is obtained
on the patients themselves. This information, including information about whether the tumor
responds to treatment or if the disease comes back in the future, can be used along with
information obtained in the laboratory to help answer questions about diffuse large B-cell
lymphoma and its treatment.
How is this study carried out?
This study will involve testing blood samples and preserving tissue samples (left over from
diagnosis). Of course, this will only be done with your permission. You may refuse to participate in
this part of the study without affecting your participation in the rest of the study or your relationship
with your doctor.
It is stated that for their participation in this substudy, it is not necessary to collect extraordinary
biopsies, in relation to the main study. The extra samples will be obtained from archival material or
surplus samples obtained from routine clinical practice procedures will be used. Biological sample
requirements are outlined below:
●
Lymph node biopsy or other tissue biopsies for diagnosis of DLBCL at baseline.
●
Lymph node biopsy at time of relapse (if available).
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
79 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​Peripheral blood will be obtained prior to the start of study treatment, at the same time as imaging
studies, and in the event of recurrence of disease after study treatment. Blood samples will be
obtained at the same time blood samples are obtained under your usual care, whenever possible.
The samples will be sent to the University Hospital Marqués de Valdecilla, the University Hospital
of Salamanca and the Hospital Clínic of Barcelona, to perform phenotypic subtyping tests,
molecular studies, mutational spectrum and determination of the cell of origin using NanoString
technology (NanoString Technologies, WA, USA) associated with this clinical study.
What will happen to me if I decide to participate?
If you choose to participate, blood samples and tissue biopsies will be sent to the central laboratory
for substudy determinations.
These samples will be handled by specialized technical personnel who will ensure the precise
quality conditions for subsequent studies. The personal data collected about you will be
confidential and processed in accordance with Organic Law 15/1999 on the Protection of Personal
Data and the current legislation on Biomedical Research (Law 14/2007 on Biomedical Research)
and the Royal Decree 1716/2011, of November 8, which establishes the basic requirements for
authorization and operation of biobanks for biomedical research purposes, treating them only in
accordance with the objectives described in this document, so any relationship between the
sample and your personal identity is strictly confidential. The results obtained from the different
studies carried out with the samples may be published in scientific journals, but your identity or
data that identifies you or may identify you will never be provided.
These additional tests will not affect your treatment in any way. If you decide not to participate in
the collection of samples for laboratory research, this will not affect your participation in the clinical
part of the IBDCL-GELTAMO-2015 study or your relationship with your doctor.
Any unused sample portions will be retained until the material is depleted in case new research is
developed in the future that may help us better understand the response of DLBCL to these
treatments. The criteria contained in Royal Decree 1716/2011, of November 8, which establishes
the basic requirements for authorization and operation of biobanks for biomedical research
purposes, will be met. For this, will be presented for additional informed consent to the biobank of
the H. Universitario de Salamanca and M. H. UniversitarioValdecilla,which will be where the
remaining samples of the determinations made in these hospitals will be stored. The surplus of the
material sent to the H. Clinic will be returned to the Hospital of origin once the determinations of the
study have been completed. These samples will also be used for other future studies related to
DLBCL. Any of these studies must be authorized by the Ethics Committees. We cannot describe in
this document all the possible tests that can be performed on the preserved samples and if you are
not comfortable with this aspect, you can not participate.
This research will be based in laboratories associated with the clinical study sites, but may involve
collaboration with commercial companies (including drug/pharmaceutical companies) or other
institutions. You will not receive any financial compensation for your participation in this study.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
80 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Will this study help patients in the future?
This substudy will provide us with important information about the most appropriate way to treat
patients in the future.
What will be the side effects of this study?
Side effects in addition to those experienced in routine practice are not expected.
However, blood samples will often, but not always, be obtained at the same time that blood tests
are required in normal practice.
What other risks can I run if I participate?
You may be contacted to request additional sample collection.
The risks related in this substudy will be the same as in normal clinical practice in terms of blood
extraction: hematoma and/or local swelling in the extraction area.
What are the possible benefits of participating in the study?
The information obtained from this substudy will help us decide the best form of treatment for
patients with your disease in the future. It could also provide prognostic information about your
disease.
What happens if new information appears?
During the study, your doctor will provide you with any new information that may affect your
decision. Sometimes, during the course of a research project, new information becomes known
about the disease being studied. If this happens, your study doctor will tell you about it and discuss
with you whether you want to continue in the study. If you decide to withdraw from the study, your
doctor will arrange your further treatment.
It is possible that, due to the conduct of this study, the results obtained may have implications for
you and your family. You can refuse to know these results. In addition, if you decide not to be
informed of these results, in the event that these may affect your family, the study doctor may
contact them. If you decide to learn about study results that may affect your family, you will be
advised to let them know.
If you want to know the results, the study doctor will provide you and your family with genetic
counseling or refer you to a place where genetic counseling can be offered.
Who organizes and finances the research?
This study is organized by the group GELTAMO, sponsor of the IBDCL-GELTAMO-2015 study.
Will the confidentiality of my information be protected?
All samples will be encrypted (all information that could identify you will be removed). This means
that the samples will be identified by a numerical code, not by your name, and neither you nor your
family members will be identified or contacted. No individual patient will be identified at the time of
publication of the results.
If you decide to participate in this clinical study, information will be collected and entered into a
study database. The scientific and medical staff of the group medical GELTAMOrecords and those
who work for them in conducting the study may need to review yours to ensure that the study is
being carried out correctly, but your confidentiality will be protected at all times. The REC or the
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
81 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
national health authorities may review your medical notes (related to this study) and the study
information to verify that the study is being carried out correctly.
Your GP will be informed about your participation in this study, although all information collected
about you during the study will be kept strictly confidential.
What will happen to the results of the research study?
The results of this clinical research study will be published in a major scientific journal. The results
will also be presented at international clinical and scientific conferences. No information on
individual patients will be provided in these publications or presentations of results. You or your
family may request a copy of the published results.
Who has reviewed this study?
This substudy has been reviewed and has obtained the favorable opinion of a reference Ethics
Committee and has the approval of the national health authority in which the study is carried out. If
you require more information, you should contact your physician in charge of the trial.
Thank you for taking the time to read this information sheet and for considering your participation in
this clinical study.
If you have any questions about your disease or clinical trials, please discuss them with your
doctor.
Names and contact telephone numbers:
………………………………………………………………………………………………………………
…………………… ………………………………………………………………
……………………………………………………………… …………………………
…………………………………………………………………………………………
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
82 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Research Consent Form Translational
Study Title: Ensayo clínico fase II multicéntrico para evaluar la eficacia y la seguridad de ibrutinib
en combinación con rituximab, gemcitabina, oxaliplatino y dexametasona seguido de ibrutinib
como tratamiento de mantenimiento en pacientes con linfoma difuso de células B grandes de tipo
no GCB resistente al tratamiento o recidivante no candidatos a recibir un TACM
EudraCT: 2015-005390-21
Protocol number: IBDCL-GELTAMO2015
Sponsor: GEL/TAMO (Spanish Group of Lymphoma/Autologous Bone Marrow Transplantation)
Coordinators: Drs. Dolores Caballero and Alejandro Martín - Hematology Service - Salamanca
University Hospital – Salamanca, Spain.
Substudy coordinators:
- Central review of molecular studies and histopathological diagnosis: Dr. Santiago Montes-Moreno
and Dr. Miguel Ángel Piris (M. Valdecilla University Hospital)
- Analysis of the mutational spectrum of 45 genes and evaluation of MRD in patients with
treatment-resistant or recurrent diffuse large B-cell lymphoma included in the phase II clinical study
IBDCL-GELTAMO-2015: Dr. Marcos González (H. Universitario de Salamanca)
-
Evaluation
of
the
cell of origin (germinal center B versus activated) in patients with
treatment-resistant
or
relapsed
diffuse
large
B-cell
lymphoma
included
in
the
phase
II
IBDCL-GELTAMO-2015 study: Dr. Armando López-Guillermo and Dr. Elias Campo (H. Clínic de
Barcelona)
Me, the undersigned (name, surname): …………………………………………………
The doctor………………………………………… of the Hospital. .................................................I has
provided all the information I have requested about the p RAFT Translational biological research
associated with the study IBDCL-Geltamo-2015 and have had the opportunity to perform all the
questions necessary to understand the study.
I understand that my participation in the study is completely voluntary and that I can withdraw my
consent at any time without providing a reason. Deciding not to participate or to withdraw from the
study will not harm or have any effect on my future treatment.
I grant my authorization to use part of my biological samples left over from the diagnosis and the
extraction and donation of 50mL of peripheral blood to participate in the research project defined in
this document.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
83 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Based on the conditions specified in the "Patient Information Form" of this document
My participation in this study is completely voluntary
YES NO 
I freely accept that samples may be obtained and processed for
research purposes:
YES NO 
- Biopsy Lymph node or other tissue biopsies for biological substudy
YES NO 
- Peripheral blood
YES NO 
- Lymph node biopsy at time of relapse
YES NO 
Date:____________________
Date: ____________________
Patient's first and last name:
IP name and surname(s):
__________________________________
________________________________
Patient's
signature: Investigator's signature:
_________________________________
________________________________
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
84 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
IV. Patient information sheet and consent form for Biobank
INFORMED CONSENT DOCUMENT
Project/Clinical Trial: CODE PROTOCOL: IBDCL-GELTAMO-2015
Principal Clinical Investigator: Drs. Dolores Caballero and Alejandro Martin. Hematology Service. University
Hospital of Salamanca
Biological Project Managers: Santiago Montes Moreno, HUMV/IDIVAL.
Information to the Participant
Purpose and description of the process
This document is to request your written authorization for the donation of part of the remaining sample of
diagnostic tissue, in order to incorporate your sample into a Biobank that exists at the Hospital Universitario
Marqués de Valdecilla/ IDIVAL (tissue node, Valdecilla Biobank) and use said surplus in a biomedical
research project related to cancer. It is important that you read this informed consent form carefully, that
you understand its content and its purpose and that, where appropriate, ask all the questions you think
necessary about it.
The advancement of science and medicine requires that research be carried out on tissues, both healthy
and pathological, in association with clinical data on their process, treatment and evolution. This advance is
especially important in the field of cancer, since it is the second leading cause of death in the world. The
main way to obtain these tissues that allow biomedical research are the leftover samples of the extractions
that are made for diagnostic purposes. Part of the tissue or blood sample is no longer necessary for the
corresponding study and to establish a diagnosis and is therefore normally destroyed.
As a patient, you can donate the remainder of your sample so that, instead of being destroyed, it can be
used in biomedical research related to cancer, incorporating the sample into a Biobank. The purpose of the
donation is to provide researchers with tissue or blood so that they can develop advances in the field of
knowledge about cancer, in particular about its appearance, evolution and treatment.
The consent that you now give for the use in research of this excess tissue, which would otherwise be
discarded, does not imply any additional risk or inconvenience for you since you are only going to authorize
its use in a research project and incorporation into a Biobank. .
The donation of this surplus tissue is voluntary, so if you give your consent for its use, you can revoke it at
any time. In the event of this revocation, this will not entail any change in the relationship with your doctor
or any damage to your diagnosis/treatment and/or follow-up. In case of revocation, your sample will no
longer form part of the investigation, although the data obtained up to that moment will form part of it.
The current project to which this consent refers has been evaluated and accepted by an independent and
accredited Ethics Committee and Scientific Committee. The objectives of the present study refer to the
identification of biological markers useful in the diagnosis and possibly prognosis of patients with aggressive
post-transplant B-cell lymphoma.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
85 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Altruistic nature of the donation
The donation is altruistic in nature by law, so you will not obtain any economic benefit from it now or in the
future. However, the insights gained from studies carried out on your sample and many others can help
medical advancement, and thus other people.
Data protection and confidentiality
The personal data collected about you will be confidential and processed in accordance with Organic Law
15/1999 on the Protection of Personal Data and the current legislation regarding biomedical research,
treating them only in accordance with the objectives described in this document, so any relationship
between the sample and your personal identity is strictly confidential. The results obtained from the
different studies carried out with the samples may be published in scientific journals, but your identity or
data that identifies you or may identify you will never be provided.
At the time that you consent to the use of surplus samples for the purposes of applied research described,
said surplus will be subjected to a dissociation process. In other words, you will only be identified by a
number and/or a code containing all your data duly coded, so the researchers involved will never know your
identity or any data that could identify you; however, they may, in any case, access other data such as their
gender or age, but always maintaining due confidentiality in accordance with current legislation. Files with
identification will have restricted access.
Likewise, once the sample has been incorporated into the biobank, your personal data will be incorporated
into an automated confidential file, duly registered with the Spanish Data Protection Agency, in accordance
with the terms established in Organic Law 15/1999 on Data Protection. Personal Data, whose ownership
corresponds to the Marqués de Valdecilla Research Institute Foundation (IDIVAL), in order to manage the
use of the surplus assigned by you for the research purposes described in this document, being able to
exercise at any time, the rights of access, rectification, cancellation or opposition, recognized by the
aforementioned regulations on the protection of personal data, by contacting the person in charge of the
tissue node Valdecilla Biobankin the Pathological Anatomy Service of the Marqués de Valdecilla, Avda de
Valdecilla 25, 39008. Tel: (34) 942203492 or at the following e-mail address: biobanco5@idival.org.
With this consent, the Hospital's specialists may consult your clinical history, only in the event that it is
necessary to update the information associated with your samples.
Information on the results of the study
The data obtained from the analysis of the sample will be archived, and will form part of the study/research
project and will be maintained during its development. The methods used in Biomedical research are
usually different from those approved for clinical practice, so they should not be considered of clinical value
to you. However, in the event that these investigations provide data that could be both clinically and
genetically relevant for you and of interest to your health or that of your family, they will be communicated
to you if you deem it appropriate. Likewise, relevant information could be obtained for your family, it will be
up to you to decide whether or not you want to communicate it. If you want such relevant information to be
communicated to you, you must enter it in the box that appears at the end of this sheet.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
86 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
The samples
We also request your consent, so that if, there are surplus tissue after the end of the study, these can be
used in other research projects. Any project for which Biobank samples are used will be previously approved
by an accredited Scientific and Ethical Committee.
We thank you for your selfless collaboration with the advancement of science and medicine and,
especially, in reference to research on the appearance, development and treatment of cancer.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
87 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
INFORMED CONSENT DOCUMENT for biological study
Project/Clinical Trial: CODE PROTOCOL: IBDCL -GELTAMO-2015
Clinical Principal Investigator: Drs. Dolores Caballero and Alejandro Martín. Hematology Service. University
Hospital of Salamanca
Biological Project Managers: Santiago Montes Moreno, HUMV/IDIVAL.
Informed Consent
PATIENT DATA
Surnames
Name
Address
DNI or similar:
Hospital:
Medical record number:
​I declare under my responsibility that I have read the Participant Information Sheet about the
aforementioned study and agree to participate in it.
​I have been given a copy of the Participant Information Sheet and a copy of this Informed Consent
(current page), dated and signed.
​The characteristics and objective of the study and the possible benefits and risks of the study have
been explained to me.
​I have been given time and opportunity to ask questions. All questions were answered to my
complete satisfaction.
​I know that the confidentiality of my data will be maintained, as long as they are not essential for
the development of the project.
​I give my consent voluntarily and I know that I am free to withdraw from the study at any time, for
any reason, and without it having any effect on my future medical treatment.
I authorize the use of possible surpluses in
other related projects
YES NO 
I authorize to be contacted in case more
information is needed
YES NO 
Date
Signature
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
88 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Data of the person providing the information and the consent form
Name and surnames
Signature
More information provide in a stand alone document
​
V. ECOG functional status
GRADE
ECOG FUNCTIONAL STATUS
0
Fully active, capable of carrying out all pre-disease activities without limitations.
1
Restriction of physically strenuous activities, but the person can walk and perform tasks of a
sedentary or restful nature, e.g. light housework or office tasks.
2
Ambulatory and able to carry out personal care but unable to carry out any work activity. Up for
more than 50% of waking hours approximately
3
Person is only capable of self-care limited, confined to bed or chair for more than 50% of waking
period.
4
Completely disabled, unable to perform personal care of any kind, totally confined to bed or
chair.
5
Death
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
89 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
VI. NCI CTCAE Criteria V4.03
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
90 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
VII. Centralized review of PET/TC
​
CENTRALIZED REVIEW PROTOCOL.
Image Subcommittee of the GELTAMO group.
Justification
PET/TC performed midway through treatment has proven to be a tool of great prognostic value in
patients with DLBCL, being capable of early classifying patients as good or poor responders (1).
For this reason, numerous clinical trials are studying the use of new therapeutic strategies based
on the results of early PET/TC; that is, escalate or de-escalate the treatment based on the
individual metabolic response of each patient (2).
In recent years, there have been numerous advances in the field of molecular imaging, especially
aimed at agreeing and unifying the criteria for evaluating and interpreting PET/TC studies. Thus, at
the First International Workshop held in Deauville, France, in 2009 (3), a visual assessment
method (Desauville 5-point scale) was adopted to assess intermediate PET (PET). In addition, with
the aim of improving the visual assessment in the interpretation of the PETi in the DLBCL, the use
of quantitative analysis was proposed. The most widely used quantitative index is the Standardized
Uptake Value (SUV), which relates the dose of FDG administered to the patient's weight. The
change in maximum SUV (SUVmax) in tumor tissue before and after treatment can be used to
measure the degree of response (4-8).
The Deauville criteria and quantification by SUV in patients with DLBCL have already been
validated (9). The latest expert consensus in Lugano reflects the mid-term and end-of-treatment
endpoints (10).
Since 2014, the group GELTAMO has had a group of nuclear medicine experts in the centralized
assessment of PET/TC studies in clinical trials using the latest international recommendations (10).
In the present work, thegroup GELTAMO PET Network, made up of nine nuclear medicine doctors,
will carry out a qualitative and quantitative prospective centralized assessment of the PET/TC
studies performed before the start of treatment as well as after the fourth cycle (the latter being
decisive for the number of cycles to be administered) and the final PET/TC after completing the
treatment to assess the remission status.
Objectives
●
Evaluate the relationship of metabolic parameters with biological markers.
●
Identify the best interpretation criteria for PET/TC studies (visual or quantitative) to predict
survival.
●
To study the prognostic value of metabolically negative residual lesions.
●
Measure the degree of agreement between the reviewers, which will be calculated by
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
91 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Cohen's K coefficients and Krippendorf's α.
●
To study the feasibility of centralized calculation of tumor metabolic volume in baseline
PET/TC (VMT0) and to establish its prognostic value.
Material and methods
PET/TC study protocol
All acquisition parameters must comply with the QTC (qualification of PET/TC systems for
participating in clinical trials).
All patients will undergo a baseline PET/TC scan before starting treatment (PET0), as well as
another PET/TC scan after the fourth cycle of IR-GEMOX (PET4), which will be scheduled
between days 10 and 14 after said cycle. cycle. In addition, all patients will undergo a final PET/TC
after the sixth or eighth cycle (PET6 or PET8) at least three weeks after completing treatment.
All PET/TC studies of each patient will be performed in the same chamber and with the same
acquisition protocol.
The preparation of the patient, injection of FDG and acquisition of the studies will be carried out
following the recommendations of the EANM (11).
Transfer of images and PET Network
The TC and PET studies with attenuation correction, anonymized, will be sent to the central
platform (http//.www.geltamodat.com) in DICOM PART 10 format within 72 hours of acquisition.
The centralized review panel will be composed of 9 expert nuclear medicine doctors. Each of them
will carry out a blind and independent evaluation of all the studies.
For each patient, a centralized review of PET0 and PET4 will be performed. In the centralized
review process, each nuclear medicine doctor will fill out a clinical form that will be available on the
platform (http//.www.geltamodat.com). The final result of the PET/TC study will be sent back to the
investigator. Finally, the PET6/PET8 will also be reviewed within a week after receiving the images.
Qualitative analysis of PET
PET0 will be informed in each local center where the study is performed, following the standard
criteria and with the available clinical information (a pathological uptake of FDG is that focal or
diffuse uptake greater than the background activity, not attributable to physiological uptake).
PET4 studies will be centrally assessed without having the patient's clinical information available,
and will be interpreted binary as positive or negative based on the 5-point Deauville scale.
Deauville scale (3)
​
no uptake
​
uptake ≤mediastinum **
​
uptake > mediastinum but ≤liver
​
uptake moderately greater than liver
​
uptake markedly greater than liver and/or new lesions
X new areas of uptake probably not related to lymphoma
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
92 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
PET4 will be considered positive if the uptake of residual disease is moderately or markedly
greater than that of the liver (Deauville >3). PET4 will be considered negative if the uptake of
residual disease is less than or similar to that of the liver (Deauville ≤3).
The result of the PET4 will be decisive for the change of treatment.
Semiquantitative analysis of PET
Maximum SUV values ​will be calculated by body weight.
SUVmax is defined as the highest SUV value in the hypermetabolic lesion with the highest FDG
uptake. For each PET/TC study, the tumor lesion with the most intense FDG uptake will be
identified among all the hypermetabolic foci using a color gradient scale. The most active
volumetric region will be determined, calculating the SUVmax on it. To calculate ΔSUVmax, the
most active region in any region or organ in PET4 will be compared to that in PET0, even if the
location in PET 4 differs from the location in PET0. The SUVmax between PET0 and PET4
(ΔSUVmaxPET0-4) will be calculated (12).
Positive PET4 is defined if ΔSUVmax PET0-4 is <70% and negative if ΔSUVmax PET0-4 is ≥70%.
In the event that the results of the qualitative and quantitative assessment differ from each other in
the PET4, the semi-quantitative analysis will be decisive to consider the study positive or negative.
The PET4 result will determine the number of cycles to be administered: in the case of complete
remission (CR), patients will receive 2 more cycles; partial response (PR): 4 more cycles; stable
disease (SE): 4 more cycles; progression: they will exit the trial.
Final response
PET6/PET8 should be analyzed qualitatively or visually following the 5-point Deauville scale. The
definition of the remission state at the end of the treatment will be carried out taking into account
the metabolic and morphological findings of the PET/TC, following the latest proposals from the
experts (10):
Complete metabolic response (CMR):
Deauville 1, 2,3 , with or without residual mass and without evidence of involvement of the
bone marrow, spleen or other extra lymphatic organs.
The CMR with residual mass should be called rMCR, and the size of the mass must be
recorded.
Residual metabolic disease (RMD):
Deauville 4 or 5 and residual mass of any size (no new lesions).
Progressive metabolic disease (PMD):
Deauville 4 or 5 and new hypermetabolic foci of FDG compatible with lymphoma or
increased uptake of previously existing foci corresponding to disease and/or ≥50% increase
in the sum of the product of the diameters of the masses .
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
93 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Bibliography.
​
Hutchings M, Barrington SF. PET/TC for therapy response assessment in lymphoma. J Nucl
Med. 2009;50 Suppl 1:21S–30.2,3
​
Moskowitz CH, Schoeder H, Teruya-Feldstein J, et al: Risk-Adapted Dose-Dense
Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-
Cell Lymphomas. Journal of Clinical Oncology 28:1896-1903, 2010
​
Meignan M, Gallamini A, Meignan M, et al: Report on the First International Workshop on
Interim-PET-Scan in Lymphoma. Leukemia & lymphoma 50:1257-60, 2009.
​
Yang DH, Min JJ, Song HC, et al: Prognostic significance of interim (18)F-FDG PET/TC after
three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell
lymphoma. European Journal of Cancer 47:1312-1318, 2011
​
Haioun C, Itti E, Rahmouni A, et al: F-18 fluoro-2-deoxy-D-glucose positron emission
tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting
patient outcome. Blood 106:1376-1381, 2005
​
Cashen AF, Dehdashti F, Luo J, et al: (18)F-FDG PET/TC for Early Response Assessment in
Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project
Interpretation. Journal of Nuclear Medicine 52:386-392, 2011
​
Lin C, Itti E, Haioun C, et al: Early 18F-FDG PET for prediction of prognosis in patients with
diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med
48:1626-32, 2007
​
Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al: SUVmax reduction improves early
prognosis value of interim positron emission tomography scans in diffuse large B-cell
lymphoma. Blood 118:37-43, 2011
​
Itti E MM, Berriolo-Riedinger A, Biggi A, Cashen A, Vera P, Siegel B, Gallamini A, Casasnovas
R, Haioun C: An international validation study of the prognostic role of interim FDG PET/TC in
diffuse large B-cell lymphoma. Journal of Nuclear Medicine 53, 2012
​
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mu¨eller SP, Schwartz
LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A,
Cheson BD. Role of Imaging in the Staging and Response Assessment of Lymphoma:
Consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
J Clin Oncol 2014; 32(27):3048-58.
​
Ronald Boellaard & Mike J. O'Doherty & Wolfgang A. Weber & Felix M. Mottaghy &Markus N.
Lonsdale & Sigrid G. Stroobants & Wim JG Oyen & Joerg Kotzerke &Otto S. Hoekstra & Jan
Pruim & Paul K. Marsden & Klaus Tatsch &Corneline J. Hoekstra & Eric P. Visser & Bertjan
Arends & Fred J. Verzijlbergen &Josee M. Zijlstra & Emile FI Comans & Adriaan A.
Lammertsma & Anne M. Paans &Antoon T. Willemsen & Thomas Beyer & Andreas Bockisch
&Cornelia Schaefer-Prokop & Dominique Delbeke & Richard P. Baum & Arturo Chiti &Bernd J.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
94 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Krause. FDG PET and PET/TC: EANM procedure guidelines for tumour PET imaging: version
1.0. Eur J Nucl Med Mol Imaging 2009; 1297-4.
​
Itti E, Lin C, Dupuis J, et al: Prognostic Value of Interim (18)F-FDG PET in Patients with
Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy.
Journal of Nuclear Medicine 2009;50:527-533.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
95 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
VII. Biological Substudy
An extensive biological study will be performed in order to further characterize this non-GCB
DLBCL patient population and evaluate the response obtained with the mutational profile of the
tumor. In the event that patients agree to participate in the biological study, peripheral blood,
paraffin-embedded blocks from the original diagnostic lymph node biopsy, and lymph node biopsy
performed at the time of recurrence (if available) are sent to a central laboratory to perform
phenotypic subtyping tests, molecular studies, mutational spectrum, and determination of the cell
of origin using NanoString technology (NanoString Technologies, WA, USA) (13). The biological
studies will be coordinated by Dr. Santiago Montes-Moreno, Dr. Miguel Ángel Piris, Dr. Marcos
González, Dr. Armando López-Guillermo and Dr. Elías Campo.
1. CENTRAL REVIEW OF MOLECULAR AND HISTOPATHOLOGICAL DIAGNOSTIC STUDIES
2. ASSESSMENT OF CELL OF ORIGIN (GERMINAL CENTER B VS ACTIVATED) IN PATIENTS
WITH TREATMENT-RESISTANT OR RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
INCLUDED IN THE PHASE II STUDY IBDCL-GELTAMO-2015
3. MUTATIONAL SPECTRUM ANALYSIS OF 45 GENES AND EVALUATION OF MRD IN
PATIENTS
WITH
TREATMENT-RESISTANT
OR
RECURRENT
DIFFUSE
LARGE B-CELL
LYMPHOMA
INCLUDED
IN
THE
PHASE
II
CLINICAL
STUDY
(IBDCL-GELTAMO-2015
GUIDELINE) (NO EUDRACT 2015-005390-21)
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
96 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
1. REVIEW oF CENTRAL AND MOLECULAR STUDIES Histopathological diagnosis
Montes Santiago Moreno, HUMV
1.1 BIOLOGICAL SAMPLES:
Is planned to collect different types of biological samples from patients enrolled in the clinical trial:
It requires tissue blocks from diagnostic lymph node/extranodal incisional or excisional
biopsies. Biopsies using thick except needles are recommended that the clinical situation
indicates that the only safe means to obtain diagnostic tissue25.
Each patient will have to sign a specific informed consent form for the molecular studies
included in this protocol.
- Diagnostic sample fixed in formalin and included in paraffin (FFIP). The FFIP tissue in which the
diagnosis of DLBCL is established. At least one FFIP block is required for central review and
further study. If two or more samples are available from a patient obtained at different times, all
representative samples should be evaluated.
- Representative neoplastic tissue frozen at the time of diagnosis. At least one block of frozen
neoplastic tissue to obtain DNA and RNA. The samples must be representative of the neoplastic
tissue. Representative sections should contain > 80% neoplastic cells and allow sufficient DNA and
RNA (0.5 - 1 g each) to be obtained for molecular studies. These samples must be obtained from
the majority of patients included in the study, included in OCT medium and stored at -80 ºC until
shipment.
- Peripheral blood (non-neoplastic) from the patient at any time during the study. Two EDTA tubes
with 10 ml of peripheral blood without any particular treatment.
All biological samples available from the patient at the time of diagnosis (FFIP,
frozen) will be sent immediately after the patient's inclusion in the clinical trial for
central diagnostic review (see below). The shipment of the BP will be made after the
extraction procedure.
All shipments will be coordinated by the staff of the HUMV/IDIVAL Cancer
Genomics/Pathology Laboratory (Laura Cereceda, Santiago Montes Moreno), together with
the Pathological Anatomy and Hematology Services of the clinical centers included in the
study. The patient must sign a specific informed consent related to biological studies.
After receipt, the samples will be coded with an Id number associated with the biological project. All
personal data in relation to the patient will be included in a database, which complies with the
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
97 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
personal data protection law. The samples will be processed for the different objectives in the
different associated laboratories:
Central review of histopathological diagnosis and extended diagnostic tests: Pathological Anatomy
Service and Cytogenetics Unit, Marqués de Valdecilla University Hospital. Responsible: Santiago
Montes Moreno. Research collaborators: Miguel Ángel Piris (pathologist and senior researcher),
Ana Batlle and Sonia González de Villambrosía (hematologists, Cytogenetics Unit).
Molecular
studies.
Cancer
Genomics
Laboratory.
Responsible:
Santiago
Montes
Moreno.
Research collaborators: Nerea Martínez.
All samples (FFIP, frozen tissue, BP and derivatives (extracted RNA and DNA, histological and
immunohistochemical samples, tissue microarrays) will be stored in the Valdecilla Biobank Tissue
Node.
1.2. CENTRAL HISTOPATHOLOGICAL DIAGNOSTIC REVIEW
Diagnostic samples from all Patients included in the trial will be evaluated by a group of
hematopathologists from the HUMV Hematopathology ServiceA diagnosis will be established
based on the current WHO classification of hematolymphoid neoplasms1The group of standard
diagnostic markers will include: Hematoxylin-eosin and IHC: CD20, CD3, CD30, CD10, BCL6,
BCL2, MUM1, C-MYC, KI67
Immunohistochemistry will be performed by automated methods and using monoclonal antibodies
and optimized visualization methods All IHC results will be evaluated in the diagnostic context in a
semi-quantitative way and the cases will be classified according to the algorithms already
published5, 8, 1 0, 12, 26.
A diagnostic report will be generated for each case within ten days of receipt of the diagnostic FFIP
sample and sent to the clinical coordinator.
1.3. EXTENDED DIAGNOSTIC PANEL
Tissue microarrays (TMA) (60 representative samples in duplicate in each TMA) will be
constructed with the tissue obtained from the FFIP blocks.27 An expanded set of biomarkers will be
performed on TMA samples:
Immunohistochemistry: A set of 15-20 monoclonal antibodies will be tested.
- Fluorescent in situ hybridization (FISH) for the detection of translocations including: IGH, C-MYC,
BCL6, BCL2, IRF4, PAX5 and tp53 (17p) deletions.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
98 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
1.4. MUTATIONAL PROFILE
DNA will be extracted from FFIP diagnostic tumor tissue and processed to allow targeted NGS
sequencing using Illumina/Miseq equipment (Pathological Anatomy Service, HUMV/IDIVAL).
Contact information:
Laura Cereceda Company (lcereceda@idival.org).
Tissue Bank Unit Technician
Cancer Genomics Laboratory. Marqués de Valdecilla Foundation
1st Floor, Offices. IFIMAV Building
Avda. Cardenal Herrera Oria s/n
39011 Santander (CANTABRIA)
Tlf. 942315515-0, ext. 74102
Santiago Montes Moreno (smontes@humv.es).
Pathologist, Pathological Anatomy Service,
Marqués de Valdecilla University Hospital, IDIVAL.
Avda. Valdecilla nº 25, 39008 SANTANDER, Spain
Tel.: (34) 942203492, ext: 73321
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
99 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
2. ASSESSMENT OF CELL OF ORIGIN (GERM CENTER B VERSUS ACTIVATED) IN
PATIENTS WITH RESILIENT DIFFUSE LARGE B-CELL LYMPHOMA TO TREATMENT OR
RECIDENT INCLUDED IN THE PHASE II STUDY IBDCL-GELTAMO-2015
PI of the clinical trial: Alejandro MARTÍN / Dolores CABALLERO (Salamanca, Spain)
PI of the biological project: Armando LOPEZ-GUILLERMO / Elías CAMPO (Barcelona, ​Spain)
Service of Hematology, Hospital Clínic, Barcelona
Address: Villarroel 170; 08036 Barcelona, ​Spain
Telephone number: +34-932275575
Fax number: +34-932275480
E-mail: alopezg@clinic.ub.es
November 11, 2015
Background
Diffuse large B-cell lymphoma (DLBCL) is the type of most common lymphoma in Western
countries, accounting for 35-50% of cases. Although considered a single category in the WHO
classification, DLBCL represents a heterogeneous group of lymphomas classified together on the
basis of morphology, immunophenotype, genetic alterations, as well as clinical behavior. Ten years
ago, the distinction of DLBCL into categories of cell of origin (CDO) based on gene expression
patterns reminiscent of germinal center B cell group (GCB group) and activated B cell group (ABC
group), as defined by the gene expression microarray (PEG) technique, showed crucial biological,
prognostic, and possibly therapeutic implications.1 Thus, ABC-type DLBCL exhibits unique
alterations, including constitutive activation of the NFkB pathway, poor response to conventional
treatment, and poor survival compared to CGB-type DLBCL.2-3 In addition, the classification into
groups based on the CDO is increasingly important due to the emergence of new treatments that
have selective biological activity in one of the groups. This is the case of ibrutinib: several studies
suggest that this drug has a high selective activity in patients with ABC-type DLBCL.4-5
DLBCL treatment outcomes have improved significantly after the introduction of rituximab (R) in
CHOP-type regimens and is now the gold standard treatment. However, even with current
immunochemotherapy, approximately 30-40% of patients will relapse or ultimately progress.6
Rescue treatment in patients with relapse/resistant to treatment shows clearly insufficient results
and the use of new drugs is warranted. A phase II study will begin in a few months to determine
the efficacy of ibrutinib in combination with R-GEMOX-dexa. A clinical trial in patients with
relapsed/refractory DLBCL is an excellent target to conduct a biological side project and gain
insight into the biology of the disease. It would be of special interest to know the CDO of tumor
cells.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
100 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
The original method for defining PEG groups used microarrays of RNA derived from frozen tissue.
This technique is not feasible in routine clinical practice, since paraffin-embedded tissue is usually
available. For this reason, different attempts to develop immunohistochemical algorithms that
capture information related to PEG have been evaluated. However, neither algorithm provided high
reproducibility in clinical practice.7 More recently, the same consortium that designed the GCB/ABC
classification, the Lymphoma and Leukemia Molecular Profiling Project, has developed a 20-gene
digital strict expression test (NanoString) for CDO assignment (Lymph2Cx assay), which can be
used on formalin-fixed and paraffin-embedded samples. This test was validated in an independent
cohort and is currently marketed in clinical practice.8,9
In summary, we are proposing a parallel biological project related to the current clinical trial
IBDCL-GELTAMO-2015, with the main objective of determining the ODCs of tumors.
Objectives
​
- To determine the CDO (GCB-type DLBCL versus ABC) in patients with relapsed/refractory
DLBCL included in the phase II clinical trial IBDCL-GELTAMO-2015.
​
- Establish a correlation between the CDO and the main clinical and biological characteristics,
the response to treatment and the outcome of the patients.
Methods (summary)
1. Samples: 62 tumor samples (paraffin-embedded tissue) at diagnosis; in addition, 15 - 20 tumor
samples at the time of recurrence (biopsy at the time of recurrence is not mandatory, but
recommended).
3. Nucleic acid extraction from paraffin-embedded material.
4. Determination of cell of origin using the Lymph2Cx assay, as described in the recent LLMPP
publication (Scott et al., Blood 2014;123:1214-7), using NanoString technology (NanoString
Technologies, WA, USA). 200 ng of RNA were used to determine gene expression levels.
5. Statistical Considerations: The primary endpoint of the trial is RESPONSE to treatment;
therefore, the main objective of the biological project will be to establish the relationship between
CDO and the mutational spectrum with response to treatment with RI-GEMOX-dexa. The main
clinical characteristics at the time of diagnosis and recurrence, and the outcome (progression-free
and overall survival) will also be analyzed.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
101 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Bibliographic references:
​
Alizadeh AA et al. Nature 2000; 403: 503-11
​
Rosenwald A, et al. N Engl J Med 2002; 346: 1937-47
​
Lenz G et al. N Engl J Med 2008; 359: 2313-23
​
Yang Y et al. CancerCell 2012; 21: 723-37
​
Wilson WH et al. NatMed 2015; 21: 922-6
​
Coiffier B, et al. Blood 2010; 116: 2040-5
​
Gutierrez-Garcia G et al. Blood 2011; 117: 4836-43
​
Scott DW et al. Blood 2014; 123: 1214-7
​
Scott DW et al. J Clin Oncol 2015; 33: 2848-56MUTATIONAL
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
102 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
3. SPECTRUM ANALYSIS OF 45 GENES AND ASSESSMENT OF MRD IN PATIENTS WITH
TREATMENT-RESISTANT OR RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
INCLUDED IN THE PHASE II CLINICAL STUDY (GUIDELINE IBDCL-GELTAMO-2015) (NO
EUDRACT 2015-005390-21)
IP of the clinical trial: Alejandro MARTÍN / Dolores CABALLERO (Salamanca, Spain)
IP of the biological project: Marcos Gonzalez / Miguel ALCOCEBA (Salamanca, Spain)
Department of Hematology, Hospital Universitario, Salamanca
Address : Paseo de San Vicente 58-182; 37007 Salamanca, Spain
Telephone number: +34-923291100 Ext. 55629 / 55765
Fax number: +34-923294660
Email: margondi@usal.es / migalcoceba@gmail.com
November 1, 2015
​
Background
​Diffuse cell lymphoma Large B lymphoma (DLBCL) is an aggressive lymphoma that represents
~40% of all NHL in adults, most of which are classified as "not otherwise specified" (NOS)
according to the 2008 WHO classification. DLBCL NOS is a heterogeneous group of lymphomas ,
subclassified as germinal center B cell (GCB) or activated B cell (ABC or non-GCB) phenotype
based on cellular origin.1,2 Despite improved treatment and the introduction of rituximab, up to 40%
of DLBCL patients relapse and die due to disease progression.4-6 In addition, the recurrence rate is
similar in the two DLBCL groups, suggesting the existence of additional oncogenic events that
influence treatment resistance.7 Rescue treatment in patients with relapse/resistance to treatment
shows clearly insufficient results and the use of new drugs is warranted. A clinical trial in patients
with relapsed/refractory DLBCL is an excellent target to conduct a biological side project and gain
insight into the biology of the disease. Of special interest would be to know the mutational
spectrum of DLBCL tumor cells.
​
​Recently, the most frequently mutated genes have been described using next generation
sequencing (NGS) in patients with DLBCL, which has led to the description of new genetic
mutations together with the frequently mutated genes described in these entities 7 -10 Thus, several
genes are more common in GCB-type DLBCL (eg, CREBB, EZH2, MLL2), while others are specific
to or more common in non-GCB-type DLBCL (loss of CDKN2A/B, mutations in TNFAIP3, MYD88
or CARD11), with biological, prognostic and possibly therapeutic implications.7-8 In addition, many
of these genes are part of the same cellular pathway, so presumably the alteration of any of these
genes would trigger the alteration of the entire pathway, with a possible implication in the
prognosis. However, studies looking at the clinical role of gene mutations are very limited.11-13 The
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
103 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
study of mutations in these genes and these pathways would be of special interest in studying the
effect of these mutations on the response to different drugs, as well as in the identification of
possible new targets or in the individualized treatment of these pathologies . In this context,
mutations in different genes in the NF-κB pathway (eg, BTK, TRAF2, BIRC3, PLCγ2, MYD88,
CD79A/B, etc.) have been shown to alter the response to ibrutinib in different disorders B-cell
lymphoproliferative disorders, including DLBCL.14-17
​
​In addition to mutations, monitoring of circulating tumor DNA as minimal residual disease (MRD) in
patients with DLBCL has been shown to be a reliable tool for predicting premature treatment
failures as well as recurrence from remission.18,19 Finally, we have shown that the HLA-B44
supertype could define a subgroup of patients who do not respond to R-CHOP regimens.20
Therefore, the study of this HLA supertype in a clinical trial would be of interest.
​
​In
summary,
we
propose
a
parallel
biological
project
related
to
the
clinical
trial
IBDCL-GELTAMO-2015 with the main objective of evaluating the mutational spectrum of the
included cases; furthermore, our aim was to establish a correlation between the presence of MRD
and response, and to assess the role of the HLA-B44 supertype in response and outcome.
​
​Objectives
​- To evaluate the mutational spectrum of 45 genes in patients with relapsed/resistant DLBCL
included in the phase II clinical trial IBDCL-GELTAMO-2015.
​- Evaluate the minimal residual disease (MRD) in the DLBCL included in the clinical trial.
​- To study the HLA status in non-tumor samples in the DLBCL included in the clinical trial.
​- Establish a correlation between the mutational spectrum, the MRD and the HLA status and the
main clinical and biological characteristics, the response to treatment and the outcome of the
patients.
​
​
Methods (summary)
​1. Samples:
​Mutational spectrum: 62 tumor samples at diagnosis; also, when available, tumor samples when
recurrence occurs. The use of fresh frozen tissue or good quality DNA extracted from fresh frozen
tissue is recommended; paraffin-embedded tissue should be a second option.
​MRD. Identification of MRD targets: The tumor sample at diagnosis will be used for amplification
of IgH and IgK rearrangements in order to select the most appropriate MRD targets for each
patient (VDJ, DJ or IgK).
​Follow-up: Plasma will be obtained from two x 10 cc peripheral blood (PB) samples in EDTA tubes
for MRD studies on each follow-up date (at the same times as imaging studies). Plasma must be
obtained at each center within four hours of SP collection, in order to avoid contamination with
DNA from circulating leukocytes. The plasma and the remaining cells (circulating leukocytes) will
be sent separately to Salamanca, where DNA from these two fractions will be isolated. MRD will be
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
104 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
assessed at the PET/TC reassessment after 4 cycles and at the end of the induction period. MRD
monitoring will be carried out at each control CT, in accordance with the protocol and from the end
of treatment during the first two years.
​HLA: non-tumorous or low tumor burden peripheral blood sample. The same samples can be used
for HLA analysis as for MRD studies. In case a new sample is needed, 1 x 10 cm sample can be
obtained 3 of SPin an EDTA tube at any time during the project.
​
​2. Mutational status of 45 relevant or possibly relevant genes in DLBCL determined by Miseq
(Illumina) and confirmed by Sanger sequencing. These genes are the following:
​ARID1A, B2M, BCL2, BCL6, BIRC3, BTK, CARD11, CCND3, CD79A, CD79B, CREBBP, EBF1,
EP300, EZH2, FBXO11, FOXO1, GNA13, GNAI2, HIST1H1B, HIST1H1C, HIST1H1D, HIST1H1E,
IRF8, MEF2B, MLL2, MYC, MYD88, NOTCH1, NOTCH2, P2RY8 PCLO, PIM1, PLCγ2, POU2F2,
S1PR2, SOCS1, SPEN, STAT3, tbl1xr1, TET2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3
​
​3. rearrangements IgH (VDJ and DJ) and IgK at the time of diagnosis will be analyzed using PCR,
in accordance with concerted action by BIOMED-221 in order to select the most suitable MRD
targets. MRD in circulating leukocytes will be evaluated using the BIOMED-2 strategy, while
plasma samples will be evaluated by high-throughput sequencing. The selected target will be
evaluated in follow-up samples at the time of reassessment after cycle 4, at the end of the
induction period, and at each control TC scan for the first two years. MRS studies will be analyzed
in both circulating leukocytes and circulating plasma tumor DNA at each follow-up. The results of
the MRD will be compared with those of the TC/PET studies.
​
​4. HLA-B typing at the low resolution level will be performed by PCR-SSO and Luminex XYP, in
accordance with the standards of the European Federation for Immunogenetics. The presence of
the HLA-B44 supertype will be evaluated as previously published.20 Briefly, patients with at least
one HLA-B*18, HLA-B*37, HLA-B*40, HLA-B*41, HLA-B*44, HLA-B*45, or HLA-B allele *50 are
considered positive for the presence of the supertype.
​
5. Statistical considerations: the objective of the biological project will be to establish the
relationship between MRD, mutational spectrum and HLA status with the response to the study
IBDCLGELTAMO2015guideline, progression-free survival and overall survival.
​
​
References
​
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
105 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma
identified by gene expression profiling. Nature 2000;403(6769):503-511.
​
Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of
diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood
2004;103(1):275-282.
​
Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP
alone
in
elderly
patients
with
diffuse
large-B-cell
lymphoma.
N.Engl.J.Med.
2002;346(4):235-242.
​
Fu K, Weisenburger DD, Choi WW et al. Addition of rituximab to standard chemotherapy
improves the survival of both the germinal center B-cell-like and non-germinal center
B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-4594.
​
Pfreundschuh M, Kuhnt E, Trumper L et al. CHOP-like chemotherapy with or without rituximab
in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an
openlabel randomized study of the MabThera International Trial (MInT) Group. Lancet Oncol.
2011;12(11):1013-1022.
​
Thieblemont
C,
Briere
J,
Mounier
N
et
al.
The
germinal
center/activated
B-cell
subclassification
has
a
prognostic
impact
for
response
to
salvage
therapy
in
relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin. Oncol.
2011;29(31):4079-4087.
​
Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in
non-Hodgkin lymphoma. Nature 2011;476(7360):298-303.
​
Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina
M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-
Favera R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011
Jul 31;43(9):830-7. doi: 10.1038/ng.892.
​
Lohr JG, Stojanov P, Lawrence MS et al. Discovery and prioritization of somatic mutations in
diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc.Natl.Acad.Sci.USA
2012;109(10):3879-3884.
​
Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W,
Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers
C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D,
Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A , Levy S, Dunson D, Dave
SS. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci US A. 2013
Jan 22;110(4):1398-403
​
Schif B, Lennerz JK, Kohler CW, Bentink S, Kreuz M, Melzner I, Ritz O, Trümper L, Loeffler M,
Spang R, Möller P. SOCS1 mutation subtypes predict divergent outcomes in diffuse large
B-Cell lymphoma (DLBCL) patients. Oncotarget. 2013 Jan;4(1):35-47
​
Trinh DL, Scott DW, Morin RD et al. Analysis of FOXO1 mutations in diffuse large B-cell
lymphoma. Blood 2013;121(18):3666-3674.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
106 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
Fernandez-Rodriguez C, Bellosillo B, Garcia-Garcia M et al. MYD88 (L265P) mutation is an
independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.
Leukemia 2014;28(10):2104-2106.
​
Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D,
Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S , Dietze K,
Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR,
Cooke VG, Gascoyne RD, Lenz G, Stegmeier F. Pharmacological and genomic profiling
identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014
Jan;20(1):87-92
​
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda
SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski
G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ,
Byrd JC. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J
Med. 2014 Jun 12;370(24):2286-94
​
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao
Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo
JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani
RH. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr
9;372(15):1430-40
​
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM,
Shaffer AL, Gerecitano J, de Vos S , Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani
R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M,
Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor
signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922-6
​
Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, Shovlin M, Jaffe ES,
Staudt LM, Lai C, Steinberg SM, Chen CC, Zheng J, Willis TD, Faham M, Wilson WH.
Circulating tumor DNA and TC monitoring in patients with untreated diffuse large B-cell
lymphoma: a correlative biomarker study. Lancet Oncol. 2015 May;16(5):541-9.
​
Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C,
Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli KS, Miklos D, Advani
RH , Levy R, Hicks RJ, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA.
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput
sequencing. Blood. 2015 Jun 11;125(24):3679-87
​
Alcoceba M, Sebastián E, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, Jiménez C,
Puig N, Corral R, Pardal E, Grande C, Bello JL, Albo C , de la Cruz F, Panizo C, Martín A,
González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M. HLA
specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood
2013 Aug 22;122(8):1448-54.
​
van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL,
Delabesse E, Davi F, Schuuring E, García-Sanz R, van Krieken JH, Droese J, González D,
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
107 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Bastard C, White HE, Spaargaren M, González M, Parreira A, Smith JL, Morgan GJ, Kneba M,
Macintyre EA. Design and standardization of PCR primers and protocols for detection of clonal
immunoglobulin and T-cell receptor gene recombinations in suspected lymphoproliferative:
report
of
the
BIOMED-2
Concerted
Action
BMH4-CT98-3936.
Leukemia.
2003
Dec;17(12):2257-317IX
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
108 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
IX. Revised criteria for response assessment
Assessment Criteria Lugano Response Assessment Criteria for Non-Hodgkin Lymphoma
(28)
Response and location
Response based on PET/TC
Complete
Complete metabolic response
Lymphatic and
extralymphatic nodes
Score 1, 2, or 3 with or without a residual mass in 5PS†
It is recognized that in Waldeyer's ring or extranodal sites with high
physiologic uptake or with activation in the spleen or marrow (eg, with
chemotherapy or myeloid colony-stimulating factors), the uptake it may
be higher than in normal mediastinum and/or liver. Under these
circumstances, the complete metabolic response can be inferred if the
uptake at the initial sites of involvement is not higher than the
surrounding normal tissue, even if the tissue exhibits high
physiological uptake.
unmeasured injuries
Not applicable
Increasing the size of the
organs
Not applicable
New injuries
None
Bone Marrow
No evidence of FDG avidity in bone marrow
Partial
Partial metabolic response
lymph nodes and
extralymphatic
Rating 4 or 5 † with reduced uptake compared to those with basal
mass(es) and residual mass(es) of any size.
At mid-treatment, these results suggest that the disease is responding
At the end of treatment, these results are indicative of residual disease
unmeasured injuries
Not applicable
Increasing the size of the
organs
Not applicable
New injuries
None
Bone marrow
Residual uptake greater than uptake in bone marrow normal, but
reduced compared to baseline (diffuse uptake consistent with reactive
changes from chemotherapy). If there are persistent focal bone
marrow changes in the setting of a nodal response, consideration
should be given for further examination with MRI or biopsy or an
interval scan.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
109 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
No response or stable disease
No metabolic response
Target lymph nodes/nodal
masses, extranodal
lesions
Score of 4 or 5 no significant change in FDG uptake from baseline to
mid- or end of treatment
unmeasured injuries
Not Applicable
Increase the size of the
organs
Not Applicable
New injuries
None
Bone marrow
No change from baseline
Disease progression
Metabolic disease progression
Individual lymph
nodes/target lymph node
masses
Score of 4 or 5 with an increase in uptake intensity over baseline
period
Extranodal injuries
New areas of FDG avidity consistent with lymphoma at mid- or
end-of-treatment assessment
unmeasured injuries
Ninguna
New injuries
New areas of FDG avidity consistent with lymphoma rather than
another etiology (e.g. infection, inflammation). If uncertain as to the
etiology of new lesions, a biopsy or interval scan may be considered.
Bone marrow
New or recurrent areas of FDG avidity.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
110 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
X. Questionnaire on comorbidities
​
CIRS SCALE
General principles of scoring
Each patient's disease must be classified in the appropriate section. If there are several diseases
in the same section, only the most severe is scored.
Level 0: No past minor problems or injuries: childhood illnesses (chickenpox), minor surgery (fully
healed carpal tunnel, cesarean section), healed uncomplicated fractures, other past problems
already resolved without sequelae or complications (pneumonia)
Level 1: Any current medical problem that causes mild discomfort or disability, or has an occasional
exacerbation, having only a minor impact on morbidity (asthma controlled with bronchodilators,
occasional heartburn relieved with antacids). Medical problems that are not currently active but
were
significant
in
the
past
(kidney
stone)
or
required
major
surgery
(hysterectomy,
cholecystectomy, appendectomy)
Level 2: Medical conditions that require daily treatment or first-line therapy (asthma controlled with
inhaled steroids, gastro-oesophageal reflux treated with daily medication, osteoarthritis that
requires non-steroidal anti-inflammatory drugs,…) and/or have moderate disability or morbidity
Level 3: Chronic conditions that are not controlled with first-line therapy (asthma that corticosteroid
therapy, symptomatic angina despite medical regimens, symptomatic heart failure or uncontrolled
hypertension despite a complex therapeutic regimen) and/or ongoing significant but not severe
disability
Level 4: Any acute condition requiring immediate treatment or hospitalization (unstable angina,
acute myocardial infarction, stroke, but also bladder obstruction) and/or extremely severe
problems, organ failure (end-stage kidney disease requiring dialysis, oxygen-dependent chronic
obstructive pulmonary disease, end-stage heart failure); severe sensory impairment (nearly
complete blindness or deafness; being in a wheelchair) and/or severely impaired quality of life;
severe functional disability; delusion due to medical (organic) conditions
Neoplasm evaluation
Level 1: Cancer diagnosed in the remote past, without evidence of recurrence or sequelae in the
last 10 years or skin cancer excised in the past without important sequelae (other than melanoma).
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
111 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Level 2: There is no evidence of recurrence or sequelae in the last 5 years.
Level 3: Required chemotherapy, radiation, hormone therapy, or surgery for cancer within the past
5 years.
Level 4: Recurrent malignancy or metastasis (other than lymph nodes) or palliative treatment
phase.
These ratings will be made in the appropriate organ category for a given neoplasm.
HEART
In this category, only heart and coronary diseases will be taken into account (not vascular):
coronary artery disease, heart failure, valvular heart disease, heart disease secondary to
hypertension, endocarditis, myocarditis, pericarditis, arrhythmias (extrasystoles , bundle branch
blocks, atrial fibrillation), malignant tumors of the heart. The functional impact must also be
considered, for example, NYHA II heart failure has a different value between dependent and
independent people.
0. No problem
1. Past myocardial infarction (more than 5 years ago); occasional angina pectoris [exertional],
asymptomatic valvular disease
2. Medication-compensated congestive heart failure (NYHA I-II); daily medications for angina
pectoris, left ventricular hypertrophy, atrial fibrillation, bundle branch block, daily antiarrhythmic
drugs (including for prophylaxis), valvular disease requiring medical treatment
3. Previous myocardial infarction (less than 5 years ago) , abnormal stress test; coronary artery
bypass surgery or other heart surgery (valve replacement), moderate congestive heart failure
(NYHA II-III), or complex medical treatment; bifascicular block, pericardial effusion, or pericarditis
4.
Acute
coronary syndrome, unstable angina, or acute myocardial infarction; intractable
congestive heart failure (NYHA III-IV acute or chronic); marked restriction of normal activities of
daily living secondary to cardiac function
HYPERTENSION
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
112 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Considering only the severity of hypertension, organ damage (complications) should be considered
within the respective categories.
0. NormotensionBorderline
1. hypertension, hypertension compensated by salt restriction and weight loss, drug-free (when
drug therapy is indicated, but patient is not on medication, score is at least 2)
2.Daily antihypertensive medications: hypertension controlled by one drug therapy (including
fixed-dose combinations)
3. Hypertension requiring two or more drugs for control
4.Malignant hypertension, or hypertension not controlled by a complex therapeutic regimen
VASCULAR -HEMATOPOIETIC
Arterial disease: carotid atherosclerosis, peripheral arterial disease (PAD), aneurysms (each site);
Venous disease: venous insufficiency, varicose veins, deep vein thrombosis (DVT), pulmonary
embolism, primary pulmonary hypertension;
Hematopoietic disease: anemia, leukopenia, thrombocytopenia, hematological neoplasms;
Lymphopoietic disease: chronic lymphatic edema, lymphoma, diseases of the spleen and thymus;
Immune disease: systemic lupus erythematosus, systemic sclerosis (scleroderma), sarcoidosis,
hypersensitivity
0. No problem
1. Venous insufficiency, varices, lymphedema, carotid stenosis <70%, hemoglobin 10-12 g/dl (in
women), 12-14 g/dl (in men), anemia of chronic "inflammatory" disease
2. Prior DVT, a symptom of atherosclerosis (claudication, murmur, amaurosis fugax, absent pedal
pulse), or daily medications (eg, antiplatelet medications); EAP-IIa IIb by Fontaine; carotid stenosis
>70%; aortic aneurysm <4 cm; hemoglobin 10.8 g/dl (in women), 10-12 g/dl (in men), anemia
secondary to iron, vitamin B12, or folate, or chronic renal failure; total white blood cells (white blood
cells) 2,000 to 4,000/mmc, mild thrombocytopenia (50,000-150,000/mmc)
3. DVT or recent DVT (<6 months ago), two or more symptoms of atherosclerosis (see above );
Fontaine III or recent PAD / previous angioplasty (with or without stent); hemoglobin <8 g/dl (in
women), <10 g/dl (in men), dyserythropoietic anemia; white blood cells <2000/mmc; Severe
thrombocytopenia (<50,000/mmc)
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
113 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
4. Pulmonary embolism (acute or recent/previous), atherosclerosis requiring surgical intervention
(eg, aortic aneurysm >4 cm, symptomatic carotid stenosis >70%, Fontaine IV PAD, or amputation
due to vascular causes, etc.); recent/previous vascular surgery, any hematological or vascular
neoplasm (including multiple myeloma)
In the case of immunological disease, the score should be assigned taking into account blood
abnormalities, stage of organ damage and/or functional disability (2: symptoms controlled by daily
medications, 3: symptoms are not adequately controlled; 4: symptoms impossible to control or poor
prognosis for a short time).
RESPIRATORY
This category includes COPD, asthma, emphysema, restrictive interstitial lung diseases, malignant
tumors of the lung and pleura, pneumonia, and tobacco use as well.
0. No problem
1. Recurrent episodes of acute bronchitis, asthma currently treated with on-demand inhalers when
needed; smoker of more than 10 but less than 20 pack-years.
2. Instrumental diagnosis of COPD or interstitial lung disease (X-rays, CT, spirometry); daily
on-demand inhalers (≤2 pharmacological classes), two or more episodes of pneumonia in the last
5 years, smoker of more than 20 but less than 40 pack-years.
3. Dyspnea on exertion secondary to limited respiratory capacity, not well controlled by daily
medications; oral steroids required for lung disease; daily PRN inhalers (3 pharmacological
classes), acute pneumonia treated on an outpatient basis
4. Chronic oxygen supplementation, respiratory failure requiring assisted ventilation, or previous (at
least one episode); any pulmonary or pleural neoplasm; acute pneumonia requiring hospitalization
Smoking is an important respiratory and cardiovascular risk, so it is considered a disease, and is
classified according to pack-years in life:
Number of packs of cigarettes smoked per day X number of years smoked in a lifetime
For example: 20 cigarettes/day (1 pack of tobacco) X 1 year = 1 pack-year
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
114 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Former smokers should also be ranked, but those who have been smoke-free in the past 20 years
deserve a rating lower than smoking
Examples:
A. Patient smoking 20 cigarettes/day (1 pack) for 25 years = 25 pack-years - CIRS score: 2
B. Patient smoking 40 cigarettes/day (2 packs) for 25 years = 50 pack-years - CIRS score: 3
C. Former smoker of 20 cigarettes/day (1 pack) for 25 years, quit 5 years ago - CIRS score: 2
D. Former smoker of 20 cigarettes/day (1 pack) for 25 years, left 20 years ago - CIRS results: 1
COPD classification could be more specific when instrumental data (objective tests) are available:
blood gasses, forced expiratory volume in 1 second (FEV1), etc
EYES, EARS, NOSE AND THROAT AND LARYNX
To simplify the potential complexity of this category it was decided to score according to severity of
disability generated by sensory diseases (degree of limited autonomy and communication) and
avoid qualifying each type of pathology. Sensory alterations should be classified after instrumental
correction (corrective lenses, hearing aids, etc.)
Eyes: glaucoma, cataracts, macular degeneration (diabetic/hypertensive retinopathy), any other
pathology
Ears: otitis, dizziness, any cause of hearing impairment
Nose and throat: rhinitis, pharyngitis, nasal polyps, sinusitis, malignant tumors
Larynx: dysphonia, acute and chronic laryngitis, malignant tumors
0. No problem
1. Visual acuity corrected with glasses, mild hearing loss, chronic sinusitis
2. Difficulty in reading newspapers or driving despite wearing glasses; hearing aid required; chronic
sinus complaints requiring medication, vertigo/dizziness requiring daily medication
3. Severely low vision, partially blind (escort required to venture out, unable to read newspaper);
severe hearing impairment; laryngeal dysphonia (non-neurological dysarthria)
4. Functional blindness/deafness: unable to read, recognize familiar face; laryngectomy (all
causes, especially malignancies); surgical intervention required for vertigo; aphonia secondary to
deterioration of the larynx.
UPPER GASTROINTESTINAL SYSTEM
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
115 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
This category includes from the esophagus to the duodenum and the pancreatic tree: dysphagia,
gastroesophageal reflux, hiatal hernia, esophageal diverticula, any type of gastritis (consider H.
pylori eradication or not), gastric/duodenal ulcer, pancreatitis acute or chronic, malignant tumors
(gastric lymphoma).
Note that type 1 diabetes is classified under "metabolic".
0. No problems
1. Hiatal hernia, gastritis or gastroesophageal reflux requiring medication on demand; previous
ulcer (more than 5 years ago); previous H. Pylori eradication treatment (more than 5 years ago)
2. Daily proton pump inhibitor/antacid medications; documented gastric or duodenal ulcer or
H.Pylori eradication therapy within 5 years
3. Active gastric or duodenal ulcer; positive fecal occult blood test, any swallowing disturbance or
dysphagia, chronic pancreatitis requiring pancreatic enzyme supplementation for digestion;
previous episode of acute pancreatitis
4. Any type of neoplasms (see "Evaluation Neoplasms"), previous gastric surgery due to cancer,
history of perforated ulcer (gastric surgery not due to cancer); melena/profuse bleeding from the
upper gastrointestinal tract, acute pancreatitis
LOWER GASTROINTESTINAL SYSTEM
Includes the rest of the digestive system, from the small intestine to the anus: Whipple's disease,
diverticulosis, irritable bowel, malignancies. Constipation is also scored by type and frequency of
laxatives needed, or history of retention.
0. No problems, prior appendectomy, prior hernia repair (no complications)
1. Constipation managed with on-demand medications, active hemorrhoids, intestinal hernia
requiring surgery; previous hernia repair with complications (intestinal adhesions, laparocele, etc.),
irritable bowel syndrome (few symptoms).
2. Constipation requiring daily bulk laxatives (psyllium, polycarbophil, Sterculia, guar gum, etc), or
laxatives; diverticulosis (anterior diverticulitis), inflammatory bowel disease in medication remission
(more than 5 years ago).
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
116 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
3. Intestinal impaction/diverticulitis in the last year, daily use of stimulants (irritants) or osmotic
laxatives (bisacodyl, senna, glycerol, docusate sodium, lactulose, polyethylene glycol) or enemas,
chronic intestinal inflammation in remission with medications (less than 5 years)
4. Recurrent diverticulitis, active inflammatory disease; current impaction; hematochezia/active
bleeding from the lower GI tract; colon carcinoma
LIVER AND BILIARY TREE
Includes liver, gallbladder, biliary trees, portal system: acute and chronic hepatitis (viral, alcoholic,
toxic, idiopathic, autoimmune), cirrhosis, portal hypertension, hemochromatosis, primary biliary
cirrhosis, cholelithiasis, cholangitis, primary malignant tumors. As the hepatobiliary system is
difficult to assess through physical examination, laboratory results should be used.
0. No problem
1. History of hepatitis (actually with normal transaminase values), cholecystectomy
2. Cholelithiasis, chronic hepatitis or previous hepatitis (less than 5 years ago) or any other liver
disease (hemochromatosis, primary biliary cirrhosis) with Mildly elevated transaminases (< 3 times
normal values), excessive alcohol use in the last 5 years (assess in "psychiatric", too)normal
values).
3. Chronic hepatitis or any other liver disease with marked elevation of transaminases (> 3 times
normal values), elevated levels of bilirubin
4. Acute cholecystitis, biliary obstruction, active hepatitis and liver cirrhosis; any carcinoma of the
liver or biliary tree
RENAL
This
category
is
exclusive
to
the
kidneys:
kidney
stones,
acute/chronic
renal
failure,
glomerulonephritis,
nephrotic/nephritic
syndrome;
active/chronic
pyelonephritis,
diabetic
or
hypertensive nephropathy (albuminuria/proteinuria), renal carcinoma.
Bence-Jones proteinuria should not be considered in multiple myeloma.
0. No problem
1.
Asymptomatic kidney stones; passage of kidney stones in the last ten years; pyelonephritis
in the last 5 years, renal cysts without hematuria
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
117 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
2.
Serum creatinine >1.5 but <3 mg/dl without diuretic or antihypertensive medications
(especially ACE inhibitors or RAAS blockers), kidney stones requiring daily medicationsdl
3.
Serum creatinine >3 mg/dl or >1.5 mg/dl in conjunction with diuretics, antihypertensives, or
bicarbonate therapy; active pyelonephritis, nephrotic syndrome; colic symptoms treated as
outpatient
4.
Dialysis required, renal carcinoma, colic symptoms requiring hospitalization
GENITOURINARY
Ureters, bladder, urethra.
Genitals, prostate, testicles, penis, seminal vesicles.
Uterus, ovaries. The mammary gland is classified under "metabolic".
This category includes all GU tract impediments: urethral or bladder stones, benign prostatic
hypertrophy (BPH), urinary tract infections (UTIs), prolapses, etc. Urinary incontinence and
indwelling catheter should also be considered.
0. No problems
1.
Stress incontinence, BPH without urinary symptoms, hysterectomy or ovariectomy (uterine
fibroid, benign tumor)
2.
Cervico-vaginal pathology (or two consecutive abnormalities), frequent UTIs (3 or more in
the last year) in women or UTIs current, urinary incontinence (not stress) in women; BPH
with urinary symptoms (frequency, urgency, hesitancy); status post TURP; any urinary
diversion procedure, catheter, bladder stones
3.
Prostate cancer in situ (for example, found on purpose during TURP), vaginal bleeding,
cervical carcinoma in situ, hematuria (any cause), urinary incontinence (non-stress) in men;
bladder polyps
4.
Acute urinary retention; current urosepsis; any GU carcinoma, except anterior
MUSCULOSKELETAL-TEGUMENTARY
This is a very broad category, including: osteoarthritis, osteoporosis, bone fractures; primary
neoplasm (bone, muscle, connective tissue, skin), distinguishing melanoma from other localized
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
118 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
skin cancers, rheumatoid arthritis and polymyalgia rheumatica, muscle lesions (rotator cuff, long
head of biceps); pressure ulcers; any dermatological disease.
The qualifications of this category are strictly linked to the disability that it causes, for the
evaluation of the degree of disability, they refer to basic and instrumented activities.
NOTE: Rate the severity of each illness based on the level of disability caused by the same illness
in this category, without taking into account disability caused by other illnesses. For example: a
patient affected by both osteoarthritis and hemiplegia from a previous attack has a high level of
disability, but you should mark 2 for disability due to osteoarthritis (in this category) and 4 for
disability due to stroke (in this category). neurological category); for a patient with rheumatoid
arthritis deformans and a previous attack with no remaining results, note 4 disability from arthritis
(in this category) and 2 disability from stroke (in the neurological category).
0. No problems
1.
Requires on-demand medications for osteoarthritis (NSAIDs) or has slightly limited IADLs
due to joint pathologies; excised skin cancer (except melanoma), skin infections requiring
antibiotics within a year
2.
Daily anti-osteoarthritis medications (NSAIDs) or use of assistive devices or some limitation
in IADLs (previous arthro-prostheses or fractures treated with low level of remaining
disability), osteoporosis without vertebral fractures; daily medications for chronic skin
conditions
(including
local,
such
as
psoriasis
or
pressure
ulcers);
non-metastatic
melanoma, daily rheumatoid arthritis medications (except steroids) with low level of
disability
3.
Osteoarthritis with moderate level of disability on IADLs; chronic steroid treatment required
for arthritic conditions or joint deformities or severe disabilities; osteoporosis with vertebral
compression fractures
4.
Wheelchair for musculoskeletal disease; severe joint deformities or severe use disability;
osteomyelitis;
any
neoplasm
of
bone,
muscle
or
connective
tissue
(see
section
"Classification Neoplasms"); metastatic melanoma.
Fractures and/or arthro-prostheses (both recent and old) have to be classified according to the
level of disability they cause (considering the results as well), in order to avoid confusion about
possible classifications of different fractures or joints. The same for muscle diseases.
CENTRAL AND PERIPHERAL NERVOUS SYSTEM
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
119 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
This category includes "somatic" pathologies of the central and peripheral nervous system: any
type
of
cerebrovascular
accident,
neurodegenerative
diseases
(Parkinson's
disease
and
parkinsonism, multiple sclerosis, amyotrophic lateral sclerosis, etc.), myelopathies, traumas with
neurological, primary or secondary epilepsy, neuropathies (diabetic, alcoholic, any other etiology),
primary tumors, chronic headaches (migraine), insomnia, etc. The severity and prognosis of the
disease, but also the functional impairment caused by the disease, must be carefully estimated.
0. No problems (or decreased seizures in childhood)
1.
Frequent headaches requiring on-demand medications without impairment of advanced
ADLs; Previous TIA (one case); Previous existence of epilepsy, really untreated, without
seizures for more than 10 years.
2.
Chronic daily headache requiring medication (even for prophylaxis) or with advanced
regular deterioration in advanced ADLs (bed rest, work abandonment, etc.); True TIA or
more than one prior TIA, prior stroke with no significant residual, neurodegenerative
diseases of mild intensity (see above), treated and well controlled; drug-controlled epilepsy.
3.
Previous
stroke
with
residual
mild
dysfunction
(hemiparesis,
dysarthria),
and
any
neurosurgical procedure; neurodegenerative diseases of moderate severity (see above) not
well controlled by medication, epilepsy under treatment but with periodic seizures.
4.
Acute or previous cerebrovascular accident with serious residual dysfunctions (hemiplegia,
aphasia, severe vascular dementia) or more than one previous stroke (multi-infarct
encephalopathy), serious neurodegenerative diseases (see above) causing disability in
ADLs, neurological coma .
Alzheimer's disease and dementia should not be classified in this category (psychiatric and
behavioral illnesses): Alzheimer's disease should appear only in psychiatric disorders; if the
dementia is due to vascular and/or mixed dementia and/or other neurological problems (for
example,
Parkinson's
disease),
they
should be approved in both the “neurological” and
“psychiatric” categories at the appropriate severity level, taking into account in this category stroke
and multi-infarct encephalopathy responsible for cognitive impairment (score 3 for stroke with
remaining outcomes, score 4 for multi-infarct encephalopathy).
ENDOCRINE-METABOLIC SYSTEM AND BREAST (also systemic infections and poisoning)
Type 1 and type 2 diabetes (organ damage must be considered in the respective categories, as
well as hypertension), obesity and dyslipidemia (hypercholesterolemia) represent the core of this
category; It also includes hypo- and hyperthyroidism, hypo- and hyperparathyroidism, adrenal
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
120 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
pathology (Cushing's or Addison's disease), hypogonadism, hypopituitarism, etc. Neoplasms of
these glands, both benign (such as thyroid nodules) and malignant (such as thyroid or adrenal
cancer, vipoma, etc.) are also included.
Even if it is an exocrine gland, the breast is included in this category because the authors did not
find a more suitable category, which also includes breast cancer.
It also includes: electrolyte disorders, sepsis, systemic infections (such as tuberculosis, syphilis,
AIDS) classified according to their severity and the functional deterioration they cause (see general
indications) and poisoning (chronic by metals or acute by pesticides or carbon monoxide).
0. No problems
1.
Diabetes and/or dyslipidemia compensated by diet, moderate obesity (BMI 30-35 kg/m2),
hypothyroidism on replacement therapy (L-thyroxine); hyperthyroidism caused by surgically
treated Plummer's adenoma.
2.
Diabetes compensated with oral hypoglycemic agents or insulin (hemoglobin A1c <7%),
dyslipidemia well controlled by daily medications (LDL-C below the recommended target
according to individual global cardiovascular risk), moderate obesity (BMI 35-45 kg/m2 ) ,
hyperthyroidism (Basedow, Plummer) with pharmacological treatment; asymptomatic or
surgically treated hyperparathyroidism, fibrocystic breast disease.
3.
Diabetes not well compensated by therapy (hemoglobin A1c 7-8.5%, presence of
complications), dyslipidemia not well controlled (LDL-C higher than the recommended goal
according to individual global cardiovascular risk, for example, LDL-C > 100 mg/dl in
patients
with
myocardial
infarction
or
stroke),
severe
obesity (BMI > 45 kg/m2),
symptomatic hyperparathyroidism (eg, hypercalcemia), adrenal insufficiency replacement
therapy, any electrolyte disturbance requiring hospitalization .
4.
Uncontrolled diabetes (hemoglobin A1c > 8.5%) or diabetic ketoacidosis or hyperosmolar
nonketotic coma in the past year, uncontrolled genetic dyslipidemia, acute adrenal
insufficiency during hormone replacement therapy, any tumor of the thyroid, breast, or
adrenal gland (see "Evaluation Neoplasms").
NOTE: When the patient is not being treated with drug therapy for diabetes or dyslipidemia but
should be treated for optimal control of disease (eg, hemoglobin A1c > 7%, total cholesterol > 250
mg/dL), score the pathology according to the laboratory values, which is what really defines its
severity.
PSYCHIATRIC AND BEHAVIORAL ILLNESSES
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
121 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
This category includes both dementia and behavioral disorders (psychosis, anxiety, depression,
agitation) and all pre-existing and/or unrelated psychiatric disorders of dementia. Since this is the
only category that analyzes the mental state of the patient (all others refer to the physical state), it
is very important to evaluate it by carefully considering the additional instructions derived from the
Comprehensive
Geriatric
Assessment
(MMSE,
Geriatric
Depression
Scale,
Neurological
Inventory). -Psychiatry if available).
0. No psychiatric problems or history of the same
1.
minor psychiatric conditions or history of the same: previous (occasional) psychiatric
treatment without hospitalization, case of major depression and/or use of antidepressants
for more than 10 years without hospitalization, occasional use from minor tranquilizers (eg,
benzodiazepines, including as hypnotherapy for insomnia); mild cognitive impairment
(MMSE 25-28).
2.
A history of major depression (according to DSM-IV criteria) in the last 10 years (treated or
not); mild dementia (MMSE 20-25), upon admission to the Department of Psychiatry for any
reason; history of substance abuse (more than ten years ago, including alcoholism).
3.
Current major depression (according to DSM-IV criteria) or more than two prior episodes of
major depression in the past 10 years, moderate dementia (MMSE 15-20), current and
regular use of daily antianxiety medications ( including such as hypnotherapy for insomnia),
substance abuse or dependence currently or in the last ten years (according to DSM-IV
criteria); requires daily antipsychotic medication; previous suicide attempt.
4.
Current mental illness requiring psychiatric hospitalization, institutionalization, or intensive
outpatient treatment (psychiatric emergency, such as suicide attempt or severe depression
for the purpose of suicide, acute psychosis or acute decompensation of chronic psychosis,
severe substance abuse, severe agitation of dementia ); severe dementia (MMSE <15);
delirium (acute confusion or altered mental status for medical (organic) reasons): in this
case the medical cause should also be coded in its own category with the appropriate level
of severity).
(Version 1.2: July 7, 2016)
Psychiatric consultation could be requested for this category; dementia and depression, the most
frequent diseases in the elderly, can be marked in detail with the MMSE and GDS. The severity of
any mental disorder (dementia, depression, anxiety, psychosis, substance abuse, and all the rest)
has to be rated according to the level of functional impairment or disability it causes.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
122 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
ASSESSMENT LIST
Medical history
1. Calendar of events and/or interventions (how long ago did you have surgery for ..., how long ago
did you have a myocardial infarction or stroke, etc.) and assessment of functional impairment
2. drug list(fundamental),including laxatives and tranquilizers (including hipno-inductivos)
3. Symptoms of atherosclerotic disease (TIA, angina, claudication, amaurosis)
4.diagnosis etiologic (reasonably reliable) of anemia
5. degree of vascular stenosis or aneurysm dimension (by Doppler and/or ultrasound and/or TC
data, if available)
6. Information about your smoking (how many cigarettes per day for how many years? when did
you stop?)
7. Wearing glasses? With this help, is the patient able to read a newspaper? Do you need a
companion to go on an adventure?
8. Any hearing aids? (It should evaluate the possibility of communicating with the patient)
9. "History peptic" of the patient (including prior therapy for H. pylori eradication)
10. Urinary symptoms incontinence, indwelling catheter (including BADL - basic activities daily life)
Physical exam
a. Height (m2) and weight (kg) (measured, not reported, if possible) to calculate BMI
b. Blood pressure, heart rate, heart murmurs, peripheral arterial pulses
c. Joint pain or limited passive stiffness (Non-x-ray based diagnosis of osteoarthritis)
d. Neurological sequelae (dysarthria/aphasia, hemiparesis/hemiplegia)
Baseline laboratory values
• Complete blood count: hemoglobin, leukocytes and platelets
• Creatinine, electrolytes
• Cholesterol levels (total, HDL) and triglycerides
• AST, ALT, fractionated bilirubin
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
123 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
• Thyroid function and vitamin serum B12 (when indicated)
• Hemoglobin A1c (for diabetics)
GAH
Geriatric assesement for Hematology
polypharmacy
number of concomitant drugs
Putting number of drugs
MOOD DURING tHE LAST WEEK
During the last week, he felt depressed ...
<3
days> 3 days
SUBJECTIVE HEALTH STATE
In general, compared to other people your age,
would you say your health is...
Excellent
Very good
Good
Fair
Poor
ACTIVITIES OF DAILY LIVING
You need help with your daily life YES NO You have a
caregiver YES NO You
have Difficulty buying personal items YES NO
Difficulty managing money YES NO
Difficulty walking YES NO
Difficulty performing daily tasks light domestics YES NO
NUTRITION
Weight (kg)
Height (m)
BMI
Have you lost weight in the last 3 months?
No
Between 1 and 3 kg
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
124 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
More than 3 kg
I don't know
Have you eaten less than usual in the last 3 months
due to loss of appetite, digestive problems or
difficulty chewing and/or swallowing?
No
Somewhat less
Much less
WALKING SPEED
How long does it take for the patient to walk there
and back? (m/sec)
MENTAL STATUS
What is today's date? Correct Incorrect
What day of the week is today? Correct Incorrect
What is your phone number? Correct Incorrect
What is your age? Correct Incorrect
When were you born? Correct Incorrect
What is the name of the president of the government? Correct Incorrect
What was the name of the previous president of the government? Correct Incorrect
What are your mother's last names? Correct Incorrect
Starting at 20, subtract 3 by 3,
until reaching the end
Correct Incorrect
COMORBIDITY AND HABITS
Diabetes mellitus YES NO
Cancer YES NO
Pulmonary disease YES NO
Heart failure YES NO
Smoking YES NO/EX-SMOKER
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
125 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
XI. Ibrutinib SmPC
Summary of product characteristics, available on file at the investigator's center or on the EMA
website:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines
/landing/epar_search.jsp&mid=WC0b01ac058001d124
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
126 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
​
XII. Screening and Inclusion Procedure
REGISTRATION OF USERS IN THE ONLINE SCREENING/INCLUSION PLATFORM:
1.- Registration of users:
The screening and inclusion process must be carried out by IP, CoIP (doctors) or personnel
designated by the IP conveniently identified in the Signature List. After the start visit, the
link to the inclusion platform will be sent to the IP along with his username and password
as the person responsible for the inclusion of patients (in the event that there are
Collaborating Researchers identified in the Signature List, they will also be provided with
the access data ).
Link to the platform: mfar.es/ce/ibdclgeltamo2015
2.- Generation of private password:
To comply with BPC, once the IP/Co-IP accesses the username and password provided by
MFAR for the first time, the system will ask you to change the password.
IMPORTANT: The password assigned from MFAR expires (approximately one week),
therefore it is recommended that users generate the private password as soon as possible
after receiving temporary access.
From this moment on, the user will keep the same access data for all the inclusion
platforms MFAR that are generated.
3. Patient RegistrationPatient:
3.1Screening (must be performed by the Center, IP or CoIP or assigned personnel):
IMPORTANT: The patient must have signed the informed consent to start the screening
process.
Link to the platform: mfar.es/ce/ibdclgeltamo2015
1.- Access the screening form by clicking on
2.- Once accessed, the user must enter the screening date, signature of the informed
consent and the patient's date of birth. Click on “save”.
3.- The system will request confirmation for what must be clicked on "accept" and the
system will automatically assign the screening number for the patient.
4.- After showing the screening number on the screen, both the hospital team registered on
the platform (indicated by the center at the start visit) and the team MFARwill receive a
confirmation email of the patient in screening.
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
127 de 128


Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine,
Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB
Diffuse Large B-cell Lymphoma Non Candidates to ASCT
3.2- Inclusion of patients (must be carried out by the Center, PI or CoIP or designated
personnel):
Once all the screening tests have been carried out and confirm that the patient meets all the
eligibility criteria, the PI/Co-PI or designated personnel must perform the inclusion process
before starting the study treatment.
Link to the platform: mfar.es/ce/ibdclgeltamo2015
1.- Click on “Edit”
of the patient in screening that you want to include.
2.- Complete if the patient meets the eligibility criteria (checkbox).
3.- Once the form has been properly completed, click on "save", the system will request
confirmation of the patient's inclusion, click on "accept", the system will assign the
patient's number automatically and send the confirmation of inclusion by email to all
persons identified at the start visit as recipients of the opt-in confirmation notification.
(Version 1.2: July 7, 2016)
Protocol IBDCL-GELTAMO-2015 – V 2, October 21, 2016
128 de 128

SAP_001.pdf: 
IBDCL-GELTAMO-2015
STATISTICAL ANALYSIS REPORT
26th of April 2021 (version 1.0)
Done by: MFAR CLINICAL RESEARCH SL
Page 1 of 41


TITLE
Phase II multicenter clinical trial to evaluate the efficacy and safety of ibrutinib in
combination with rituximab, gemcitabine, oxaliplatin, and dexamethasone followed by
ibrutinib as maintenance treatment in patients with diffuse large B-cell lymphoma
refractory to the treatment or relapsing, non-candidates to receive a TACM.
SPONSOR
Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO)
COORDINATORS
Dra. Dolores Caballero Medical and Dr. Alejandro Martín. Hospital Universitario de
Salamanca / IBSAL.
MONITORING ORFANISATION
MFAR Clinical Research
Balmes 243, Escalera A 5º1ª - 08006 Barcelona.
Phone: (+34) 93 434 44 12
e-mail: investigacion@mfar.net. Web: www.mfar.es
Page 2 of 41


INDEX
LIST OF ABBREVIATIONS………………………………………………………. 7
1.
DEFINITIONS
9
1.1. POPULATIONS FOR ANALYSIS
9
1.2. EFFICACY ANALYSIS
9
2.
RESULTS
10
2.1. POPULATIONS
10
2.1.1. Patients registered in the eCRF
10
2.1.2. Analyzable patients
11
2.1.3. Analysis populations
12
2.2. BASELINE CHARACTERISTICS
12
2.2.1. Vital signs
13
2.3. DIAGNOSIS
15
2.3.1. Diagnosis: Immunohistochemical type of LDCBG
16
2.3.2. Diagnosis: Other histological data
17
2.3.3. Current lymphoma exploration
18
2.3.4. Current stage: Rebiopsy and other current results
20
2.3.5. Current histology: diagnosis and agreement
21
2.3.6. Current Immunohistochemistry: diagnosis and agreement
22
2.3.7. Global diagnosis
23
2.4. PREVIOUS TREATMENTS LYMPHOMA
25
2.5. AUTOLOGOUS STEM CELL TRANSPLANT
28
2.6. ALEOGENIC TRANSPLANT HEMATOPOIETIC PROGENITORS
28
2.7. EXTRANODAL AND NODAL AFFECTATION
29
2.8. BASELINE ANALYTICS
32
2.8.1. HEMOGRAM
32
2.8.2. BIOCHEMISTRY
32
2.8.3. COAGULATION TEST
32
2.8.4. IPI
33
2.8.5. LYMPHOMA SITUATION
33
2.8.6. SEROLOGY
33
2.9. OTHER TESTS
35
2.9.1. OTHER TESTS    : PREGNANCY
35
2.9.2. OTHER TESTS    : CARDIOLOGY TEST
35
2.9.3. OTHER TESTS    : COMORBIDITIES QUESTIONNAIRE
36
2.10.
TREATMENT COMPLIANCE
39
2.11.
END OF TREATMENT
41
Page 3 of 41


2.12.
EFFICACY: RESPONSE
42
2.12.1.
SUMMARY RESPONSE AT 4TH CYCLE AND AFTER INDUCTION IN
TREATED PATIENTS
42
2.12.2.
RESPONSE AT 4TH CYCLE IN TREATED PATIENTS
43
2.12.3.
RESPONSE AT 4TH CYCLE IN PATIENTS FROM AVAILABLE
RESPONSE POPULATION
44
2.12.4.
RESPONSE AT 6-8TH CYCLE IN TREATED PATIENTS
45
2.12.5.
RESPONSE AT 6-8TH CYCLE IN PATIENTS FROM AVAILABLE
RESPONSE POPULATION
46
2.12.1.
ORR IN TREATED PATIENTS
47
2.12.2.
ORR IN PATIENTS FROM AVAILABLE RESPONSE POPULATION
48
2.13.
EFFICACY: SURVIVAL
49
2.13.1.
OVERALL SUVIVAL IN TREATED PATIENTS
49
2.13.1.
OVERALL SUVIVAL IN AVAILABLE RESPONSE POPULATION
52
2.13.2.
PROGRESSION FREE SURVIVAL IN TREATED PATIENTS
55
2.13.3.
PROGRESSION FREE SURVIVAL IN AVAILABLE RESPONSE
POPULATION
58
2.13.4.
EVENT FREE SURVIVAL IN TREATED PATIENTS
61
2.13.5.
RESPONSE DURATION IN TREATED PATIENTS
64
2.13.1.
COMPLETE RESPONSE DURATION IN TREATED PATIENTS
66
2.13.2.
PARTIAL RESPONSE DURATION IN TREATED PATIENTS
68
2.13.3.
RESPONSE DURATION IN AVAILABLE RESPONSE POPULATION
70
2.14.
SAFETY: TOXICITY
71
2.14.1.
MOST FREQUENT ADVERSE EVENTS AND TOXICITIES
72
2.14.1.
HEMATOLOGICAL AND NON-HEMTOLOGICAL TOXICITIES
74
2.14.1.
SAES
78
3.
ANNEXES
81
3.1. ANNEX 1: RELEVANT PREVIOUS EVENTS
81
3.2. ANNEX 2: PREVIOUS MEDICATION
85
3.3. ANNEX 3: ALL TOXICITIES
88
Page 4 of 41


LIST OF ABBREVIATIONS
Abbreviations
Term explanation
AE
Adverse Event
CR
Complete response
eCRF
Case Report Form
ECOG
Eastern Cooperative Oncology Group
EFS
Event Free Survival
GEL/TAMO
Grupo  Español de Linfoma/Trasplante Autólogo de Médula Ósea
HLA
Human Leukocyte Antigen
LDCBG
Linfoma difuso de células B grandes
LNH
Linfoma no Hodgkin
NA
Not aplicable
ND
Not Done
OR
Overall Response
OS
Overall survival
PET
Positron Emission Tomography
PR
Partial Response
PD
Progression disease
PFS
Progression Free Survival
R-GEMOX
Rituximab-GEMOX
SAE
Serious Adverse Event
SD
Stable Disease
UK
Unknown
Page 5 of 41


1. DEFINITIONS
1.1. POPULATIONS FOR ANALYSIS
The analysis populations are defined as:
- Population of all treated patients: defined as all patients receiving at least 1 dose of
study drug.
- Population with evaluable response: defined as all patients with measurable
disease at baseline, receiving at least 1 dose of study drug, and having at least 1
adequate post-baseline disease evaluation. An adequate disease assessment is
defined as having sufficient evidence to correctly indicate whether or not disease
progression has occurred. Patients who have died from progression are also
considered to have had an adequate evaluation.
- Safety population: defined as all patients receiving at least 1 dose of study drug,
which is the same definition as for the population of all treated patients.
1.2. EFFICACY ANALYSIS
Efficacy analysis: final analysis of the primary endpoint, ORR (CR + PR) after 4
cycles, can be carried out 4 months after the last patient was enrolled, and will be
based on the population of all treated patients. Response rates with confidence
intervals (95% interval) will be presented. The TRG will be evaluated in accordance
with local and centralized PET / CT evaluations.
Overall survival, PFS, event-free survival, and duration of response are defined as
follows (Cheson et al., 2007):
Overall survival (OS): defined as the time between entry into the trial and death from
any cause. It will be analyzed using the Kaplan-Meier method. Data on patients
withdrawn from the study or unavailable for follow-up will be censored on the date of
the last contact.
Progression-free survival (PFS). It is defined as the time elapsed from the inclusion
of the first patient in the study until the progression of the disease or death from any
cause.
Event-free survival (EFS). It is defined as the time elapsed from inclusion in the trial to
lymphoma progression, treatment failure, or death from any cause. It will be analyzed
using the Kaplan-Meier method.
Duration of response. It will be calculated from the date there is an indication of CR or
PR to the date of disease recurrence or progression. It will be analyzed using the
Kaplan-Meier method.
Page 6 of 41


2. RESULTS
2.1. POPULATIONS
2.1.1. Patients registered in the eCRF
Table 1. Patients registered by hospital
N
%
Hospital
Total
Analyzable
Yes
No
Total
2.1.2. Analyzable patients
Table 2. Not analyzable patients
No.
Study Subject ID
Hospital
Reason
Table 3. Analyzable patient by hospital
Analyzable
No
Yes
Total
N
%
N
%
N
%
Hospital
Total
Page 7 of 41


2.1.3. Analysis populations
Table 4. Analysis population
N
%
Treated patient
population
Yes
Total
Available response
patient population
Yes
No
Total
Reason considered
response not
available
At least one post-baseline evaluation
Death due to progression
Total
Table 5. List of patients excluded from Available response patient population
Study
Subject ID
Hospital
Available response
patient population
Reason considered
response available (or
not)
Overall
survival
Reason of
Death
Specify reason
of Death
1
2
3
4
2.2. BASELINE CHARACTERISTICS
Table 6. Gender
N
%
Gender (Baseline)
Male
Female
Total
Table 7. Age
N
Mean
SD
Median
Min
Max
Age (years)
Vital signs
Table 8. Vital signs 1
N
Mean
SD
Median
Min
Max
Systolic blood pressure
(Baseline)
Diastolic blood pressure
(Baseline)
Temperature (Baseline)
Weight (Baseline)
Height (Baseline)
Page 8 of 41


Table 9. Vital signs 2
N
%
ECOG (Baseline)
0
1
2
Total
B symptoms (Baseline)
Yes
No
Total
Pre-existing condition,
relevant signs or
symptoms (Baseline)
Yes
No
Total
All relevant previous events are listed in ANNEX 1: RELEVANT PREVIOUS
EVENTS (page 40), and the following table contains those events present in at least
5% of the patients.
Table 10. Most frequent relevant previous events (present in at least 5% of
patients)
N
Relevant
previous
events
Table 11. Previous medication
N
%
Previous
medication
Yes
No
Total
All previous medications are listed in ANNEX 2: PREVIOUS MEDICATION
(page 40), and the following table contains those medications present in at least 5% of
the patients.
Table 12. Most frequent previous medication (present in at least 5% of patients)
N
Previous
medication
Page 9 of 41


2.3. DIAGNOSIS
Table 13. Time from diagnosis and age at diagnosis
N
Mean
SD
Median
Min
Max
Time from diagnosis to study
inclusion (months)
Age at diagnosis
Table 14. Local histological diagnosis, centralized and agreement
N
%
Histological subtype at
diagnosis, local
(Baseline)
LDCBG without specification
Others1
LDCBG specified2
Total
2: LDCBG specified
LDCGB rich in T
1: Others Follicular lymphoma
N
%
Histological subtype at
diagnosis, centralized
review (Baseline)
LDCBG without specification
Others3
NA
ND
Total
3: Others
CD5+ B lymphoma
Could not be
determined with
submitted sample
MO cylinder biopsy
without evidence of
neoplastic infiltration
N
%
Agreement in histology at diagnosis
No
Yes
Total
Table 15. Patients without agreement in Histological type at diagnosis
Study
Subject
ID
Hospital
Diagnosis date
(Baseline)
Histological subtype at
diagnosis, local (Baseline)
Histological subtype at
diagnosis, centralized
review (Baseline)
Agreement in
histology at
diagnosis
1
2
3
4
Page 10 of 41


1.1.1.Diagnosis: Immunohistochemical type of LDCBG
Table 16. Immunohistochemical type of LDCBG at diagnosis
 
N
%
Immunohistochemical
type at diagnosis,
local (Baseline)
no-CGB
Others
UK
Total
Immunohistochemical
type of LDCBG at
diagnosis, centralized
review (Baseline)
CGB
no-CGB
NA
ND
UK
Total
Agreement in
immunohistochemical
at diagnosis
Non-CGB local and centralized
Non-CGB local and CGB centralized
Non-CGB local and missing centralized
Missing local and centralized
Other local and missing centralized
Total
Agreement in
immunohistochemical
at diagnosis
Yes
No
Total
Table 17. Patients without agreement in Immunohistochemical type of LDCBG at
diagnosis
Study
Subject
ID
Hospital
Diagnosis date
(Baseline)
Immunohistochemical
agreement at
diagnosis (Yes/No)
Immunohistochemical agreement
at diagnosis
1
2
3
4
5
1.1.2.Diagnosis: Other histological data
Other histological data at diagnosis.
Table 18. Other histological data
N
%
Nanostring result at
diagnosis (Baseline)
ABC
Not done
NA
ND
UK
Total
Lymphoma stage at
diagnosis (Baseline)
I
II
III
IV
ND
Page 11 of 41


UK
Total
ECOG diagnosis
(Baseline)
0
1
2
3
ND
UK
Total
LDH at diagnosis
(Baseline)
Normal
Increased
ND
UK
Total
IPI diagnosis
(Baseline)
0-1
2
3
4
5
ND
UK
Total
1.1.3. Current lymphoma exploration
Table 19. Current lymphoma exploration
 
N
%
Adenopathy (Baseline)
Yes
No
Total
Specify adenopathy
(Baseline)
Example: Bilateral supraclavicular, Axillary, mediastinal,
hilar…
Total
Hepatomegaly
(Baseline)
Yes
No
Total
Splenomegaly
(Baseline)
Yes
No
Total
Lymphomatous
involvement (Baseline)
Yes
No
Total
Specify Lymphomatous
involvement (Baseline)
Example: Bone, liver and bone marrow…
Total
Page 12 of 41


1.1.4. Current stage: Rebiopsy and other current results
Table 20. Histological, molecular and current stage
 
N
%
Rebiopsy (Baseline)
Yes
No
Total
Current nanostring result
(Baseline)
CGB
ABC
Not done
NA
ND
UK
Total
Current lymphoma clinical
stage (Baseline)
I
II
III
IV
NA
ND
UK
Total
Current Bone marrow biopsy -
histological affectation
(Baseline)
Yes
No
NA
ND
UK
Total
Current cytometry involvement
(Baseline)
Yes
No
NA
ND
UK
Total
1.1.5. Current histology: diagnosis and agreement
Table 21. Current Histological subtype
 
N
%
Current, local histological subtype
(Baseline)
LDCBG without specification
LDCBG specified
NA
ND
UK
Total
Specify other histological
subtypes current, local (Baseline)
Example: LDCBG gastric…
Total
Current histological subtype,
centralized review (Baseline)
LDCBG without specification
Others
NA
ND
Page 13 of 41


UK
Total
Specify other current histological
subtypes, centralized review
(Baseline)
Example: Lymphoma B of the marginal
zone/Lymphoma B with plasmocellular
differentiation…
Total
Current concordance in Histology
at diagnosis
No
Yes
Total
Table 22. Patients without agreement in current histology diagnosis
Study
Subject
ID
Hospital
Current, local
histological subtype
(Baseline)
Specify other
histological
subtypes
current, local
(Baseline)
Current
histological
subtype,
centralized
review
(Baseline)
Specify other current histological
subtypes, centralized review
(Baseline)
1
2
3
1.1.6. Current Immunohistochemistry: diagnosis and agreement
Table 23. Agreement current immunohistochemical diagnosis
 
N
%
Current
immunohistochemical
type, local (Baseline)
no-CGB
NA
ND
UK
Total
Immunohistochemical
type of current
LDCBG, centralized
review (Baseline)
CGB
no-CGB
NA
ND
UK
Total
Current
immunohistochemical
agreement
No
Yes
Total
Table 24. Patients without agreement in current immunohistochemical diagnosis
Study
Subject
ID
Hospital
Current
immunohistochemical
agreement
Current
immunohistochemical
type, local (Baseline)
Immunohistochemical
type of current
LDCBG, centralized
review (Baseline)
1
2
3
4
Page 14 of 41


1.1.7. Global diagnosis
Table 25. Agreement current immunohistochemical diagnosis
 
N
%
Global local
diagnosis
no-CGB
Total
Global
centralized
diagnosis
no-CGB
CGB
LDCBG without specification
Others: Follicular lymphoma, Lymphoma B with plasmocellular differentiation…
ND
UK
Total
Global
agreement
No
Yes
Total
Table 26. Patients without agreement in current immunohistochemical diagnosis
Study
Subject
ID
Hospital
Global local
diagnosis
Global centralized diagnosis
1
2
3
Page 15 of 41


1.2. PREVIOUS TREATMENTS LYMPHOMA
Table 27. Number of previous treatment lines
 
N
%
Number of previous treatment lines
(Baseline)
1
2
3
4
5
Total
 
N
Mean
SD
Median
Min
Max
Number of previous treatment
lines (Baseline)
Table 28. Previous treatment: 1st line
 
N
%
Best response previous
treatment line 1
(Baseline)
CR
PR
SD
PD
ND
UK
Total
Relapse or previous
progression line 1
(Baseline)
Yes
No
NA
ND
Total
First line treatment
(Baseline)
Example: R- CHOP, Rituximab, Splenectomy…
Total
Table 29. Previous treatment: 2nd line
 
N
%
Best response
previous
treatment line 2
(Baseline)
CR
PR
SD
PD
NA
UK
Total
Relapse or
previous
progression line
2 (Baseline)
Yes
No
NA
UK
Total
Second line
treatment
(Baseline)
NA 
Example: R-ESHAP, R-DHAP
Total
Page 16 of 41


Table 30. Previous treatment: 3rd line
 
N
%
Best response
previous
treatment line 3
(Baseline)
PR
SD
PD
NA
UK
Total
Relapse or
previous
progression line
3 (Baseline)
Yes
No
NA
Total
Third line
treatment
(Baseline)
NA 
Example: BeGEV + Transplant
Total
Table 31. Previous treatment: 4th line
 
N
%
Best response previous
treatment line 4 (Baseline)
PR
PD
NA
UK
Total
Relapse or previous
progression line 4
(Baseline)
Yes
NA
Total
Fourth line treatment
(Baseline)
NA
Example: Prednisone + Brentuximab
Total
1.3. AUTOLOGOUS STEM CELL TRANSPLANT
Table 32. Autologous stem cell transplant
 
N
%
Autotransplantation
(Baseline)
Yes
No
Total
Situation
autotransplantation
(Baseline)
1st CR
1st PR
2nd CR
2nd PR
Others
NA
Total
Specify other
(Baseline)
Example: PD located in right axillar region…
Total
Best response
autotransplantation
(Baseline)
CR
PR
PD
NA
UK
Total
Page 17 of 41


Response duration
(Baseline)
Example: 0, 3, 6, 9…
NA
UK
Total
Relapse or
progression (Baseline)
Yes
NA
Total
Table 33. Response duration (autologous stem cell transplant)
 
N
Mean
SD
Median
Min
Max
Response duration (Baseline)
1.4. ALEOGENIC
TRANSPLANT
HEMATOPOIETIC
PROGENITORS
Table 34. Allogenic transplant hematopoietic progenitors
 
N
%
Allotransplant (Baseline)
No
Total
1.5. EXTRANODAL AND NODAL AFFECTATION
Table 35. Extranodal Affectation
 
N
%
Extranodal affectation
at diagnosis
(Baseline)
Yes
No
ND
Total
Locations extranodals
(Baseline)
ND
Example: 0, 1, 2, 3…
Total
Specify extranodal
affectation (Baseline)
Example: Bone, Lung, Bone marrow…
Total
Table 36. Nodal Affectation
 
N
%
Nodal
affectation at
diagnosis
(Baseline)
Yes
No
ND
Total
Nodal
locations
(Baseline)
ND
Example: 0, 1, 2, 3…
Total
Specify nodal
affectation
(Baseline)
Example: Bilateral adrenal burky mass, Retroperitoneal…
Total
Page 18 of 41


1.6. BASELINE ANALYTICS
1.6.1. HEMOGRAM
Table 37. Baseline analytics: Hemogram
 
N
Mean
SD
Median
Min
Max
Hemoglobin Value (Baseline)
Leukocytes Value (Baseline)
Lymphocytes Value (Baseline)
Monocytes Value (Baseline)
Eosinophils Value (Baseline)
Neutrophils Value (Baseline)
Platelets Value (Baseline)
1.6.2. BIOCHEMISTRY
Table 38. Baseline analytics: Biochemistry
 
N
Mean
SD
Median
Min
Max
Creatinine Value (Baseline)
Urea Value (Baseline)
Urate Value (Baseline)
Sodium Value (Baseline)
Potassium Value (Baseline)
Calcium Value (Baseline)
Glucose Value (Baseline)
Protein Value (Baseline)
Albumin Value (Baseline)
LDH Value (Baseline)
Gamma globulin Value (Baseline)
Meta2-seric microglobulin Value (Baseline)
OSTP/ALT Value (Baseline)
OSOT/AST Value (Baseline)
FA Value (Baseline)
GGT Value (Baseline)
BIL Value (Baseline)
IgG Determination Value (Baseline)
IgA Determination Value (Baseline)
IgM Determination Value (Baseline)
1.6.3. COAGULATION TEST
Table 39. Baseline analytics: Coagulation test
 
N
Mean
SD
Median
Min
Max
TTP Value (Baseline)
TP Value (Baseline)
Fibrinogen Value (Baseline)
Page 19 of 41


1.6.4. IPI
Table 40. Baseline analytics: IPI
 
N
%
IPI (Baseline)
0
1
2
3
4
5
UK
Total
 
N
Mean
SD
Median
Min
Max
IPI (Baseline)
1.6.5. LYMPHOMA SITUATION
Table 41. Baseline analytics: Lymphoma situation
 
N
%
Situation
lymphoma
(Baseline)
Partial Response
Refractory disease
Relapse early untreated (<1 year after diagnosis)
Relapse late untreated
UK
Total
1.6.6. SEROLOGY
Table 42. Baseline analytics: Serology
 
N
%
HIV antibodies
(Baseline)
Negative
Total
Hepatitis C
(Baseline)
Positive
Negative
UK
Total
RNA VHC
(Baseline)
Negative
NA
ND
UK
Total
HbsAg (Baseline)
Positive
Negative
NA
ND
UK
Total
Page 20 of 41


Anti Hbc
(Baseline)
Positive
Negative
ND
UK
Total
Anti Hbs
(Baseline)
Positive
Negative
ND
UK
Total
DNA VHB
(Baseline)
Positive
Negative
NA
ND
UK
Total
1.7. OTHER TESTS
1.7.1. OTHER TESTS: PREGNANCY
Table 43. Other test: Pregnancy
 
N
%
Pregnancy test at inclusion (Baseline)
Negative
NA
ND
UK
Total
1.7.2. OTHER TESTS: CARDIOLOGY TEST
Table 44. Other test: Cardiology test
 
N
%
ECG at inclusion
(Baseline)
Without significative alterations
Significative alterations
NA
ND
UK
Total
Cardiac
ventricular
ejection fraction
(Baseline)
Yes
No
NA
ND
UK
Total
Technique FE
(Baseline)
Ecocardio
MUGA
NA
ND
Total
Result FE
(Baseline)
Normal
Total
Page 21 of 41


1.7.3. OTHER TESTS: COMORBIDITIES QUESTIONNAIRE
Table 45. Comorbidities questionnaire: Item results
 
N
%
CRS-G comorbidity scale has been done
(Baseline)
Yes
No
Total
Hearth (Baseline)
Example: 0, 1…
Total
Hypertension (Baseline)
Example: 0, 1…
Total
Hematopoietic vascular (Baseline)
Example: 0, 1…
Total
Respiratory (Baseline)
Example: 0, 1…
Total
ORL (Baseline)
Example: 0, 1…
Total
Upper GI apparatus (Baseline)
Example: 0, 1…
Total
Lower GI apparatus (Baseline)
Example: 0, 1…
Total
Liver (Baseline)
Example: 0, 1…
Total
Renal (Baseline)
Example: 0, 1…
Total
Genitourinary (Baseline)
Example: 0, 1…
Total
Skeletal muscle (Baseline)
Example: 0, 1…
Total
Nervous system (Baseline)
Example: 0, 1…
Total
Endocrine-metabolic system and breast
(Baseline)
Example: 0, 1…
Total
Psychiatric problems (Baseline)
Example: 0, 1…
Total
GAH (Baseline)
Yes
No
NA
ND
Total
Table 46. Comorbidities questionnaire: Scores
 
N
%
Number of categories that have scored: of the total
of 14 categories, count those that have not
received a score of 0
Example: 0, 1…
Total
Total score (adding all the points)
Example: 0, 1…
Total
Severity index (total score/number of categories
that have scored)
Example: 0, 1…
Total
Page 22 of 41


Number of categories that have scored with a
score>=3
Example: 0, 1…
Total
Number of categories that have scored with score
4
Example: 0, 1…
Total
 
N
Mean
SD
Median
Min
Max
Score > 0 (Baseline)
Score (Baseline)
Severity index (Baseline)
1.8. TREATMENT COMPLIANCE
Table 47. Treatment compliance Induction: Received cycles/completed
 
N
%
Number of induction cycles received
Example: 1.00, 2.00…
Total
Number of induction cycles received
complete (according to protocol)
Example: 1.00, 2.00…
Total
Patients with delayed induction cycles
No
Yes
Total
% of induction cycles received complete
(according to protocol)
% of induction cycles
received
Total
Number of induction cycles received
with delay
Example: 1.00, 2.00…
Total
% of induction cycles received with
delay
% of induction cycles
received with delay.00
Total
No. of induction cycles delayed due to
hematological toxicity
Not delayed cycle due to
hematological toxicity
Example: 1.00, 2.00…
Total
 
N
Mean
SD
Median
Min
Max
Number of induction cycles received
Number of induction cycles received
complete (according to protocol)
% of induction cycles received complete
(according to protocol)
Number of induction cycles received with
delay
% of induction cycles received with delay
No. of induction cycles delayed due to
hematological toxicity
Table 48. Ibrutinib dosage
 
N
%
Minimum dose of ibrutinib received per
patient
560mg/day
420mg/day
280mg/day
Total
Ibrutinib dose reduced
No
Yes
Total
Page 23 of 41


Table 49. Treatment duration
 
N
Mean
SD
Median
Min
Max
Treatment duration (months)
1.9. END OF TREATMENT
Table 50. End of treatment
 
N
%
Treatment ends
Yes
Total
Reason end of
treatment (End of
treatment)
Progression
Unacceptable toxicity
End of maintenance
Investigator criteria
Patient withdrawal of continuing with treatment
Others
Total
Specify
Other/Unacceptable
toxicity or
Investigator criteria
Example: Allogeneic transplant, Cardiac
complications…
Total
1.10. EFFICACY: RESPONSE
1.10.1.
SUMMARY RESPONSE AT 4TH CYCLE AND AFTER
INDUCTION IN TREATED PATIENTS
Table 51. Summary of local response in the 4th cycle, 6-8th cycles in local
evaluation (treated patients) and ORR
After 4th
cycle
N (%)
After
induction
N (%)
ORR (as
Best
Overall
Response)
Complete response (CR)
Partial response (PR)
Global response (GR=CR+PR)
Stable disease (SD)
Progression
Not evaluated due to lack of follow-up at
cycle 6-8
Not evaluated due to other reasons
Total
Page 24 of 41


1.10.2.
RESPONSE AT 4TH CYCLE IN TREATED PATIENTS
Table 52. Response at 4th cycle in local evaluation (treated patients)
 
N (%, CI 95%)
Local
evaluation CT
scan 4th cycle
CR
PR
SD
Progression
Study ends due to Exitus without CT scan 4th cycle
Study ends due to IC withdrawal without CT scan  4th cycle
Total
CR or PR at 4th
cycle in local
evaluation
PR or CR
No PR or CR
Total
Table 53. Response at 4th cycle in centralized evaluation (treated patients)
 
N (%, CI 95%)
Centralized
evaluation
CT scan 4th
cycle
CR
PR
SD
Progression
Study ends due to Exitus without CT scan 4th cycle
Study ends due to IC withdrawal without CT scan  4th cycle
Without centralized response CT scan 4th cycle (local available)
Total
CR or PR at
4th cycle in
centralized
evaluation
PR or CR
No PR or CR
Without centralized response CT scan 4th cycle (local available)
Total
1.10.3.
RESPONSE
AT
4TH
CYCLE
IN
PATIENTS
FROM
AVAILABLE RESPONSE POPULATION
Table 54. Response at 4th cycle in local evaluation (evaluable assessment)
 
N (%, CI 95%)
Local
evaluation CT
scan 4th cycle
CR
PR
SD
Progression
Study ends for Exitus without CT scan 4th cycle
Total
CR or PR at 4th
cycle in local
evaluation
PR or CR
No PR or CR
Total
Page 25 of 41


Table 55. Response at 4th cycle in centralized evaluation (evaluable assessment)
 
N (%, CI 95%)
Centralized
evaluation
CT scan 4th
cycle
CR
PR
SD
Progression
Study ends for Exitus without CT scan 4th cycle
Without centralized response CT scan 4th cycle (local available)
Total
CR or PR at
4th cycle in
centralized
evaluation
PR or CR
No PR or CR
Without centralized evaluation
Total
1.10.4.
RESPONSE AT 6-8TH CYCLE IN TREATED PATIENTS
Table 56. Response at 6-8th cycle in local evaluation (treated patients)
 
N (%, CI 95%)
Local
evaluation CT
scan 6-8th cycle
CR
PR
SD
Progression
Study ends for Exitus without CT scan 6-8th cycle
Study ends for IC withdrawal without CT scan 6-8th cycle
Without CT scan 6-8th cycle due to lack of follow-up
Total
CR or PR at
6-8th cycle in
local evaluation
PR or CR
No PR or CR
Without CT scan at 6-8th cycle due to lack of follow-up
Total
Table 57. Response at 6-8th cycle in centralized evaluation (treated patients)
 
N (%, CI 95%)
Centralized
evaluation
CT scan
6-8th cycle
Positive*
Negative*
Progression in PET-TAC 4th cycle centralized (without evaluation
at 6-8th cycle)
Ends study due to Exitus without CT-scan 6-8th cycle
Ends study due to withdrawal of IC without CT-scan 6-8th cycle
Without CT-scan 6-8th cycle due to lack of follow-up
Without centralized evaluation 6-8th cycle (local available)
Without centralized evaluation 6-8th cycle
Total
CR or PR at
6-8th cycle in
centralized
evaluation
Positive (Response)*
Negative (No response)*
Without CT scan at 6-8th
Total
64
Page 26 of 41


1.10.5.
RESPONSE
AT
6-8TH
CYCLE
IN
PATIENTS
FROM
AVAILABLE RESPONSE POPULATION
Table 58. Response at 6-8th cycle in local evaluation (evaluable assessment)
 
N (%, CI 95%)
Local
evaluation
CT scan
6-8th cycle
CR
PR
SD
Progression
Study ends for Exitus without CT scan 6-8th cycle
Without CT scan 6-8th cycle due to lack of follow-up
Total
CR or PR at
6-8th cycle
in local
evaluation
PR or CR
No PR or CR
Without CT scan at 6-8th cycle due to lack of follow-up
Total
Table 59. Response at 6-8th cycle in centralized evaluation (evaluable
assessment)
 
N (%, CI 95%)
Centralized
evaluation
CT scan
6-8th cycle
Positive*
Negative*
Progression in PET-TAC 4th cycle centralized (without evaluation
at 6-8th cycle)
Ends study due to Exitus without CT-scan 6-8th cycle
Without CT-scan 6-8th cycle due to lack of follow-up
Without centralized evaluation 6-8th cycle (local available)
Without centralized evaluation 6-8th cycle
Total
CR or PR at
6-8th cycle in
centralized
evaluation
Positive (Response)*
Negative (No response)*
Without CT scan at 6-8th
Total
1.1.1. ORR IN TREATED PATIENTS
Table 60. ORR in local evaluations (treated patients)
 
N (%, CI 95%)
Best Overall
Response
(including
CT-scans after
EOT)
CR
PR
SD
Relapse
Progression
Study ends due to Exitus without CT scan 4th cycle and
after
Study ends due to IC withdrawal without CT scan  4th cycle
and after
Total
Page 27 of 41


BOR: CR or PR
(including
CT-scans after
EOT)
No
Yes
Total
Table 61. ORR in centralized evaluations (treated patients)
 
N (%, CI 95%)
BOR: CR or PR as
Positive/Negative*
(including CT-scans
after EOT)
centralized
No
Yes
Total
1.10.6.
ORR
IN
PATIENTS
FROM
AVAILABLE
RESPONSE
POPULATION
Table 62. ORR in local evaluations (evaluable assessment)
 
N (%, CI 95%)
Best Overall
Response
(including
CT-scans after
EOT)
CR
PR
SD
Relapse
Progression
Study ends due to Exitus without CT scan 4th cycle and
after
Total
BOR: CR or PR
(including
CT-scans after
EOT)
No
Yes
Total
Table 63. ORR in centralized evaluations (evaluable assessment)
 
N (%, CI 95%)
BOR: CR or PR as
Positive/Negative*
(including CT-scans
after EOT)
centralized
No
Yes
Total
Page 28 of 41


1.11. EFFICACY: SURVIVAL
1.11.1.
OVERALL SUVIVAL IN TREATED PATIENTS
Table 64. Overall survival in treated patients
Estimated OS
N events
N at risk
% patients
without exitus
CI 95%
% with exitus
at 6 months
at 12 months
at 24 months
N events (%)
Median
Min-Max
Standard
error
CI 95%
Estimated OS
Table 65. Overall survival in treated patients: Events and death reason
N (%; CI 95%)
Overall
survival
Alive
Death
Total
Death
reason
Lymphoma/Progression
Toxicity
Others
Not specified
Total
Specify death
reason
N (%)
Example: CART-T therapy, Nosocomial respiratory infection
Table 66. Follow-up time in treated patients
N
Mean (SE)
Median (Min-Max)
Time until Death or last follow-up (from inclusion)
1.11.1.1
OVERALL
SUVIVAL
IN
COMPLETE
RESPONDERS (TREATED PATIENTS)
Table 67. Overall survival in complete responders (treated patients)
Estimated OS
N events
N at risk % patients without
Death
CI 95%
% with Death
at 6 months
at 12 months
at 24 months
N events (%)
Median
Min-Max
Standard
error
CI 95%
Estimated OS
Page 29 of 41


Table 68. Overall survival in complete responders (treated patients): Events and death
reason
N (%; CI 95%)
Overall
survival
Vivo
Death
Total
Death
reason
Lymphoma/Progression
Others
Total
Specify death
reason
N (%)
Example: Respiratory insufficiency due to progression…
Table 69. Follow-up time complete responders (treated patients)
N
Mean (SE)
Median (Min-Max)
Time until exitus or last follow-up (from inclusion)
1.1.1. OVERALL SUVIVAL IN AVAILABLE RESPONSE POPULATION
Table 70. Overall survival in available response population
Estimated OS
N events
N at risk
% patients
without exitus
CI 95%
% with Death
at 6 months
at 12 months
at 24 months
N events (%)
Median
Min-Max
Standard
error
CI 95%
Estimated OS
Table 71. Overall survival in available response population: Events and death reason
N (%; CI 95%)
Overall
survival
Vivo
Death
Total
Death
reason
Lymphoma/Progression
Others
Not specified
Total
Specify death
reason
N (%)
Example: CART-T therapy, Respiratory insufficiency due to
progression…
Table 72. Follow-up time in available response population
N
Mean (SE)
Median (Min-Max)
Time until exitus or last follow-up (from inclusion)
Page 30 of 41


1.1.1.1
OVERALL
SUVIVAL
IN
COMPLETE
RESPONDERS
(AVAILABLE
RESPONSE
POPULATION)
Table 73. Overall survival in complete responders (available response
population)
Estimated OS
N events
N at risk % patients without
exitus
CI 95%
% with exitus
at 6 months
at 12 months
at 24 months
N events (%)
Median
Min-Max
Standard
error
CI 95%
Estimated OS
Table 74. Overall survival in complete responders (available response population):
Events and death reason
N (%; CI 95%)
Overall
survival
Vivo
Death
Total
Death
reason
Lymphoma/Progression
Others
Total
Specify death
reason
N (%)
Others: Probable septic shock with multi-organ failure
(post-haploidentical transplantation)
Others: Respiratory insufficiency due to progression
Table 75. Follow-up time complete responders (available response population)
N
Mean (SE)
Median (Min-Max)
Time until exitus or last follow-up (from inclusion)
1.11.2.
PROGRESSION FREE SURVIVAL IN TREATED PATIENTS
Table 76. Progression Free Survival in treated patients
Estimated PFS
N events
N at risk
% of patients
without PFS
CI 95%
% with PD
at 6 months
at 12 months
at 24 months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated PFS
Page 31 of 41


Table 77. PFS in treated patients: Events and PD assessment
N (%; CI 95%)
Progression Free
Survival
Vivo sin PD
PD
Death
Total
PD assessment
N (%)
PD assessment
1.11.2.1
PFS IN COMPLETE RESPONDERS (TREATED
PATIENTS)
Table 78. Progression Free Survival in complete responders (treated patients)
Estimated PFS
N events
N at risk
% of patients
without PFS
CI 95%
% with PD
at 6 months
at 12 months
at 24 months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated PFS
Table 79. PFS in complete responders (treated patients): Events and PD assessment
N (%; CI 95%)
Progression Free
Survival
Vivo sin PD
PD
Death
Total
PD assessment
N (%)
PD assessment
Page 32 of 41


1.11.3.
PROGRESSION FREE SURVIVAL IN AVAILABLE
RESPONSE POPULATION
Table 80. Progression Free Survival in available response population
Estimated PFS
N events
N at risk
% of patients
without PFS
CI 95%
% with PD
at 6 months
at 12 months
at 24 months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated PFS
Table 81. PFS in available response population: Events and PD assessment
N (%; CI 95%)
Progression Free
Survival
Vivo sin PD
PD
Death
Total
PD assessment
N (%)
PD assessment
1.11.3.1
PFS IN COMPLETE RESPONDERS (AVAILABLE
RESPONSE POPULATION)
Table 82. Progression Free Survival in complete responders (available response
population)
Estimated PFS
N events
N at risk
% of patients
without PFS
CI 95%
% with PD
at 6 months
at 12 months
at 24 months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated PFS
Table 83. PFS in complete responders (available response population): Events and PD
assessment
N (%; CI 95%)
Progression Free
Survival
Vivo sin PD
PD
Death
Total
PD assessment
N (%)
PD assessment
Page 33 of 41


1.11.4.
EVENT FREE SURVIVAL IN TREATED PATIENTS
Table 84. EFS in treated patients
Estimated EFS
N events
N at risk
% patients
without event
CI 95%
% patients with
event
at 6 months
at 12 months
at 24months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated EFS
Table 85. EFS in treated patients: Events
N (%; CI 95%)
Type of events
Alive (without event)
PD
Death
Therapeutic failure (Toxicity)
Total
1.11.4.1
EFS IN COMPLETE RESPONDERS (AVAILABLE
RESPONSE POPULATION)
Table 86. EFS in available response population
Estimated EFS
N events
N at risk
% patients
without event
CI 95%
% patients with
event
at 6 months
at 12 months
at 24months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated EFS
Table 87. EFS in available response population: Events
N (%; CI 95%)
Type of events
Alive (without event)
PD
Death
Therapeutic failure (Toxicity)
Total
Page 34 of 41


1.11.5.
RESPONSE DURATION IN TREATED PATIENTS
Table 88. TAC at which the CR or PR is reached (treated patients)
 
N
%
TAC at which the CR
or PR is reached
Cycle X
Total
Table 89. Response duration (treated patients)
N
Mean (SD)
Median (Min-Max)
Time since CR/PR until PD/exitus or
censored
1.11.5.1
PFS FROM RESPONSE (CR or PR) IN TREATED
PATIENTS
Table 90. PFS from response until PD/exitus (estimated by Kaplan-Meier) (in treated
patients)
Estimated PFS from response
N events
N at risk
% of patients
without event
CI 95%
% of patients with
event
at 6 months
at 12 months
at 24 months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated PFS from response
Table 91. PFS from response (in treated patients): Events
N (%; CI 95%)
PFS from response
events
Alive without PD
PD
Exitus without previous PD
Total
Pts with response
longer than 12m
No
Yes
Total
1.1.1.COMPLETE
RESPONSE
DURATION
IN
TREATED
PATIENTS
Table 92. TAC at which the CR is reached (treated patients)
 
N
%
TAC at which the CR
is reached
Cycle X
Total
Page 35 of 41


Table 93. CR duration (treated patients)
N
Mean (SD)
Median (Min-Max)
Time since CR until PD/exitus or censored
1.1.1.1
PFS FROM COMPLETE RESPONSE IN
TREATED PATIENTS
Table 94. PFS from CR until PD/exitus (estimated by Kaplan-Meier) (in treated patients)
Estimated PFS from CR
N events
N at risk
% of patients
without event
CI 95%
% of patients with
event
at 6 months
at 12 months
at 24 months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated PFS from CR
Table 95. PFS from response (in treated patients): Events
N (%; CI 95%)
PFS from CR
events
Alive without PD
PD
Death without previous PD
Total
Pts with CR longer
than 12m
No
Yes
Total
PARTIAL
RESPONSE
DURATION
IN
TREATED
PATIENTS
Table 96. TAC at which the PR is reached (treated patients)
 
N
%
TAC at which the PR
is reached
Cycle X
Total
Table 97. PR duration (treated patients)
N
Mean (SD)
Median (Min-Max)
Time since PR until PD/exitus or censored
1.1.1.2
PFS FROM PARTIAL RESPONSE IN TREATED
PATIENTS
Table 98. PFS from PR until PD/exitus (estimated by Kaplan-Meier) (in treated patients)
Estimated PFS from PR
N events
N at risk
% of patients
without event
CI 95%
% of patients with
event
at 6 months
Page 36 of 41


at 12 months
at 24 months
N (%)
Median
Min-Max
Standard
error
CI 95%
Estimated PFS from PR
Table 99. PFS from response (in treated patients): Events
N (%; CI 95%)
PFS from PR
events
PD
Death without previous PD
Total
Pts with PR longer
than 12m
No
Yes
Total
1.2. SAFETY: TOXICITY
As per protocol, the following definition is used to determine which adverse
events are considered as toxicities:
“Adverse event related to drug use
An adverse event is considered to be drug-related if the attribution is possible,
probable, or very probable, based on the definitions provided below. (see page 54 of
the protocol)”.
Table 100. Toxicities
 
N (%, IC 95%)
AE
No
Yes
Total
Toxicity: AE related to the
treatment (possible, probable or
definitively)
No
Yes
Total
AE grade ≥3
No
Yes
Total
Hematological Toxicity
No
Yes
Total
SAE
Yes
No
Total
Page 37 of 41


1.2.1. MOST FREQUENT ADVERSE EVENTS AND TOXICITIES
The following table shows the most frequent Adverse events taking a threshold
of 5% and in overall and also taking into account the treatment phase at the
date that the AEs first appeared.
Table 101. Most frequent AEs with 5% threshold
Induction
Maintenance
Start day
missing
Total
N (%)
N (%)
N (%)
N (%)
Example: Platelet count decreased, Neutrophil count decreased…
The following table shows the most frequent Toxicities taking a threshold of 5%
and in overall and also taking into account the treatment phase at the date that
the AEs first appeared.
Table 102. Most frequent Toxicities with 5% threshold
Inductio
n
Maintenanc
e
Start day missing
Total
N (%)
N (%)
N (%)
N (%)
Example: Diarrhea, Anemia…
The following table shows the most frequent Toxicities taking a threshold of
5%, according to their maximum grade in overall:
Table 103. Grades of most frequent Toxicities with 5% threshold. Overall
No
G-UK
G-1
G-2
G-3
G-4
Total
N (%)
N (%)
N (%)
N (%)
N (%)
N (%)
N (%)
Example: Nausea, Anemia…
Table 104. Grades of most frequent Toxicities (5% threshold). Induction phase.
No
G-UK
G-1
G-2
G-3
G-4
Total
N (%)
N (%)
N (%)
N (%)
N (%)
N (%)
N (%)
Example: Nausea, Anemia…
Table 105. Grades of most frequent Toxicities (5% threshold).Maintenance phase.
No
G-UK
G-1
G-2
G-3
G-4
Total
N (%)
N (%)
N (%)
N (%)
N (%)
N (%)
N (%)
Example:
Nausea,
Anemia…
1.1.1. HEMATOLOGICAL AND NON-HEMTOLOGICAL TOXICITIES
The following table shows all the hematological toxicities (with maximum grade)
taking into account the treatment phase at the date that the AEs first appeared.
Page 38 of 41


Table 106. List of all hematological toxicities
Inductio
n
Maintenance
Total
N (%)
N (%)
N (%)
Example: Anemia - Grade 1, Lymphocyte count decreased - Grade 2…
The following table shows all the non-haematological toxicities with maximum
grade ≥3, taking into account the treatment phase at the date that the AEs first
appeared.
Table 107. List of non-hematological toxicities G≥3
Inductio
n
Maintenanc
e
Total
N (%)
N (%)
N (%)
Example: Cefalea - Grade 3, Diarrhea - Grade 3…
The following table shows all the non-haematological toxicities with their
maximum grades, taking into account the treatment phase at the date that the
AE first appeared.
Table 108. List of non-hematological toxicities any grade
Induction
Maintenance
AE
start
day
missing
Total
N (%)
N (%)
N (%)
N (%)
Example: Abdominal pain - Grade 2, Anorexia - Grade 2…
1.1.1. SAES
Table 109. List of non-hematological toxicities G≥3
Induction
Maintenance
Total
N (%)
N (%)
N (%)
Example: Abdominal pain - Grade 3, Anemia - Grade 3, Vomiting - Grade 3…
Page 39 of 41


Table 110. List of all adverse events reported as SAEs
Study
Subject
ID
Hospital
AE with grade
Date AE start Date AE end
Continuing
at the end
of study
AE related with
treatment (possible
/probable/
definitely)
Status
AEs according
to treatment
2. ANNEXES
2.1. ANNEX 1: RELEVANT PREVIOUS EVENTS
Table 111. List of all relevant previous events
N
Relevant
previous
events
Example: Arterial hypertension, Acute cholecystitis, Dyslipidemia…
2.2. ANNEX 2: PREVIOUS MEDICATION
Table 112. List of all previous medication
N
Previous
medication
Example: Acetylsalicylic acid, Omeprazole,
Trimethoprim/sulfamethoxazole…
Page 40 of 41


2.3. ANNEX 3: ALL TOXICITIES
Table 113. List of all toxicities
Study
Subjec
t ID
Hospital
AE with grade
Date AE start
Date AE
end
Continuing
at the end
of study
SAE
Status
Hematological
AE
AEs according
to treatment
Page 41 of 41